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Abstract 
 
Biochemical and computational studies towards selective inhibition of the 
immunoproteasome. 
Allardyce, D.J., Bell, C. and Loizidou, E. 
Department of Natural Sciences, Middlesex University, London, NW4 4BT. 
 
The proteasome pathway degrades >90% of cytosolic proteins deemed redundant, misfolded or 
toxic, thereby influencing key regulatory pathways including: cell cycle control, DNA repair and 
apoptosis. As such, proteasome inhibitors (PI) have exhibited broad therapeutic applications, 
particularly for multiple myeloma and mantle cell lymphoma with 3 inhibitors gaining FDA 
approval. However, covalent binding and lack of targeted action cause severe toxicity. Upon 
stimulation by inflammatory cytokines, constitutive proteasome (CP) active sites β1c, β2c and β5c 
are replaced with corresponding β1i, β2i and β5i subunits; forming the immunoproteasome (IP). 
The abundant CP is required for regular cell function, however due to upregulation in diseased 
states selective IP inhibition is associated with an increased therapeutic index. Recent 
identification of structural differences between CP and IP specificity pockets (S1-4) allows 
structure-based drug design. 
 
The cyclic peptides argyrin A and F exhibit potent, reversible CP inhibition with mechanisms 
distinct to existing therapeutics. In this project, argyrin B inhibition and binding interactions 
between the CP and IP are investigated, using purified enzyme assays alongside computational 
molecular modelling. Kinetic assays revealed argyrin B IC50 values of 146.5 µM and 8.76 µM at β1c 
and β1i, respectively; a 16-fold difference with statistical significance. Whilst argyrin B also 
showed slight preference towards β5i over β5c, with low micromolar IC50 values. The same trends 
were supported by Ki values and molecular docking estimated binding energies. AutoDock and 
FRED simulations suggest increased β1i S1 pocket hydrophobicity, T21S and G97H substitutions 
from β1c to β1i as key towards favourable β1i binding. At β5c, small, hydrophobic characteristics 
of S2 become polar in β5i that enhances argyrin B interactions. These findings facilitate design of 
further IP selective inhibitors, whilst the identification of the first known β1i selective and non-
covalent PI shows great therapeutic potential with reduced toxicity proposed in comparison to 
existing therapeutics.  
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Chapter 1.  Introduction 
1.1  Protein degradation 
1.1.1  Proteostasis 
 
The role of protein degradation is vital for cellular growth and viability. Degradation rate controls 
the half-life of proteins, thereby influencing intracellular protein levels to maintain proteostasis. 
In eukaryotic cells, there are two major pathways that control protein degradation; lysosomal 
proteolysis and the ubiquitin-proteasome system (Etlinger and Goldberg, 1977).   
Lysosomes contain a concoction of digestive enzymes such as proteases and cathepsins, which 
allow the degradation of proteins that have been engulfed through endocytosis and autophagy. 
This process is generally non-selective; however under nutrient deprivation, degradation of 
specific proteins can serve as an energy supply (Cuervo and Dice, 1996). Lysosomes play a vital 
role in immune response through presentation of peptide fragments on immune cells, via major 
histocompatibility complex (MHC) class II receptors. The pathway was originally identified as the 
main process of proteolysis resulting in the hydrolysis of diverse macromolecules. 
However, in 1977, the nonlysosomal, ubiquitin-proteasome pathway was first introduced by 
Etlinger and Goldberg (1977), presenting a role in degradation of polyubiquitin tagged proteins 
that are deemed redundant, misfolded or potentially toxic (Goldberg, 2003). This selective 
degradation system is present in all eukaryotic cells and is responsible for >90% of intracellular 
degradation. Key regulatory proteins and molecular pathways are affected such as: cell cycle 
control, DNA repair, differentiation, stress response, antigen presentation and apoptosis (Pellom 
and Shanker, 2012). With greater understanding of the molecular mechanisms involved, the 
proteolytic pathway was soon linked with several disease states and has since become a long 
standing therapeutic target. The proteasome complex, found within the nucleus and cytoplasm 
and constituting approximately 0.5%-0.8% of total cellular protein itself (Parlati et al., 2009), is the 
machinery of nonlysosomal protein degradation.  
 
1.1.2  Polyubiquitylation 
 
The proteasome architecture of regulatory caps determines the type of proteins recognised and 
mechanism of action, using polyubiquitylation as the most common pathway. 
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Specific conjugation of ubiquitin (Ub) with distinct length and linkage, tags the protein targets for 
recognition and rapid degradation by the proteasome. The ubiquitination process, summarised in 
figure 1, involves activation, conjugation and ligation steps, facilitated by E1, E2 and E3 enzymes 
respectively. Adenosine triphosphate (ATP) is required for the attachment of ubiquitin as well as 
26S proteasome actions. 
 
Firstly, ubiquitin is activated by E1, using ATP and is transferred to E2. E3 recognises and binds the 
specific substrate based on primary protein sequences, therefore accounting for substrate 
selectivity. E3 is able to transfer the ubiquitin to covalently bind the substrate, generally at a 
lysine residue, thereby tagging for recognition by the 19S cap (Glickman and Ciechanover, 2002). 
The polyubiquitination mechanism remains contested, with either elongation by sequential 
addition of ubiquitin, or ready-formed poly-Ub chains wholly added to the protein (Pellom and 
Shanker, 2012). 
 
 
 
Figure 1 - Summary of the ubiquitin degradation process – Ubiquitin (Ub) undergoes 3 key steps of: 
activation, conjugation and ligation at E1, 2 and 3 enzymes, respectively. Upon covalent binding of 
substrate to a ubiquitin chain, the substrate is tagged for recognition by the 26S proteasome complex. The 
proteasome regulatory cap is able to unfold and open the complex allowing cleavage within the core at β 
catalytic sites. Peptide fragments are produced and ubiquitin is recycled. 
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Once the protein is signalled for degradation, the proteasome is able to recognise and process the 
breakdown into peptide fragments, typically of 5-25 residues in length. Before processing in the 
complex structures of the 26S proteasome, proteins are de-ubiquitinated by deubiquitinating 
enzymes (DUBs) and unfolded by the 19S cap, using ATP (Glickman and Ciechanover, 2002).  
 
1.2  The proteasome 
1.2.1  Proteasome structure 
 
The 26S proteasome is a large (150x115 Å), cylindrical complex comprised of approximately 66 
proteins arranged in a 20S catalytic core and 2 19S regulatory caps at either end, as shown in 
figure 2 (Pellom and Shanker, 2012). The 19S regulatory proteins are each comprised of base and 
lid structures, containing at least 19 subunits, with key proteins highlighted in figure 2, that 
facilitate the opening of the proteasome and unfolding of proteins (Huang et al., 2016). The 20S 
core contains 2 stacked, heteroheptameric catalytic β1-7 subunit rings (figure 2, red spheres) 
between 2 structural α1-7 subunit rings (figure 2, orange spheres).  
The constitutive proteasome (CP) is required for regular cell function with proteolytic activity 
occurring within β1, 2 & 5 active sites. Figure 3 shows substitution of active sites to create the 
immunoproteasome (IP) and thymoproteasome (TP) variants. IP formation is stimulated by 
inflammatory signals and bears the same function, with slightly different active sites (Huber et al., 
2012). The IP is therefore upregulated in diseased states and not commonly found in healthy cells. 
The TP is significantly less abundant, found only in cortical thymic epithelial cells and plays a role 
in the adaptive immune system (Nitta et al., 2010). However, it is also important to note that 
mixed, intermediate proteasomes containing a split of both CP and IP active sites have been 
reported in a variety of cell types, at widely varying levels up to an abundance of 50% (Guillaume 
et al., 2010).   
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Figure 2 - Representation of mammalian 26S proteasome - Displaying 20S core comprised of heptameric α 
(orange) and β (red) rings, with β-subunit active sites. The 19S cap consists of lid and base structures for 
recognition and unfolding of substrates. The lid is comprised of regulatory particle of non-ATPase (Rpn) 
subunits, whilst base consists of select Rpn subunits and a regulatory particle of triple-ATPase (Rtp) subunits 
ring. 
 
 
Figure 3 - Illustration of 20S proteasome variants – Constitutive proteasome, immunoproteasome and 
thymoproteasome structures are shown with substituted β-active site subunits in each β-ring. α-subunit 
rings remain unchanged. 
 
The human 20S proteasome (PDB: 4R30) was first crystallised in 2015 by Harshbarger et al. (2015) 
using x-ray diffraction, to a resolution of 2.6 Å. The characterisation of active sites and recognition 
proteins allows further understanding of molecular mechanisms involved in the degradation 
process. During protein recognition and degradation, 3 dynamic conformations of the 26S 
proteasome have been proposed: accepting substrates, an intermediate positioning and 
translocation to the 20S particle (Huang et al., 2016). These dynamic conformations facilitate 
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understanding of protein recognition and control of peptides to be degraded within the catalytic 
core.  
Upon reaching the 20S subunit, there are 3 main active sites: β1, β2 and β5 subunits, with distinct 
mechanisms of action that allow for levels of specificity as discussed in the following sections. 
 
1.2.2  Threonine protease activity mechanism 
 
The active sites work synergistically to cleave proteins using the same mechanism; however each 
displays distinct substrate specificities on account of the interactions at specificity pockets 
surrounding the active site. After series of mutation studies, it was found that the N-terminal 
threonine 1 (Thr1) residues at the beginning of β1, β2 and β5 subunit chains provide the site for 
proteolytic activity. Despite β7 also displaying an N-terminal Thr residue, its’ removal results in no 
change to activity, suggesting that this is catalytically inactive (Dick et al., 1998). The threonine 
acts as a nucleophile hydrolase in an endoprotease reaction to cleave the scissile bond of 
substrates, as summarised in figure 4. 
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As a weak nucleophile, water 
interacts to deprotonate 
Thr1Oγ, thereby increasing 
nucleophilic properties. Thr1N 
then acts as a proton acceptor. 
 
 
 
The nucleophilic Thr1Oγ then 
attacks the electrophilic 
carbonyl on the peptide bond, 
creating a tetrahedral 
intermediate with ester bond. 
 
 
 
The intermediate stabilises into 
an acyl-enzyme, with the 
release of the substrate amino 
component. 
 
 
The acyl-enzyme is 
hydrolysed by water 
donating a proton to 
Thr1Oγ. The C-terminus 
becomes occupied to 
release the second 
substrate component. 
 
The N-terminal Thr1 
resumes its original 
state and can undergo 
further reactions. 
 
Figure 4 - Schematic representation of substrate proteolysis mechanism - The N-terminal threonine residue, 
shown in red, is the catalytic centre within each proteasome active site β-subunit. The substrate amide bond 
is shown in green and water molecules in blue. (Adapted from; Kisselev and Goldberg, 2001). 
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Understanding of the proteolysis mechanism can facilitate drug design of the target. Inhibitors 
with an electrophilic group to react with the nucleophilic N-terminal Thr1Oy residue at active sites 
are established as effective whilst other modes of inhibition are also possible (Kisselev et al., 
2012).  
 
1.2.3  Active sites and specificity pockets 
 
The surrounding residues of Thr1 create specific pockets that contribute to the selectivity and 
stabilisation of substrates. The specificity binding pockets S1-3 accommodate the amino acid side 
chains, as shown in figure 5 (Huber et al., 2012). Due to amino acid variation between β1, β2 and 
β5, the characteristic activity of each active site differs. 
 
Figure 5 - Proteasome active site substrate binding channels – Within each β active site, amino acid side 
chains P1-3 of the substrate, bind specificity pockets S1-3. Specificity pockets each have characteristic 
shapes and properties that produce preference for particular substrates. Upon binding, the Thr1 residue 
cleaves the scissile peptide bond of the protein (Huber et al., 2012). 
 
β1, β2 and β5 are characterised with basic, acidic and nonpolar specificity pockets, respectively. 
As such, β1 displays caspase-like activity with cleavage after acidic amino acids, β2 cleaves after 
basic amino acids with trypsin-like activity and β5 cleaves after hydrophobic residues in a 
chymotrypsin-like activity (Dick et al., 1998). These properties are summarised in table 1 below 
and visualised in figure 6. 
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Table 1 - CP active site characteristics – Each active site is termed according to its general proteolysis 
activity, it does not perfectly represent the sole mechanism. 
• 
indicates quicker than glutamate, * is not 
applicable if followed by proline, 
ᵩ 
denotes decreased cleavage rates. (Adapted from; Dick et al., 1998). 
Active Site Activity Cleaves after  
β1 Caspase-like Acidic amino acids Asp•, Glu 
β2 Trypsin-like Basic amino acids Arg, Lys 
β5 Chymotrypsin-like Hydrophobic residues Phe, Trp, Tyr*, Hisᵩ, Metᵩ, Leuᵩ 
 
 
Figure 6 – Representation of characteristic size and properties of CP and IP active sites – Substrate peptide 
chains are displayed in green with protruding R-groups. Red represents active site surrounding catalytic 
Thr1, revealing differences in size and charges. Preference of substrate characteristics are highlighted 
within text labels. 
 
Based upon these activities, inhibitor compounds can exhibit greater selectivity towards particular 
active sites. β5 was originally considered a significantly more influential active site than β1 and β2, 
therefore becoming a focus in early proteasome inhibitor development. However, Kisselev (2006) 
showed the inhibition of β5c to reduce overall protein breakdown by 11-50%, whilst β1 and β2 
inhibition reduce overall activity by 12-22% and 3-35%, respectively. This shows a hugely varying 
impact on overall degradation, as well as the importance of each active site. In addition, there 
appears to be some compensatory actions since the inhibition of 2 active sites displayed a greater 
reduction of degradation than the sum of each individually. 
As well as key differences between β1, 2 & 5, there are variations in the active subunit sequences 
between the CP and IP corresponding sites. This leads to different binding preferences of 
substrates and inhibitors. As shown in figure 6, β1i generally accepts smaller, hydrophobic 
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substrates as opposed to acidic preference at β1c. β2c and β2i sites are similar and β5i are able to 
accommodate larger hydrophobic residues than β5c.  
 
1.3  The immunoproteasome 
1.3.1  Formation and structure of the immunoproteasome 
 
Upon stimulation by inflammatory cytokines such as interferon gamma (IFN-γ) and to a lesser 
extent, tumour necrosis factor alpha (TNF-α), the proteasome is phosphorylated and transcription 
of IP specific subunits begins. Large multifunctional peptidase 2 (LMP2), multicatalytic 
endopeptidase complex-like-1 (MECL-1) and LMP7 genes encode for β1i (proteasome subunit 
beta-9 - PSMB9, LMP2), β2i (PSMB10, LMP10, MECL-1) and β5i (PSMB8, LMP7), respectively which 
replace corresponding 20S CP subunits; reviewed by Johnston-Carey et al. (2015). In addition, 
combinations of 19S and 11S regulatory caps are formed as displayed in figure 7. This 11S 
structure performs the same function as 19S although it allows for non-ubiquitinated peptide 
degradation, improves efficiency and plays a greater role in antigen presentation (Engelhard, 
1994). 
 
Figure 7 - Immunoproteasome structure variation – Representation of different 11S and/or 19S regulatory 
caps combinations on 20S core particles. The 19S regulatory cap (blue and purple) performs the same 
function as Pa28/11S cap (green), although the presence of Pa28/11S also allows for non-ubiquitinated 
peptide degradation and increased rates. 
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Under standard conditions, the levels of IP are low in comparison to CP, however, during 
inflammatory and diseased states, levels of IFN-γ and oxidative stress are increased, resulting in 
elevated proportions of IP. Interestingly the IP is proposed to exhibit approximately double the 
activity of the CP and a half-life of 27 hours, compared to 133 hours of the CP (Heink et al., 2005). 
IFN-γ is able to upregulate proteasome maturation protein (POMP) expression that increases the 
speed of formation as well as preference to IP subunits over CP (Gregerson and Ferrington, 2012). 
This suggests that the IP is upregulated upon demand, for rapid degradation in select tissues 
before returning to normal states. Indeed, there are high levels of IP reported in inflammatory 
and autoimmune disorders, diseases of the central nervous system and some cancers (Miller et al., 
2013). 
Although largely conserved, there are slight differences between the amino acid chain and 
therefore active site structure of the CP and IP corresponding active sites. Figure 8 compares a 
surface representation view based around the catalytic Thr1 (red), of human β1c (blue) compared 
to humanised β1i (green), with visible changes circled. These may lead to different substrate or 
compound binding preferences.   
 
Figure 8 - Structural differences between CP and IP β1 active site - Surface representation of human β1c 
(blue) and humanised β1i (green), with threonine-1 catalytic centre in red. Significant structural differences 
are circled. 
  
1.3.2  Function of the immunoproteasome 
 
The IP is shown to play a vital role in immunity, providing peptides for MHC antigen presentation 
that differ from those the CP produces. Whilst β2i and β5i share the characteristic trypsin-like and 
chymotrypsin-like activities of their CP counterparts, β1i exhibits trypsin-like activity as opposed 
to caspase-like of β1c as figure 6 displays. This contributes towards the IP’s overall increased 
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chymotrypsin-like activity compared to the CP (Pellom and Shanker, 2012; Johnston-Carey et al., 
2015). The absence of β5 was shown to lower MHC class I expression by up to 50%, whilst β1 and 
β2 showed no impact. This led to the discovery that the hydrophobic residues produced by 
chymotrypsin-like activity, bind with greater affinity to MHC class I molecules (Engelhard, 1994; 
Nitta et al., 2010). 
In addition, the TP composed of β1i, β2i and β5t subunits as shown in figure 3 plays a vital role in 
immunity. Interestingly, the β5t shows lower chymotrypsin-like activity compared to constitutive 
and immune counterparts. Despite this, the TP is required for production of hydrophobic residues 
to facilitate development of cytotoxic CD8+ T cells (Nitta et al., 2010). 
As well as established adaptive immune function, the IP has been shown to regulate activation of 
alveolar macrophages, revealing a novel role in the innate immune response. β5i specific 
inhibition is proposed as a suitable approach for pneumonia and sepsis related acute respiratory 
distress syndrome (Chen et al., 2016).  
Beyond immune functions, the IP is linked with an increasing variety of disease states, later 
discussed in section 1.4.3 and provides a promising avenue for more targeted treatment on 
account of their distribution in types of cells.  
 
1.4  The proteasome as a drug target 
1.4.1  Classes of proteasome inhibitors 
 
It has been reported that approximately half of existing drugs target enzymes (Copeland, 2005). 
The CP and IP are highly influential enzymes in the progression of many diseases, making these 
major drug targets. Research utilising proteasome inhibitors has significant clinical benefit, as well 
as use in advances of understanding disease mechanisms, cell regulation, quality control systems 
and the immune response (Goldberg, 2012).  
The proteasome, like most enzymes, is amenable to small molecule drugs that may use a range of 
mechanistic actions. Most inhibitors contain a peptide backbone that mimics the substrate with a 
pharmacophore that defines the class and mechanism of inhibitor. Increasingly, CP and IP 
inhibitors in development are also providing co-crystallised structures with the proteasome to 
help further elucidate mechanism of action. The main classes are summarised in table 2.
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Table 2 – Major classes of proteasome inhibitors – General inhibitor classification classes alongside chemical bonds formed and associated examples of existing inhibitors. 
 
Class Structure Bonding Compounds 
Aldehydes 
 
Covalent, reversible hemiacetal adduct with N-terminal Thr1 MG132 (Rock et al., 1994) 
Boronates 
 
  
 
 
Boron accepts oxygen lone pair of N-terminal Thr1OH, 
forming a stable, tetrahedral complex. Reversible, slow 
dissociation rates. 
Bortezomib (PS-341, Velcade) (Groll et al., 
2006a) 
 
 Pro-drug with citrate ester - hydrolysis releases boronic acid 
Ixazomib (MLN9708, Ninlaro) (Moreau et al., 
2016) 
 
Vinyl sulphones 
 
Covalent ether bond formed with Thr1O
γ
 Vinyl sulfone (Kisselev et al., 2012) 
Vinyl ketones 
(syrbactins) 
 
Covalent, irreversible ether bond Michael type 1-4 addition 
to Thr1OH 
 
Syringolin A (Clerc et al., 2009) 
 
  
Irreversible covalent bond forms 7-membered ring adduct 
with Thr1N 
Epoxomycin (Groll et al., 2000) 
Epoxyketones 
 
 
 
 
Irreversible bivalent reaction with Thr1O
γ
 and Thr1N 
Carfilzomib (PR-171, Kyprolis) (Harshbarger et 
al., 2015) 
 
ONX 0914 (PR-957) (Muchamuel et al., 2009)  
 
Oprozomib (ONX-0912) (Parlati et al., 2009) 
 
 
PR-924 (Parlati et al., 2009) 
β-lactones 
 
Reversible or irreversible. Ester bond to Thr1 and 
tetrahydrofuran ring formation. 
Marizomib (Salinosporamide A) (Feling et al., 
2003; Groll et al., 2006b) 
 
Ketoaldehydes 
 
Reversible cyclic Schiffbase formed with Thr1O
γ
 and Thr1N Peptidyl glyoxal (Gräwert et al., 2011) 
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Each class of inhibitor has benefits and limitations. From a therapeutic point of view, initially 
potency is of the utmost importance. However, many drugs have subsequently suffered with poor 
selectivity and unwanted interactions in vivo. For example, peptide aldehydes are broken down 
into inactive forms within the cell, rendering these unsuitable therapeutics, despite their potency 
(Pellom and Shanker, 2012). Acting upon other targets such as serine and cysteine proteases 
create unwanted side effects and provide an additional obstacle to overcome. Similarly, the 
formulation and delivery of drugs are often additional complications to overcome later in the 
development process (Strelow et al., 2012). 
As displayed in table 2, many existing proteasome inhibitors contain variations of an electrophilic 
warhead group, forming covalent bonds with the catalytic Thr1 of each active site. A strong 
chemical bond at this site can cause irreversible inhibition, associated with more severe toxicity 
since proteasomes are vital for regular functioning within cells (Kisselev et al., 2012). Non-
covalent inhibitors without a reactive group may have lower potency, although generally have 
fewer side effects with time limited inhibition. Rapid binding and dissociation, possible with 
reversible inhibitors, can also allow greater tissue distribution (Gräwert et al., 2012). With 
synthetic motifs able to enhance interactions and affinity, non-covalent inhibitors are an 
emerging class of proteasome inhibitors. Upon understanding how inhibitors bind to the 
proteasome and active sites, it is important to elucidate the molecular pathways triggered by this 
event. 
 
1.4.2  Proteasome inhibition molecular pathways 
 
Beyond the binding mechanism, the downstream effects of proteasome inhibitors are diverse, 
with some examples of simplified pathways summarised in figure 9. Ultimately, many of these 
lead to apoptosis and cell cycle regulation. 
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Figure 9 – Molecular pathways triggered by proteasome inhibition – Examples of key pathways and 
molecular changes as a result of proteasome inhibtion. 
Proteasome inhibition activates autophagy in order to remove protein aggregates (Zhu et al., 
2010). An accumulation of damaged proteins triggers endoplasmic reticulum (ER) stress and an 
unfolded protein response (Pandey et al., 2007). Due to the roles of the proteasome it is 
suggested that inhibitors reduce the activity of nuclear factor kappa B (NFkB) (Palombella et al., 
1994), a key transcription regulator, however this has not been consistently observed (Parlati et 
al., 2009). Furthermore, the extrinsic apoptosis pathway is promoted through fas-associated 
death domain (FADD) induced caspase-8 activation (Brooks et al., 2010). In addition, several 
pathways of intrinsic apoptosis are stimulated through a number of pro-apoptotic factors 
(Nickeleit et al., 2008; Parlati et al., 2009; Singh et al., 2009). However, the complexity of the 
molecular mechanisms is evident by contradictory effects, such as the activation of p38 
microtubule associated protein kinase (MAPK) anti-apoptotic pathways (Shi et al., 2006). 
It is important to note that the effector pathway varies with different cells and inhibitors. 
However, the broad impact provides promising avenues for drug development since differing 
mechanisms may allow for more targeted actions or help overcome resistance. 
 
1.4.3  Therapeutic potential 
 
With a greater understanding of the molecular mechanisms involved, the proteolytic pathway was 
soon linked with several diseases states including those shown in figure 10 and has been a long 
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standing therapeutic target. In particular, the proteasome’s proposed role in activation of the 
transcription factor NF-κB (Palombella et al., 1994), a key regulator in the cell cycle, kick-started 
research for the potential of proteasome inhibitors in cancer treatment.  
Since malignant cells display characteristically rapid proliferation and genetic instability, the 
proteasome is a vital system required to remove any damaged proteins. Therefore inhibition of 
the proteasome will exhibit a more profound effect on cancer cells, compared to healthy, normal 
cells (Singh et al., 2010). Irregular elevated levels of immunoglobulins and lymphocytes in multiple 
myeloma (MM) and mantle cell lymphoma (MCL) respectively make these diseases amenable to 
proteasome inhibitors, with 3 currently food and drug administration (FDA) approved for 
treatment by selectively destroying immunoglobulin-producing plasma cells (Groll et al., 2006a). 
However, proteasome inhibitors that either reduce or stimulate cancer progression is often 
specific to the CP or IP as well as particular subunit upregulation or downregulation (Johnston-
Carey et al., 2015). IP levels are varied between different types of cancers, with little current 
understanding to the significance of downregulated levels. MM, lung and prostate cancer have all 
displayed high levels of the IP (Miller et al., 2013), therefore providing opportunities for a more 
targeted treatment if selectivity can be achieved. 
Beyond cancers, the proteasome also impacts the immune system partly because degraded 
peptides can act as antigens on the surface of immune cells through binding MHC class I receptors. 
Proteasome inhibitors therefore show potential in the treatment of autoimmune disorders such 
as arthritis (Muchamuel et al., 2009), colitis (Basler et al., 2010) and encephalomyelitis (Basler et 
al., 2014). Furthermore, other peptide fragments generated by the proteasome would be 
expected to retain some biological function that is currently unknown. 
More diverse applications are also under investigation such as anti-parasitics in malaria 
(Stadelmann et al., 2014; Li et al., 2016), anti-bacterials in tuberculosis (Hsu et al., 2017), crop 
protection agents (Citovsky et al., 2009), promotion of bone growth and treatment of male 
pattern baldness (Mundy et al., 2007); highlighting the diverse and complex pathways effected. As 
well as clinical benefits, the development of proteasome inhibitors continues to progress the 
understanding of the proteasome and the cells' intracellular functions (Kisselev et al., 2006). 
In disease states with increased demand for protein degradation, IP levels are raised as a coping 
mechanism. This phenomenon is observed in neurodegenerative diseases including Alzheimer’s 
(Mishto et al., 2006) and Huntington’s (Díaz-Hernández et al., 2003). IP levels can also be directly 
increased by the pro-inflammatory cytokine immune response to the disorder, as observed in 
Duchenne muscular dystrophy (Azakir et al., 2014; Chen et al., 2014; Farini et al., 2016) as well as 
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cancers. Interestingly, the activation of advanced-glycation-end-product receptors (RAGE), an 
Alzheimer’s hallmark, produces an alternative mechanism pathway for IP activation, distinct from 
IFN-γ (Grimm et al., 2012). Due to the upregulation observed in disease states, the IP has arguably 
emerged as a more attractive drug target over the CP that is abundant in all cells (Miller et al., 
2013). 
 
 
Figure 10 – Therapeutic potential of proteasome inhibition - Classes and examples of diseases and 
disorders for which proteasome inhibitors show therapeutic potential. Bold denotes that proteasome 
inhibitors are currently FDA approved for a form of treatment. 
Ultimately, with such diverse impacts and therapeutic potential, the proteasome is a powerful 
drug target.  However, IP over CP as well as active site selectivity is sought to potentially increase 
the therapeutic index. Between more diverse variants, species specific proteasome targeting over 
human proteasomes, has recently been achieved in Plasmodium falciparum (Li et al., 2016) as 
well as Mycobactirium tuberculosis (Hsu et al., 2017), through structural studies. In addition, 
despite few conserved changes, it has also been shown that human IP over CP selectivity is 
possible, although further investigation is required to bolster understanding on how to best 
achieve this (Kuhn et al., 2009; Huber et al., 2012). 
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1.4.4  Existing Proteasome Inhibitors 
 
Inhibitors of the proteasome began as simple peptide aldehydes, which crucially, did not denature 
cells nor prevent regular functioning, or cross the blood-brain barrier (Rock et al., 1994). Originally 
designed as analogues of chymotrypsin-like active site substrates; modifications of these peptide 
aldehydes soon developed more successful compounds such as MG132, a highly selective, potent, 
irreversible proteasome inhibitor (Lee et al., 1998). This subsequently led to the discovery of 
bortezomib and further classes of inhibitors outlined in table 2. 
Despite initial scepticism regarding toxicity and therapeutic efficacy, bortezomib gained FDA 
approval for MM treatment in 2003 after only phase II trials, and in 2006 for MCL treatment. By 
2012, bortezomib was the first line treatment for MM, with >400,000 patients using the drug 
worldwide and annual sales greater than a billion pounds (Goldberg, 2012).  However, common 
relapses and peripheral neuropathy remain issues associated with the treatment. Although 
bortezomib favours β5 inhibition, it does not discriminate greatly between the CP, IP or each 
active site and some off-target serine protease inhibition is observed (Groll et al., 2006a). New 
classes of inhibitors are in continued development with different modes of action aiming to 
overcome these issues. 
The second generation inhibitor carfilzomib gained FDA approval in 2012 for advanced MM 
(Siegel et al., 2012; Herndon et al., 2013) as well as relapsed and refractory MM combination 
therapies by 2016. This displays preference to β5 sites over β1 and β2, associated with lower 
toxicity; however it is not specific towards the CP or IP. 
In addition, the first orally available proteasome inhibitor, ixazomib was FDA approved in MM 
combination therapy in 2015, predominantly targeting the β5 site (Moreau et al., 2016). This acts 
as a prodrug shown in figure 11 that reveals the same boronate warhead group as bortezomib, 
but has a quicker dissociation of reversible binding.  
 
      
Figure 11 - Structures of FDA approved proteasome inhbitors – A) Bortezomib, B) Carfilzomib, C) Ixazomib. 
A) B) C) 
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Of existing proteasome inhibitors, the β5 site is most commonly blocked, although some also co-
target other sites (Beck et al., 2015). It has been shown that sensitivity to proteasome inhibitors 
can be enhanced by β1 or β2 selective inhibitors, to a greater extent than existing combination 
therapies (Geurink et al., 2013). This can be explained by resistance mechanisms such as 
mutations within the active site reducing binding affinity of inhibitors or overexpression of the 
effected subunits (Manansanch and Orlowski, 2017).  
Novel proteasome inhibitors are often created by altered peptide backbones to improve the 
compound’s interactions with the proteasome active sites (Micale et al., 2014). This is evident 
with carfilzomib as displayed in figure 11 where bulky and characteristic amino acid R-groups 
complements the specificity pockets of the active site. In some cases, non-natural amino acids can 
improve the potency (Geurink et al., 2013) and influence the pharmacokinetic drug properties. 
Since hydrophobic residues are more permeable to the cells, β5 selective drugs have shown 
greater success rate in development (Kisselev et al., 2006). Clinical trials are ongoing for 
oprozomib targeting β5 in haematological malignancies and marizomib targeting all active sites in 
a variety of cancers (Manansanch and Orlowski, 2017).  
As well as targeting the catalytic centre, it is worth mentioning the potential of alternative sites of 
inhibitor binding. Drugs focussed on targeting active site binding pockets and non-catalytic 
residues have shown pharmacokinetic benefits in comparison to directly blocking Thr1 (Beck et al., 
2015; Duibella et al., 2015). In addition, the 19S subunits contain multiple targets for drug 
interaction that can impact the recognition and acceptance of proteins for degradation (Kisselev 
et al., 2012). In addition, the molecular pathways involved in the formation of the CP and IP are 
potential targets undergoing investigation.  
The success of existing proteasome inhibitors validates the potential of the proteasome as a drug 
target, although further investigations are required to improve on current compounds. A key 
strategy to ameliorate side effects is to target only the proteasome over other proteases and it 
has also been shown that cytotoxicity in MM cell lines correlates with loss of active site specificity 
(Gräwert et al., 2012; Geurink et al., 2013). Therefore IP and active site selective compounds are 
sought after.   
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1.4.5  Immunoproteasome inhibitors 
 
Given the proposed therapeutic benefits of IP selective inhibitors, discussed in 1.4.3  Therapeutic 
potential, this has become a focus for many leading research groups. Most existing proteasome 
inhibitors block the active sites of both the CP and IP at similar potencies. However, a significant 
recent advancement within the field has been the identification of structural differences in the 
binding pockets of CP versus IP (Huber et al., 2012). This has led to structure-based design of IP 
inhibitors that show a greater affinity to the substituted residues within IP active sites over 
corresponding CP sites. Basic, characteristic changes are summarised in figure 6.  
Carfilzomib inhibits both β5c and β5i at similar potencies although interestingly, further studies 
with β5c knockout in lymphoma cell lines retained a similar potency; suggesting therapeutic 
effects of β5i inhibition alone (Singh et al., 2010; Miller et al., 2013). From this, investigations into 
epoxyketone derivatives produced PR-924 with up to 250-fold selectivity towards β5i over β5c 
(Huber et al., 2016; Parlati et al., 2016). With this available, testing the β5i selective PR-924 on 
normal cells did not induce apoptosis suggesting a method for targeting only diseased cells (Singh 
et al., 2010). Ho et al. (2007) and Kuhn et al., (2009) also researched synthetic compounds to 
selectively inhibit β1i and showed sufficient potency to trigger cell death with in vivo mouse and 
in vitro hematologic malignancies. However in contrast, Parlati et al. (2009) showed reduced 
effect of IP selective compounds alone on malignant cells. Key pathways such as those outlined in 
figure 9 were not triggered, compared to use in combination with β5c inhibitors or inhibitors 
targeting all active sites. PR-957 is another epoxyketone with up to 20-fold greater inhibition at 
β5i over β5c (Huber et al., 2016).  
Whilst most inhibitors in development continue to target β5, there are β1 (Ho et al., 2007; de 
Bruin et al., 2014) and β2 (Geurink et al., 2013; Koroleva et al., 2015) selective inhibitors showing 
that active site specificity is possible despite few structural changes. Although there is also the 
added complexity from allosteric effects on β5 sites occasionally observed (Ho et al., 2007). 
From PR-957 and PR-924, research groups have successfully improved potency and selectivity of 
new, synthetic compounds through structure-based design (de Bruin et al., 2014; Duibella et al., 
2014). Furthermore the successful approaches have been further applied to different compound 
backbones and warhead groups (Fan et al., 2014). This includes non-peptide (Groll et al., 2015; 
Sosič et al., 2016) and non-covalent (Koroleva et al., 2015) compounds exhibiting IP selective 
inhibition. New avenues targeting away from the active site are also being investigated, revealing 
influential roles of previously overlooked residues. For example, a conserved, non-catalytic Cys48 
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in β5i has been successfully targeted with altered inhibitor P3 groups combined with ligand 
stabilisation at S3 pockets (Duibella et al., 2015).  
Overall, there is an expanding wealth of knowledge, with proven success that is facilitating the 
design of IP and active site selective compounds in a diverse range of inhibitor classes. Many 
resulting compounds have further supported the association of improved therapeutic index on 
account of targeting IP diseased state cells. As previously discussed in section 1.4.1  Classes of 
proteasome inhibitors, non-covalent compounds show many favourable properties as 
proteasome inhibitors although, there is currently little research on the area (Bellavista et al., 
2013). 
 
1.5  Non-covalent proteasome inhibitors 
1.5.1  Existing non-covalent proteasome inhibitors 
 
Recent research has been orientated towards development of non-covalent inhibitors lacking a 
reactive group that instead display weaker intermolecular interactions and reversible inhibition. 
Intermolecular interactions, particularly hydrogen bonding, allow for the inhibitor to stabilise 
within the active site. Whilst specificity pockets allow selective interaction for the proteasome 
over proteases, as well as particular active sites (Lee and Goldberg, 1998). The catalytic Thr1 is not 
necessarily directly blocked; instead reducing the ability of the substrate to bind achieves 
proteasome inhibition. Known examples are summarised in table 3. 
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Table 3 - Current non-covalent proteasome inhibitiors – Details of class, general structure, bonding interactions and origin of example non-covalent inhibitors. 
Class Structure Non-covalent Bonding Compounds Origin 
Cyclic 
peptides 
 
 
 
Hydrogen bonds and Van der Waals interactions at S1-4 pockets 
surrounding Thr1 
Argyrin A (R2 = CH3) (Nickeleit et al., 
2008)  
Naturally derived from 
myxobacterium 
 Argyrin F (R2 = CH2OH)(Bülow et al., 
2010)  
 
 
 
 
Hydrogen bonds and Van der Waals interactions at S1-4 pockets 
surrounding Thr1 
 
 
 
 
Hydrophobic interactions at S1 pocket 
 
 
TMC-95A (Groll et al., 2006c)  
 
 
 
 
Scytonemide A&B (Krunic et al., 2010)  
 
 
Naturally derived from apiospora 
 
 
 
Naturally derived from 
cyanobacterium 
Non-cyclic 
peptides 
 
 
Occupy S1-4 pockets 
C- and N- terminally capped dipeptides 
(Blackburn et al., 2010) 
 
Synthetic 
 
 
 
Non-peptide 
inhibitors 
 
 
 
 
 
 
 
 
 
 
Occupies S1 and S3 pockets, not Thr1 directly 
 
 
Van der Waals, hydrophobic and hydrophilic interactions. Single polar 
interaction. 
 
 
 
Targeting only S3 pocket of B5 site 
 
Modified hydroxyurea (Gallastegui et al., 
2012) 
 
Sulphonamide 
Compound 4 (Beck et al., 2015) 
 
 
 
Compound 4 indolo analogue of 
dibromophakellin (Beck et al., 2015)  
 
Synthetic 
 
 
 
Synthetic 
 
 
 
Natural – based on pentacyclic 
alkaloid 
Allosteric 
inhibitors 
Proline-arginine rich peptide 
 
 
Non-competitive binding to α7 subunit 
 
 
 
Non-competitive binding to α7 subunit, possible metabolite binding β-
sites simultaneously 
PR-39, PR-11 (Gaczynska et al., 2003) 
 
 
 
5-amino-8-hydroxyquinoline (Li et al., 
2010) 
Naturally derived from porcine 
bone marrow 
 
 
Synthetic 
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TMC-95A is a naturally derived, cyclic tripeptide that inhibits all CP active sites and shows a slight 
preference towards β5c. The inhibitor does not undergo any conformational changes when non-
covalently binding, providing favourable entropy. Despite displaying lower potency, structural 
based optimisation can be used to enhance binding affinity in synthetic analogues, as 
demonstrated by (Groll et al., 20006c, 2010). Argyrin A is also a cyclic peptide, although formed of 
8 amino acids. These display well characterised anti-tumour effects through binding all active sites 
of the CP (Nickeleit et al., 2008, Loizidou and Zeinalipour-Yazdi, 2014). In addition, smaller, non-
cyclic peptides have shown strong inhibition. From high throughput screening, (Blackburn et al., 
2010) identified a C- and N- terminally capped tripeptide, subsequently optimised to develop 
potent, non-covalent, di-peptide proteasome inhibitors as shown through x-ray crystallography. 
Other non-covalent inhibitors show non-competitive modes of action, in some cases binding far 
from the active site on alpha subunits proposed to cause conformational changes and disrupt 19S 
interaction (Gaczynska et al., 2003, Li et al., 2010).   
Overall, a diverse class of inhibitors vary in binding mode and origin, with a mixture of peptide, 
non-peptide, natural and synthetic compounds showing non-covalent, yet potent inhibition. 
Understanding the energetically favourable interactions and orientations associated with 
specificity will help to facilitate development of future inhibitors.  
 
1.5.2  The argyrin family 
 
Naturally derived products have been successful contributors to cancer therapeutics, including 
proteasome inhibitors, with several outlined in table 2-3. Furthermore, although many 
compounds have been synthetically optimised, these originated from natural sources such as 
microbial metabolites (Gräwert et al., 2012). Recently, the argyrin A-F cyclic peptides, derived 
from the myxobacterium Archangium gephyr, have emerged as an exciting family of compounds 
(Sasse et al., 2002). Subtle differences in structure between analogues are shown in figure 12. 
These cyclic peptides have been identified as proteasome inhibitors that target all 3 active sites, 
with varying potencies (Bülow et al., 2010).  
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Argyrin R1 R2 R3 R4 
A H CH3 H OCH3 
B CH3 CH3 H OCH3 
C H CH3 CH3 OCH3 
D CH3 CH3 CH3 OCH3 
E H CH3 H H 
F H CH2OH H OCH3 
G CH3 CH2OH H OCH3 
H H H H OCH3 
 
Figure 12 - Structure of argyrin analogues A-H – Table represents R group variants amongst different 
analogues (Adapted from: Vollebrecht et al., 2002). 
 
Interestingly, the anti-tumour activity of argyrin A and F is non-covalent CP inhibition dependent 
on p27kip1 expression. This is distinct from existing bortezomib treatment that acts through 
inhibitory kappa B alpha (IκBα) stabilisation. Therefore may offer a novel molecular pathway 
effect that can help overcome resistance. Furthermore, the reduced vascular endothelial growth 
factor (VEGF) expression from argyrin A treatment has anti-angiogenic properties leading to loss 
of endothelial cell adherence, to target tumour vascularisation (Nickeleit et al., 2008). These 
effects were shown in purified proteasomes, multiple cell lines and xenograft tumours. Gene 
expression profiling in MCF7 cells revealed argyrin A treatment to affect approximately 500 genes, 
all related to the proteasome. In comparison, bortezomib treatment resulted in 10900 genes with 
altered expressions, including effects beyond the proteasome (Nickeleit et al., 2008). The targeted 
action of argyrin A is therefore promising for drug development with lower cytotoxic effects. In 
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addition, a different mode of action can overcome relapsed and refractory cancer patients where 
resistance has been developed. 
Following these findings, argyrin F was identified to have even more pronounced anti-tumoural 
activities, in the same manner as argyrin A (Bülow et al., 2010). Recent studies show argyrin F as a 
potential combination therapy treatment for pancreatic adenocaracinoma. In vitro human cell 
line studies and in vivo mouse models revealed reduced cell proliferation due to dose and time 
dependant upregulation of tumour suppressor cyclin kinase inhibitors p27kip1 and p21waf1/cip1, 
alongside a reduction in cell migration, invasion, angiogenesis and tumour growth (Chen et al., 
2017). 
The ability of argyrins A and F to exhibit biological activity at low concentrations, with targeted 
actions, distinct molecular pathways and proven anti-cancer effects in vitro and in vivo; make 
these naturally derived analogues promising therapeutics. To date, remaining analogues have not 
yet received further investigation as proteasome inhibitors and none have been tested with the IP. 
 
1.5.3  Argyrin B 
 
Differing from argyrin A, analogue B possesses an α-amino butyric acid in place of alanine, 
creating an additional methyl group extension. The same is observed in comparison to argyrin F, 
although this also contains an additional hydroxyl group at R2 (Vollbrecht et al., 2002), as shown 
in figure 12. With similar structures it is therefore likely that argyrin B exhibits closely related 
mechanisms to its analogues.  
Argyrin B was initially discovered in screening for antibiotics and has displayed some antibacterial 
as well as antifungal activities. In human B cells, argyrin B exhibits immunoglobulin G (IgG) 
inhibition which combined with murine studies showing reduced activity of T and B lymphocytes, 
shows strong immunosuppressive effects of the compound (Sasse et al., 2002). This area has 
received greater attention recently with further antibacterial activity and associated mechanisms 
outlined (Jones et al., 2017). Despite the promising actions of analogues A and F as proteasome 
inhibitors, there is little research on argyrin B in this role. Only basic percentage remaining activity 
from purified CP and colon cancer (SW-480, HCT116) cytotoxicity assay data is known (Bülow et 
al., 2010).  
With few cyclic peptides and non-covalent inhibitors researched as proteasome inhibitors as well 
as no current investigations into argyrin action at the IP, there remains a gap in current research. 
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Argyrin B is a promising compound for further investigation as a CP and IP inhibitor. Furthermore, 
with crystal structures available there is the opportunity for computational structural studies such 
as molecular docking. 
 
1.6  Approaches for investigating proteasome inhibitors 
1.6.1  Laboratory based inhibition studies  
 
Proteasome activity assays are important tests for the efficacy and specificity of compound 
inhibition. These can be performed as purified assays or in cell lines and there are a wide range of 
fluorogenic substrates available that are designed to be specific at particular active sites. Typically 
substrates are short peptides attached to a fluorescent component that becomes cleaved upon 
binding the catalytic site (Kisselev and Goldberg, 2005). The release of free fluorogenic substrate, 
detectable at particular wavelengths, is then proportional to the activity of the enzyme. To 
achieve an overall view of inhibition it is required to measure activity at each active site. These 
assays can be performed with commercially available purified 20S CP or IP, and is a common 
approach used, as outlined in table 22. This allows a variety of kinetic tests that can establish 
inhibitor potency and actions. Tests in cell lines with fluorogenic substrates incur additional 
challenges to allow the substrate access to the proteasome (Harris et al., 2001). Commonly cells 
are lysed and the 26S proteasome is broken down, losing the 19S cap. Therefore a complete 
picture of cellular interactions is difficult to model with fluorogenic substrates.  
To overcome this, it is possible to use chemical proteasome probes to measure activity in live cells 
or their lysates (Berkers et al., 2005). Probes containing a potent inhibitor are able to covalently 
bind Thr1. The attached motif can then be detected using antibodies in enzyme linked immuno 
sorbent assay (ELISA) methods (Kuhn et al., 2009). Alternatively fluorescent motifs can be 
visualised or analysed with flow cytometry, allowing tests at different stages of the cell cycle 
(Muchamuel et al., 2009). Using cell based assays it is also possible to measure proteasome 
activity in vivo. Proteasome substrates with a ubiquitin and fluorescent tag, such as green 
fluorescent protein (GFP) or luciferase, can enter the cell and undergo degradation, thereby 
reducing fluorescence (Dantuma et al., 2000). Upon inhibition of the proteasome, the GFP and 
luciferase remain present and produce intracellular fluorescence. However, using this method is 
difficult to account for possible degradation through other mechanisms.  
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With established inhibition, crystallisation of compound and proteasome complexes can reveal 
details of the binding mode. This will help to elucidate specific residues that the inhibitor binds or 
interacts with and plays a key role in facilitating understanding of inhibitor selectivity. As well as 
laboratory methods, computational modelling can be used to predict binding of the inhibitor and 
screen libraries of compounds.  
 
1.6.2  Computational methods 
 
The CP can be purified from erythrocytes, and crystal structures have recently been elucidated in 
humans (Harshbarger et al., 2015, Huang et al., 2016). However, difficulties in isolating IP due to 
their induced formation means that human IP crystal structures have not yet been produced with 
only yeast and mice IP crystal structures available (Huber et al., 2012). Homology models can be 
used, for example humanised IP structures through sequence substitution of human amino acid 
sequences with existing yeast structural data. This approach has been successfully used to model 
drug interactions at human IP active sites (Bellavista et al., 2013, Loizidou and Zeinalipour-Yazdi, 
2014). 
With structural data of the enzyme and active site, a variety of computational software can be 
used to model proteasome-ligand interactions. Although not as accurate as generating 
crystallisation data with the enzyme and compound, molecular docking can be a useful tool for 
indications of binding modes and interactions. 
Molecular modelling approaches simulate the enzyme and ligand binding; predicting the most 
energetically favourable pose of interaction. Various algorithms can predict binding energy, 
thereby affinity for multiple conformations and orientations on the target. Most docking tools are 
able to identify non-covalent interactions, including hydrogen bonding, Van der Waals forces and 
electrostatic interactions, with associated scoring functions. Whilst some are also capable of 
covalent docking where the ligand and target undergo a reaction to establish a bond (Jones et al., 
1997). 
Overall, molecular docking has been proven as a valuable resource in drug design and 
development, including applications to inhibitors of the proteasome. With human CP and murine 
IP structures now available, it is becoming an increasingly used research tool. However, it is 
important to note that scoring functions have proven inconsistent between different software 
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and in comparison to laboratory studies (Chen, 2015). It is therefore preferable that molecular 
docking is used to supplement laboratory research. 
 
1.7  Aims 
 
This project investigates the inhibitory effect and specific interactions of argyrin B at each active 
site of the CP and IP, with the aim of identifying factors that confer IP over CP selectivity. This can 
be achieved through the following sub aims: 
- Establish argyrin B inhibitory activity of the CP and IP, testing at β1 and β5 active sites using in 
vitro assays of purified 20S proteasome. 
- Determine argyrin B IC50 and inhibition constants at β1 and β5 active sites of the CP and IP. 
- Develop a suitable homology model of human IP active sites for use in molecular docking. 
- Predict molecular interactions of argyrin B at each active site of the CP and IP, through 
molecular docking simulations. 
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Chapter 2.  Methods 
2.1  Laboratory methods 
2.1.1  Materials 
 
The following reagents and materials outlined in table 4-5 were used for enzymatic assays. 
Table 4 - Proteasome and immunoproteasome buffer contents and concentrations. 
Name Constituents Concentration 
Proteasome assay buffer, pH 7.5 
 
(BML-KI340-0020, Enzo Life Sciences, Exeter, UK) 
Tris/HCl 50 mM 
KCl 25 mM 
NaCl 10 mM 
MgCl2 1 mM 
SDS 0.03% (w/v) 
20S proteasome (purified human erythrocyte) 
enzyme, 1 mg/ml in buffer (see right), pH 7.2 
 
(BML-PW8720-0200, Enzo Life Sciences, Exeter, UK) 
Tris/HCl 20 mM 
EDTA 1 mM 
DTT 1 mM 
Sodium azide 1 mM 
20S immunoproteasome (purified human) enzyme, 
0.5 mg/ml in TEAD buffer (see right), pH 7.4 
 
(BML-PW9645, Enzo Life Sciences, Exeter, UK) 
Tris/HCl 20 mM 
DTT 1 mM 
Sodium azide 1 mM 
 
Table 5 - Laboratory reagents and materials. 
Consumable name Details Product number 
96 well microplates ½ volume NBS, white 80-2406, Enzo Life Sciences, Exeter, UK 
AMC Standard 7-amino-4-methylcoumarin BML-KI122-0014, Enzo Life Sciences, Exeter, UK 
Argyrin B C41H46N10O8S, MW 838.9Da Donation from Novartis, Surrey, UK 
β1c substrate Z-Leu-Leu-Glu-AMC BML-ZW9345, Enzo Life Sciences, Exeter, UK 
β1i substrate Ac-Pro-Ala-Leu-AMC S-310, BioTechne, Abingdon, UK 
β5c substrate Suc-Leu-Leu-Val-Tyr-AMC BML-P802-9090, Enzo Life Sciences, Exeter, UK 
β5i substrate Suc-Leu-Leu-Val-Tyr-AMC BML-P802-9090, Enzo Life Sciences, Exeter, UK 
DMSO Dimethyl sulphoxide BP231-1, Fisher Scientific, Loughborough, UK 
Epoxomycin C28H50N4O7, MW 554.7g/mol BML-PI127-9090, Enzo Life Sciences, Exeter, UK 
Methanol MeOH, HPLC grade 99% 268280025, Acros Organics, Loughborough, UK 
SDS Sodium dodecyl sulphate BML-KI341-0012, Enzo Life Sciences, Exeter, UK 
Vinyl sulfone Ada-(Ahx)3-(Leu)3-vinyl sulfone BML-AW9155, Enzo Life Sciences, Exeter, UK 
 
 
Substrate and inhibitor reagents were dissolved in dimethyl sulphoxide (DMSO) for stock solutions 
and subsequently diluted in proteasome assay buffer to desired concentrations. Although 
required for compound solubility, DMSO levels were minimised to reduce any potential toxic 
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effects. Specific concentrations used in purified assays are outlined in supplementary table 1. 
Assay reagents were added to 96-well plates to a final volume of 50 µl per well, throughout. 
Concentrations of CP and IP were maintained constant at 0.1 µg/well, whilst inhibitor and 
substrate were varied according to kinetic parameters tested. A 7-amino-4-methylcoumarin (AMC) 
standard was prepared from a 1:2 serial dilution of 8 µM to 0.25 µM and blank. 
 
2.1.2  Purified enzymatic assays 
 
Purified assay positive controls were performed through the reaction of CP or IP enzyme with 
active site specific substrates: Z-LLE-AMC (β1c), Ac-PAL-AMC (β1i) and Suc-LLVY-AMC (β5c/i). The 
liberation of AMC was measured over time using a BMG Labtech fluorescence plate reader set at 
355/460 nm (excitation/emission). 
For inhibitor analysis, argyrin B was incubated with the enzyme at 37 ᵒC, for 10 minutes prior to 
substrate addition and maintained at this temperature throughout the reaction. A range of 
inhibitor and substrate concentrations were used to determine Km, IC50 and Ki values. Negative 
controls performed for each assay were low concentrations of epoxomycin and vinyl sulfone; 
potent inhibitors of β5c/i and β1c/i active sites, respectively. Blanks were performed with 
substrate only and additional controls for solvent (DMSO) concentration were used where 
applicable.  
Tests were run for at least one hour and 50 reading cycles. An appropriate gain was set according 
to background fluorescence and the speed of reaction, to ensure the equipment’s detection limit 
of 250,000 was not met within an hour of running. A summary of the assay process, including 
plate reader settings are provided in figure 13. 
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Figure 13 – Purified kinetic assay method flowchart - Using 20S proteasome enzyme, subunit specific 
substrates (Z-LLE-AMC, Ac-PAL-AMC & Suc-LLVY), argyrin B inhibitor and controls of epoxomycin or vinyl 
sulfone. 
 
 
Using 0.1 µg/well of enzyme, a range of at least 7 substrate concentrations each in triplicate, were 
used to generate Michaelis-Menten plots for Michealis-Menten constant (Km) analysis at each 
active site. Subsequent Km values were used as the single substrate concentration in IC50 plots that 
covered a logarithmic range of at least 10 argyrin B concentrations. 3 independent repeats were 
performed for each IC50 active site assay. For kinetic assays to determine inhibition constant (Ki), 4 
concentrations of inhibitor were used, each at 5 different substrate concentrations. Argyrin B 
concentrations ranged from estimated IC50 value (β1c = 183.7 µM, β1i = 10.4 µM, β5c = 11.4 µM, 
β5i = 10.3 µM) x 0, 0.33, 1 and 3, whilst substrate concentration covered Km (β1c = 95.4 µM, β1i = 
69.9 µM, β5c = 72.4 µM, β5i = 89.8 µM) x 2.5, 1.25, 0.625, 0.3125 and 0.15625.   
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2.1.3  Data analysis and statistics 
 
Each test was performed with triplicates at every control and concentration variant, whilst AMC 
standards were in duplicate. Firstly, values for substrate only blanks were subtracted from 
corresponding substrate concentration data. An AMC standard curve was produced to convert all 
data from fluorescence, into product concentration. DMSO correction was performed where 
equivalent concentrations to those from argyrin preparation elicited an effect compared to 
control. For each replicate, the initial rate of reaction was determined from the linear phase of 
the graph at which less than 10% of substrate had been consumed.  
Using GraphPad Prism 6 software, non-linear curve fitting analysis was used for calculation of Km, 
IC50 and Ki values. The preferred model to determine Km was a Michaelis-Menten plot, based on 
equation 1 where ‘y’ represents initial velocity and ‘x’ refers to substrate concentration. Graphs 
are depicted with average values, displaying the standard error of mean (SEM), calculated from 3 
replicates. To enhance statistical accuracy of all non-linear analysis, the degrees of freedom were 
increased by treating all replicates as individual points rather than a single average value. 
 
Equation 1 – Michaelis-Menten model – Equation fit used in GraphPad analysis. 
𝒀 =
𝑽𝒎𝒂𝒙 ∗ 𝑿
(𝑲𝒎 + 𝑿)
 
 
For IC50 analysis, velocities were expressed as a percentage of control values with an expected 
range from approximately 100% to 0%. As such, a normalised response curve was fit against 
logarithmic inhibitor concentration. A variable slope function was allowed, fitting a hill slope 
determined from the data with analysis based on equation 2. Data were reported with mean, SEM 
and 95% confidence interval. 95% confidence was determined as the mean plus and minus 2.306 
times the standard error of mean; based upon the 2-tailed inverse student’s t-distribution test 
with 9 degrees of freedom. Graphpad analysis or Excel syntax ‘=T.INV.2T(0.05,N-1)’ was used for 
any variation in degrees of freedom.     
Equation 2 – IC50 analysis equation fit - Model for log(inhibitor) vs normalised response - variable slope.  
𝒀 =  
𝟏𝟎𝟎
(𝟏 + 𝟏𝟎((𝑳𝒐𝒈𝑰𝑪𝟓𝟎−𝑿)∗𝑯𝒊𝒍𝒍𝑺𝒍𝒐𝒑𝒆)))
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A standard, unpaired, t-test shown in equation 3 (Spence, 1976), analysed significance between 3 
IC50 value repeats of argyrin B at different active sites. A 95% confidence level was estimated for 
the difference between the means and assigned a probability value, deemed significant if p<0.05.     
 
Equation 3 - Standard t-test between IC50 values – Used between different active sites and CP vs IP analysis. 
Calculated from 3 independent repeats with associated standard error. 
𝒕 =  
𝑰𝑪𝟓𝟎𝑨 − 𝑰𝑪𝟓𝟎𝑩
√𝑺𝑬𝑨
𝟐 + 𝑺𝑬𝑩
𝟐
 
 
To determine Ki values, tests were first performed to determine the best-fit model between: 
competitive, non-competitive, uncompetitive and mixed inhibition. To distinguish between 
competitive and other models, the graphical representation alongside Km and Vmax values were 
used. Additionally, for a more quantifiable measure, Akaike’s information criterion (AICc) was 
used to select the most suitable model (Motulsky and Christopolous, 2003). For each model, the 
AICc is calculated based upon the sum-of-squares that measures goodness of fit, and degrees of 
freedom.  In the case of 2 nested models whereby one is a special case of the other, for example 
non-competitive and mixed inhibition, an extra sum of squares F test can also be used. Further to 
the AICc test, the F test hypothesis testing approach was used to determine statistical significance 
at p<0.05. Here, unless p=<0.05, the simpler model was chosen. 
Once the most suitable model was defined, simultaneous non-linear regression (SNLR) analysis 
was performed with the relevant Michaelis-Menten derived regression analysis formulae and 1/y2 
weighting applied. Estimates of the inhibition constant Ki were reported with SEM and 95% 
confidence intervals.  
In addition to SNLR analysis, equivalent analysis methods were used to further validate 
calculations. Dixon plots of 1/v against [I], combined with Cornish-bowden plots of [S]/v against [I], 
allowed for determination of inhibition modality as well as a Ki estimation. In addition, the y-
intercepts from Woolf plots of [S]/v against [S], produced values for Km/Vapp. An additional plot of 
Km/Vapp against [I] subsequently yields a Ki value from the x-intercept. Analysis was performed 
using Microsoft Excel linear regression and errors from ‘LINEST’ function.     
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2.2  Computational methods 
2.2.1  Software 
 
The computational software and websites used have been summarised in table 6.    
Table 6 - Computer software and websites. 
Software Source 
AutoDock (v4.2.6) The Scripps Research Institute (California, USA) (Morris et al., 2009) 
http://autodock.scripps.edu 
AutoDockTools (v1.5.6) The Scripps Research Institute (La Jolla, USA) http://mgltools.scripps.edu 
Avogadro (v.1.2) Avogadro Chemistry (Hanwell et al., 2012) 
http://avogadro.openmolecules.net  
ChemDraw (v14.0) Perkin Elmer Informatics (Cambridge, US) 
EMBL-EBI Clustal Omega European Bioinformatics Institute (Hinxton, UK) (McWilliam et al., 2013) 
http://www.ebi.ac.uk/Tools/msa/clustalo/ 
GraphPad Prism 6 GraphPad Software (La Jolla, USA) (GraphPad 6.04, 2014) 
www.graphpad.com 
Minitab 17 Minitab Ltd (Coventry, UK) (Minitab 17.1.0, 2013) 
Open Eye Scientific Software-  
OEDocking FRED (v3.2.0.2) 
http://www.eyesopen.com (Santa Fe, NM) (McGann, 2012) 
PyMol (v1.7.4.5) Schrodinger LLC (Delano et al., 2002)  https://www.pymol.org 
RSCB Protein Data Bank Research Collaboratory for Structural Bioinformatics (Berman et al., 2000) 
http://www.rcsb.org 
SwissPDB viewer (V.4.10) Swiss Institute of Bioinformatics (Guex and Peitsch, 1997) 
http://spdbv.vital-it.ch/ 
UniProt UniProt consortium (2014) (UK, CH, USA) http://www.uniprot.org/ 
 
 
2.2.2  Structural data preparation 
 
All 3-dimensional structures were obtained from open access to RCSB Protein Data Bank (PDB) 
and prepared using the molecular graphics package PyMOL (v1.7.4.5). An argyrin B structure was 
isolated from PDB:4FN5 (Nyfeler et al., 2012) and energetically optimised to a stable structure 
using Avogadro (Hanwell et al., 2012). Bonds connecting the tryptophans to the cyclic ring, as well 
as the Trp2-OMethoxy bond were allowed rotational freedom, as shown in figure 14. 
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Figure 14 – Chemical structure of argyrin B - Displaying rotatable bond positions when used in AutoDock 
modelling simulations. 
 
The Human constitutive 20S proteasome structural data was available from PDB:4R3O 
(Harshbarger et al., 2015). All active sites were cut for residues within 28 Å from the catalytic Thr1 
position of the active subunit chain which includes overlap into neighbouring chains, as shown in 
figure 15. β1, β2 and β5 cuts were all taken from the same β-ring on the same monomer. Any 
charged iodide, potassium and chloride ions as well as waters were removed from the structures 
for compliance with the modelling software. 
IP structural data was obtained from PDB:3UNH (Huber et al., 2012) murine IP and subsequently 
modified in order to create a humanised IP model. Active site cuts were initially prepared as 
previously described for the CP. Human active site IP sequences β1i, β2i and β5i (UniProt: P28065, 
P40306, P28062, respectively) were aligned to murine IP FASTA sequences using EMBL-EBI 
ClustalOmega, EMBOSS Smith-Waterman alignment algorithm. Utilising the amino acid mutation 
utility of SwissPDB viewer (v.4.10) individual amino acid substitutions were performed from 
murine IP structural data to corresponding human IP active subunit sequences. 
Further sequence similarity comparisons were performed using basic local alignment search tool 
(BLAST) with the blastp algorithm and visualised alignments were produced using PyMOL 
functions. 
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2.2.3  AutoDock simulations 
 
AutoDock (v.4.2.6) in conjunction with AutoDockTools (v.1.5.6) were used to simulate argyrin B 
binding (Morris et al., 2009). In each case, ‘PDBQT’ files were created for both the ligand and 
macromolecule. The grid box was set at 70x, 70y, 70z dimensions, positioned at the Thr1 co-
ordinates on the active subunit chain, before performing an Autogrid simulation. All co-ordinates 
of Thr1 catalytic centres are summarised in supplementary table 3. The large grid box size, shown 
in figure 15 allows the possibility of allosteric binding. The macromolecule was set with a rigid 
filename and genetic algorithm with 50 runs for each test as well as further parameters 
summarised in supplementary table 2. A Lamarckian genetic algorithm (4.2) output was set and 
run through AutoDock. The final file was analysed displaying the different binding energetics at 
the 50 different conformations. The conformation with the lowest binding energy from each test 
was selected for further analysis of interactions. Each active site was run for a minimum of 10 
repeats with 50 conformations per test. From the transition of unbound to ligand-protein bound 
states, predictions of binding energy and Ki values are generated.  These are based upon 
intermolecular interactions including: electrostatic interactions, Van der Waals forces, hydrogen 
bonding and desolvation energy (Morris et al., 2009).  
 
Figure 15 – Active site cut grid box size and subunit chains – Left; size of 70x-70y-70z grid box centred at 
Thr1 of β5c active site cut. Right; colours representing different chain active site subunits from β5c cut. 
 
In order to validate the docking model, docking pose predictions required comparison against 
experimental data. To achieve this, a molecule similar to argyrin B was chosen, that also has 
crystallised, structural data available. PDB:1JD2 provides crystallisation studies of the non-
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covalent, cyclic peptide TMC-95A in complex with the yeast 20S proteasome where binding is 
observed at β2 sites. Pose predictions from AutoDock simulations were compared to crystal 
structures, testing the frequency of similar poses. Structural preparation and docking settings 
followed the same aforementioned procedures with grid box coordinates shown in 
supplementary table 3 and 5 repeats performed of 50 runs each. 
 
2.2.4  FRED Docking 
 
Tests were performed to compare interactions from AutoDock simulations, run using alternative 
software, OEDocking FRED (v.3.2.0.2) (McGann, 2012). Identical 28 Å active site cuts to those 
previously used were prepared with the grid box originating from the Thr1 position at a 
corresponding size. Argyrin B was docked using an exhaustive search algorithm, with 100 poses 
using the argyrin B conformation from AutoDock simulation best-fit at each corresponding active 
site. Following the exhaustive search at different ligand rotations and conformations, the top 
scores undergo further optimised searches and are scored using Chemgauss4 that accounts for 
shape interactions and hydrogen bonding.   
 
2.2.5  Statistical analysis 
 
The binding energy estimations produced from AutoDock simulations were compared between 
active sites of both the CP and IP. From each set of 10 replicate best binding energies, the data 
were tested for normality where those with p>0.05 show normal distribution. For normally 
distributed sets, equal variance was tested between each active site. A 2-sample t-test was used 
for those of equal variance, whilst a non-parametric Mann-Whitney test was used for results not 
of equal variance, to test for significance. Generated p-values of <0.05 show statistical difference, 
whilst >0.05 are not statistically significant.  
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Chapter 3.  Results 
3.1  Purified enzymatic assays 
3.1.1  Solvent toxicity 
 
DMSO is required in preparation of stock solutions for solubility of compounds, as shown in 
supplementary table 1. As levels of DMSO remain present in the final reaction, the toxic impact of 
DMSO solvent alone was tested at the CP and IP. 
 
 
 
Figure 16 – Effect of solvent on CP rate of reaction –  Increasing DMSO and methanol solvent concentration 
on a logarithmic scale, against the percentage of control CP reaction rate. β1c purified assay with Z-LLE-
AMC substrate. Non-linear regression analysis fit with normalised response and variable slope. Data 
presented as average with standard error bars.  
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In addition, the impact of methanol was tested as a potential alternative solvent. Figure 16 shows 
a slightly lower impact of DMSO compared to methanol and no impact on CP activity at 1% or 
below. At higher levels, the solvents each reduced the rate of reaction significantly. However, IP 
tests shown in supplementary figure 1 reveal a greater sensitivity of the IP to DMSO exposure 
with concentrations above 0.5% showing a reduction in rate. Therefore subsequent CP tests 
containing a final DMSO percentage greater than 1% and IP tests with DMSO greater than 0.5% 
require additional DMSO control tests to account for the toxic effect of the solvent.  
 
3.1.2  Km values 
 
Michaelis-Menten plots at β1c, β1i, β5c and β5i are represented in figure 17 and summarised with 
statistics in table 7.
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Figure 17 – Michaelis-Menten plots to determine Km at each active site – Average velocity and SEM error bars at range of substrate concentrations, A. β1c Z-LLE-AMC, B. β1i Ac-
PAL-AMC, C. β5c Suc-LLVY-AMC, D. β5i Suc-LLVY-AMC.  Non-linear Michaelis-Menten analysis generated Km values: β1c = 95.4 µM, β1i = 69.9 µM, β5c = 72.4 µM, β5i = 89.8 µM.  
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0 .0 0 0
0 .0 0 2
0 .0 0 4
0 .0 0 6
0 .0 0 8
 1 c  s u b s tr a te  c o n c e n tra t io n  (M )
V
e
lo
c
it
y
 (

M
/m
in
)
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0 .0 0
0 .0 1
0 .0 2
0 .0 3
0 .0 4
0 .0 5
 1 i s u b s tra te  c o n c e n tr a t io n  ( M )
V
e
lo
c
it
y
 (

M
/m
in
)
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0 .0 0
0 .0 4
0 .0 8
0 .1 2
0 .1 6
 5 c  s u b s tr a te  c o n c e n tr a t io n  ( M )
V
e
lo
c
it
y
 (

M
/m
in
)
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0 .0 0
0 .0 1
0 .0 2
0 .0 3
0 .0 4
 5 i s u b s tra te  c o n c e n tr a t io n  ( M )
V
e
lo
c
it
y
 (

M
/m
in
)
A. B. 
C. D. 
 
 
53 
 
Table 7 - Summary of Km values at β1 and β5 sites of CP and IP. 
 β1c β1i β5c β5i 
Km (µM) 95.4 69.9 72.4 89.8 
SEM 9.33 6.80 4.22 7.10 
95% CI 75.8 - 115.0 55.6 - 84.0 63.6 - 81.2 74.9 – 104.6 
Vmax (µM/min) 0.010 0.055 0.165 0.044 
R-square 0.9876 0.9858 0.9948 0.9916 
 
Figure 17 data shows small SEM bars and well fit analysis curves producing high r-square values. 
However, 95% CI levels remain broad due to low degrees of freedom.    
Lineweaver-burk analysis shown in supplementary figure 3 provide an alternative method of 
analysis, generating Km = 119.3 µM and 115.7 µM for β5c and β5i respectively. However, the 
increased influence of outer points affected the overall orientation of the regression fit, as 
evidenced by Km values of 89.9 µM (β5c) and 100.1 µM (β5i) after removal of the lowest substrate 
concentration. 
 
3.1.3  IC50 Values 
 
For all tests shown, negative controls displayed near complete rate inhibition at low 
concentrations of epoxomycin or vinyl sulfone.  
Figure 18 (A) analysis produces argyrin B IC50 values of 8.76 µM at β1i and 146.5 µM at β1c from 3 
independent tests. Supplementary figure 2 shows trial, independent tests at β1i and β1c, 
revealing similar final values for IC50 at 9.6 µM and 173.9 µM respectively. However these were 
performed at a substrate concentration of 50 µM and a higher range of argyrin B concentrations 
was required. At the β5 site, figure 18 (B) also showed a greater effect on the IP with IC50 values of 
8.30 µM for β5c and 3.54 µM for β5i. A summary of calculated values and associated statistics are 
summarised in table 8. 
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Figure 18 – Argyrin B IC50 plots at β1 and β5 sites of CP and IP - Logarithmic argyrin B concentration against 
percentage of control, initial rate velocity. Tested at [CP] and [IP] = 0.1 µg/well and [S] = Km. Data were 
normalised to DMSO solvent controls where applicable. Non-linear regression analysis with variable hill 
slope and 1/y
2
 weighting generated IC50 values with respective SEM from 3 independent repeats. A) β1i IC50 
= 8.76 µM +/-1.08, β1c IC50 = 146.5 µM +/-1.10.  B) β5c = 8.30 µM +/- 1.07, β5i = 3.54 µM +/- 1.08. 
-2 -1 0 1 2 3
2 0
4 0
6 0
8 0
1 0 0
1 2 0
A rg y r in  B  L o g 1 0  co n ce n tra t io n  ( M )
P
e
rc
e
n
ta
g
e
 c
o
n
tr
o
l
v
e
lo
c
it
y
 (
%
)
 1 c
 1 i
-2 -1 0 1 2 3
2 0
4 0
6 0
8 0
1 0 0
1 2 0
A rg y r in  B  L o g 1 0  co n ce n tra t io n  ( M )
P
e
rc
e
n
ta
g
e
 c
o
n
tr
o
l
v
e
lo
c
it
y
 (
%
)
 5 c
 5 i
A. 
B. 
 
 
55 
 
Table 8 - Summary of IC50 analysis and associated statistics at β1 and β5 sites of CP and IP - * denotes 
statistical significance from t-test.  
 β1c β1i β5c β5i 
Average IC50 
(µM) 
146.5* 8.76 8.30 3.54 
SE 1.10 1.08 1.07 1.08 
95% CI 122.3 – 175.5 7.6 – 10.1 7.8 – 9.4 3.0 – 4.1 
Hill Slope -0.5784 -0.7487 -0.9881 -0.8153 
R-square 0.8165 0.9271 0.9123 0.8977 
 
Overall, β5i displayed the lowest IC50 value and β1c the highest. Comparing IC50 values from each 
replicate, t-tests were performed between means of each active site data with p-values detailed 
in supplementary table 6. At p<0.05, β1c IC50 was determined statistically significant to all other 
active sites whilst statistical significance was not observed between other active sites.   
 
3.1.4  Ki values 
 
High concentration of argyrin B at 3 x IC50, 439.5 µM are required for β1c Ki range tests, resulting 
in high DMSO levels on account of argyrin solubility. As such, consistent with previous findings, 
(figure 16), high levels of DMSO alone have a significant impact on the enzyme substrate reaction 
(figure 19). With high DMSO levels causing a dramatic shift in reaction conditions such as 
proteasome concentration, the effect of argyrin B cannot be appropriately measured even with 
DMSO control correction. Tests at upper limits of DMSO concentrations, shown in supplementary 
figure 4  predict a Ki value of over 250 µM, using a single argyrin B concentration. It can be 
estimated that Ki is >100 µM, however further data points are required to accurately determine Ki. 
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Figure 19 – β1c DMSO control data at high concentrations – DMSO concentration corresponding to argyrin 
B at 0 µM, 183.7 µM and 551.1 µM concentrations. Tested at [CP] = 0.1 µg/well, and range of Z-LLE-AMC 
concentrations. Based upon argyrin B preparations from from 10 mg/ml stock. 
 
For data on β1i, β5c and β5i, best-fit model comparisons were first performed using Akaike's 
information criteria with results shown in supplementary table 7. The probabilities clearly 
disfavour competitive model fit against others, whilst comparison with un-competitive provided 
ambiguous and incomparable fits. In β1i and β5i, the non-competitive model was the preferred fit, 
whilst β5c showed marginal preference towards the mixed inhibition model. Further analysis 
using extra sum-of-squares F tests are shown in supplementary table 8. Contrary to the AICc test, 
the low p-value concludes that β5c showed statistically significant preference towards the non-
competitive model. β1i and β5i best-fit outcomes associated with AICc tests and confirmed a 
suitable use of non-competitive analysis. As such to determine Ki values, non-competitive SNLR 
was used for all sets data shown in figure 20 and summarised in table 9. 
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Figure 20 – Ki analysis at β1i, β5c and β5i active sites – All using 0.1 µg/well proteasome concentration and 
range of [argyrin B] at original IC50 x 0, 0.33, 1 and 3. [S] at Km x 2.5, 1.25, 0.625, 0.1325, 0.15625 for each 
active site. Initial velocity determined and analysed by simultaneous non-linear regression using the best-fit 
inhibition model. Standard error bars from triplicates displayed for all data points. A) β1i, B) β5c, C) β5i. 
 
Table 9 - Summary of Ki values at β1 and β5 sites of the CP and IP – Determined from non-competitive 
simultaneous non-linear regression analysis. 
 β1c β1i β5c β5i 
Ki (µM) >100 5.2 13.9 6.6 
SE - 0.34 0.96 0.49 
95% CI - 4.54 – 5.89 11.93 - 15.76 5.63 – 7.59 
R-square - 0.9639 0.9447 0.9127 
 
 
Ki values reveal a greater effect of argyrin B at β1i and β5i, compared to other sites. However, 
statistical analysis could not be performed due to single replicate data available. This data 
correlates with IC50 estimations showing greater impact of argyrin B at the IP over CP. However, 
quantitatively Ki estimations differ from IC50 values previously determined (table 8) furthermore, 
β5i and β1i show different trends between IC50 and Ki estimations. Although Ki could not be 
specified at β1c, a high value was evident in comparison to all other active sites. 
C. 
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Further to SNLR analysis, alternative analysis methods were also tested with Cornish-Bowden and 
Dixon plots to estimate the inhibition type for β1i data. Supplementary figure 5 Dixon plot 
represents a mixed inhibition type that is close to non-competitive due to line intersections near 
the x-axis. Analysis of x-axis intersections between each line shown in supplementary table 4, 
revealed an average competitive Ki (Kic) value of 4.08 µM +/- 0.31. Combined with a Cornish-
Bowden plot shown in supplementary figure 6, a mixed inhibition is confirmed, again close to non-
competitive. Supplementary table 5 shows each line intersection, generating an average un-
competitive Ki (Kiu) value of 10.55 µM +/-0.73. These findings match those of the previous analysis, 
although final Ki values slightly differ. 
In addition, a conventional Hanes-Woolf plot was used to determine Km/Vapp shown in 
supplementary figure 7 and subsequently plotted for each inhibitor concentration to estimate Ki in 
supplementary figure 8. This plot estimates -Ki at the x intercept. Calculated from the line 
equation with y=0 as well as slope SE from least squares curve fitting analysis, a Ki of 4.14 µM +/- 
0.26 was determined. Small error bars and similar values to SNLR analysis help to verify findings 
and analysis techniques used. 
 
3.2  Computational modelling results 
3.2.1  Sequence alignments 
 
All substitutions from murine to humanised structural data were based upon Blastp alignments 
shown in supplementary figure 9-11 and sequence changes are summarised in supplementary 
table 9. Furthermore, sequences from structural data active site cuts were each aligned for 
similarity with percentage scores summarised in table 10.  
Overall, relatively few amino acids are substituted from murine to humanised IP in each active site, 
at around 10%, with many of these changes conservative. There are no common substitutions 
observed between all active sites. At β2, many changes are towards the end of the chain, further 
from the Thr1 catalytic centre and its surrounding binding pockets. 
 
β1c 
β2c 
β2i 
      
  
  
  
  
  
  
  
  
  
  
Figure x -  Most energetically favourable conformational fit with Argyrin 
B at human CP and humanised IP catalytically active sites. Molecular 
β1i 
Figure x - Argyrin B, cyclic peptide molecular structure. 
Arrows represent rotatable bonds, Trp = tryptophan 
(adapted from ref). 
Trp2 
Trp1 
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Table 10 - Percentage sequence similarity between human, mouse and humanised CP & IP chains - 
pBLAST performed on sequence of active site cuts. β1in red, β2 in blue and β5 in green expressed as 
percentage values. 
β1, β2, β5 Human CP Human IP Mouse CP Mouse IP 
Humanised 
IP 
Human CP   62, 57, 70 97, 97, 97 64, 58, 72 62, 57, 68 
Human IP 62, 57, 70   60, 59, 70 90, 89, 91 99, 97, 98 
Mouse CP 97, 97, 97 60, 59, 70   63, 59, 69 60, 57, 69 
Mouse IP 64, 58, 72 90, 89, 91 63, 59, 69   90, 89, 91 
Humanised 
IP 
62, 57, 68 99, 97, 98 60, 57, 69 90, 89, 91   
 
 
Protein sequence similarity searches reveal similar trends amongst conservation of β1, 2 and 5 
across human, mouse and humanised IP & CP. Human and murine CP show near identical active 
sites, whilst human and murine IP show a little variance with approximately 90% similarity. 
Humanised IP sequences derived from structural data bear near perfect similarity to human IP 
sequences, with small discrepancies due to gaps.  
 
To facilitate understanding of differences between the active sites modelled, complete structural 
alignment of human CP and humanised IP data are shown in supplementary figure 12. This 
includes type of substitution characterised by conservation of chemical properties. Amino acids of 
strongly similar properties score >0.5 in the Gonnet point accepted mutation (PAM) 250 matrix, 
whereas weakly similar properties are scoring <0.5. There are numerous amino acid differences 
between the CP and humanised IP at approximately 30-40%. This may result in overall chemical 
properties and structural characteristics of the active site. However, some residues pertain more 
to ligand binding affinity than others, dependent upon positioning around the catalytic centre and 
specificity pockets.  
As well as sequence alignments, active site cuts were structurally aligned to observe any overall 
changes in positioning. Figure 21 part A represents an overview of the entire cut centred at Thr1 
and including surrounding chains, whilst part B shows differences around the binding region of 
argyrin B. 
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Figure 21 – CP overlaid humanised IP active site cuts – Human CP active site cuts in red, aligned to 
humanised IP active site cuts in green with differences highlighted in blue. A) Displaying entire cut, 28 Å 
from Thr1. B) Displaying area around the Thr1 catalytic centre, with overlaid argyrin B at proposed binding 
position from best-fit in humanised IP simulations. 
 
From figure 21, β1 shows the greatest difference in structural positioning that is likely due to the 
P115 deletion in humanised β1i observed in supplementary figure 12 and conserved across 
various species (Huber et al., 2012). In contrast, β2 and β5 remain relatively similar in structures 
of the active subunit chain. The difference observed in β5 overall cut is largely within a 
neighbouring subunit chain and is caused by a single deletion. Closer inspection around the active 
site reveals an overall shift between β1 chains, whilst β2 remains very similar and β5 has minor 
differences observed. 
 
3.2.2  AutoDock molecular modelling 
3.2.2.1  AutoDock summary 
 
 
The binding affinity properties of argyrin B were recorded from the best-fit conformation of each 
10 repeats, with results summarised in table 11 from raw data shown in supplementary table 10. 
β5 β1 β2 
A. 
B
. 
 A. 
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Results from 2-sample t-tests or non-parametric Mann-Whitney tests shown in supplementary 
table 12-14 and supplementary figures 13-15, reveal statistical significance between lowest 
binding energy for sets of data.  
 
Table 11 – Predicted binding energies of argyrin B at each active site of the CP and humanised IP from 
AutoDock docking simulations – Argyrin B docked using Lamarckian genetic algorithm with 10 independent 
repeats, each of 50 runs. Statistical tests for normality and equal variance followed by mann-whitney or 2-
sample t-test to determine significance. Red * = statistically significant to all other data sets. Green * is 
statistically significant to other green * only. 
Binding properties 
β1 β2 β5 
Human 
CP 
Humanised 
IP 
Human 
CP 
Humanised 
IP 
Human 
CP 
Humanised 
IP 
Lowest Binding Energy 
(Kcal/mol) 
-10.12 -11.83 -11.13 -11.05 -10.72 -10.97 
Average Binding Energy 
(Kcal/mol) 
-9.81* -11.66* -10.73 -10.69 -10.58* -10.73* 
 Binding Energy SE of mean 
(Kcal/mol) 
0.062 0.045 0.097 0.080 0.027 0.056 
Average Ki (nM) 68.34 2.94 16.06 15.09 17.84 14.78 
 
Argyrin B displayed a significant difference in binding energy preference towards β1i compared to 
any other CP & IP active site. Interestingly the CP counterpart β1c was the least favourable site for 
argyrin B binding, with a significant difference to all other sites. Argyrin B interactions at β2c and 
β2i were very similar in estimated binding energy, although showed the greatest variance in 
binding energies, reflected by higher SEM values. β5 and β2 interactions were similar, although a 
significant difference is observed between β5c and β5i, with β5i more energetically favourable. 
Average Ki estimations follow a similar trend to average binding energies.  
The positioning and coordinates of each best scoring repeat were also analysed to measure 
reproducibility and consistency. Overlays of argyrin B are shown in figure 22, revealing the 
frequency at which the overall best score (highlighted in purple) adopted a similar position to all 
other replicate best scores.   
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Figure 22 – Overlaid most energetically favourable argyrin B conformation of each 10 repeats – All tests 
from AutoDock docking simulations at human CP and humanised IP active site cuts. Overall best 
conformation presented in bold purple. 
 
For β1c docking simulations, 2 major conformations were amongst the top scoring fits. These 
exhibited a 60:40 split and occupied significantly different areas of the active site. In contrast, β1i 
pose predictions showed 90% in a very similar position within the active site. Only β1 sites 
showed similar orientations of argyrin B between the CP and IP, although this is only true in terms 
β1c β1i
β2c
β2i
β5c
β5i
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of shape and does not match in positioning or interacting residues. The β2 site followed a similar 
trend of the IP showing greater consistency of conformations; however orientations between β2c 
and β2i greatly differ. At the β5 site, argyrin B binds a similar area in all repeats, although the 
rotation of tryptophan groups and orientation differs both amongst repeats and between each 
proteasome. β5c displayed 2 main conformations almost equally, in which the argyrin is flipped 
with the tryptophans positioned on opposing sides. 
 
Nonetheless, variations within the most favourable binding energy score were similar in repeats, 
evidenced by low standard errors, despite the different conformations and interactions. It should 
also be noted that only the top binding energy score for each is recorded, therefore the same 
conformation may well be identified, although not ranked as top. 
  
 
3.2.2.2  Control TMC-95A 
 
Pose predictions and lowest binding energy estimates from TMC-95A docking at yeast β2 sites, 
were compared to crystallography derived structural data. The overall upper quartile of binding 
energy conformations were recorded in supplementary table 15 . From these, 38% represent a 
close resemblance to crystal structure data, also producing consistent binding energies and 
interactions. These 38% were identified as the dominant conformational cluster from the 50 
poses of each run, using an RMSD tolerance of 2 Å. The best predicted interaction bound to the 
Thr1, although the orientation differs to that suggested by crystallisation data, shown in figure 23. 
Whilst other favourable conformations deviated from specificity pockets and the catalytic centre 
with no particular trends or common positions identified. 
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Figure 23 – Comparison of crystallisation data to AutoDock simulation predicted binding using TMC-95A 
at yeast β2c - Green represents the most energetically favourable pose against the crystallisation structural 
data in yellow. Red represents conformation similar to crystal data, that constituted 38% of the upper 
quartile ranked repeats.  Surface colour red indicates position of Thr1 catalytic centre. 
Overall, the most commonly predicted conformation shows similarity to structural data however, 
this is not always identified as the lowest binding energy. This highlights the importance of a high 
number of repeat tests and use of supporting laboratory data. 
 
3.2.2.3  β1 site 
 
 
From molecular docking simulations, the most energetically favourable conformation from each 
repeat was investigated in greater detail. The residues within the active site that interact closely 
with argyrin B were recorded, along with any hydrogen bonding. Findings of the frequency are 
noted in table 12 whilst the best scoring conformation is displayed in figure 24. 
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Table 12 - β1c and humanised β1i residue interactions from argyrin B AutoDock simulations – Best-fit of 
each 10 replicates analysed. Bold denotes presence in best conformational fit overall and italics denote 
residues in different subunit chain. 
β1c Human 
 
β1i Humanised 
Amino Acid 
Interactions 
Occurrence 
/10 
H bond 
occurrence 
/10   
Amino Acid 
Interactions 
Occurrence 
/10 
H bond occurrence 
/10 
ARG35 10 4 x single   ALA49 10   
GLY47 10 6 x single   ARG19 10   
GLY97 10     HIS97 10   
MET116 10 6 x single   MET5 10   
MET95 10     SER129 10 9 x single 
GLY129 7 4 x single   SER46 10 10 x single 
ALA49 6     SER48 10   
GLY23 6 6 x single   SER95 10   
SER130 6 1 x single   THR1 10 2 x single, 9 x triple 
SER46 6 4 x single   VAL20 10   
THR1 6     GLY128 9   
THR20 6     GLY47 9   
THR21 6 6 x single   SER21 9 9 x single 
THR22 6     ALA96 6   
TYR30 6     LEU115 1   
GLY128 4     TYR30 1   
LEU33 4        
MET5 4        
PRO115 4        
SER133 4           
GLY31 2           
ASN3 1           
TYR134 1           
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Figure 24 – 3D representation of all argyrin B interactions at β1c and humanised β1i sites from AutoDock 
predicted best conformation – Displayed residues are interacting with argyrin B whilst green dotted line 
represents H-bonding. 
β1c 
β1i 
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Figure 25 – AutoDock simulated argyrin B best-fit with surface representation at β1c and humanised β1i 
active sites – All nearby residues labelled and visible, interacting residues underlined. Coloured by general 
amino acid characteristics where red = polar, green = hydrophobic, blue = basic, orange = acidic. 
 
β1c 
β1i 
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Interactions at β1i showed greater consistency with 13 amino acid interactions and strong H-
bonding around Thr1, observed in at least 90% of best-fit replicates. Likewise, many of the 
hydrogen bonds were between the same amino acid and part of argyrin B, on most repeats; also 
at a greater abundance compared to β1c.  In contrast, β1c displayed 2 main conformations, 
therefore a greater variety of interacting residues and split frequency of hydrogen bonding. 
However, 5 core residue interactions were observed throughout, highlighting the importance of: 
Arg35, Gly47, Met116, and Met95 in argyrin B binding at β1c. Argyrin B also displayed interactions 
with residues from neighbouring and opposing chains from β1c. There are few interactions in 
common observed at both the CP and IP, affirming the possibility of selectivity. 
In addition to the interacting residues, this information was also investigated with consideration 
of changes to the active site characteristics. A surface representation of best-fit conformation at 
each active site is shown in figure 25. In general, the β1i pocket appears to adopt more polar and 
basic characteristics, as well as different specificity pocket sizes compared to its constitutive 
counterpart. In β1i, argyrin B is positioned close to Thr1 and with part of the molecule interacting 
around the S1 specificity pocket. In contrast, at β1c a more unconventional position is adopted, 
away from the specificity pockets. Differences in key residues appear to significantly alter the 
shape of the active site, subsequently changing argyrin orientation.  
 
3.2.2.4  β2c & β2i sites 
 
β2 active site interactions from best-fit conformations of argyrin B molecular modelling repeats 
are summarised in table 13. Furthermore, figure 26 displays the orientation of binding 
interactions of the overall, most energetically favourable pose revealing sites of interaction on 
argyrin B.  
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Table 13 – β2c human and humanised β2i residue interactions from argyrin B AutoDock simulations – 
Best-fit of each 10 replicates analysed. Bold denotes presence in best conformational fit overall and italics 
denote residues in different subunit chain. 
β2c Human   β2i Humanised 
Amino Acid 
Interactions 
Occurrence 
/10 
H bond 
occurrence /10 
 
Amino Acid 
Interactions 
Occurrence 
/10 
H bond occurrence 
/10 
ALA97 10   
 
ALA49 10   
GLY47 10 1 x single 
 
ASP124 10   
GLY95 10   
 
GLY128 10 7 x single 
PRO115 
10 
  
 
THR1 10 
2 x single, 6 x 
double, 1 x triple 
SER129 
10 
7 x single, 1 x 
double 
 
THR21 10 
1  x single, 1 x 
double 
MET127 8   
 
ALA20 9 1 x single 
ALA96 7   
 
ALA46 9   
LEU132 7   
 
GLY47 9   
PHE33 7   
 
ARG19 8   
SER131 7 3 x single 
 
GLN131 8   
THR126 7   
 
GLY95 8   
THR48 7   
 
PRO115 8   
TYR25 7   
 
SER97 8 2 x single 
TYR144 7   
 
VAL48 8   
GLY128 4   
 
GLY92 3   
THR1 3 3 x single 
 
GLY45 2 2 x single 
THR21 3   
 
LYS33 2   
ALA20 2 1 x single 
 
PHE33 2   
ALA46 2   
 
SER129 2 8 x double 
ALA49 2   
    ARG19 2   
    GLY92 2   
    TYR114 2   
    ASP125 2   
    ALA50 1   
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Figure 26 - 3D representation of all argyrin B interactions at β2c and humanised β2i sites from AutoDock 
predicted best conformation – Displayed residues are interacting with argyrin B whilst green dotted line 
represents H-bonding. 
β2c 
β2i 
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Figure 27 - AutoDock simulated argyrin B best-fit with surface representation at β2c and humanised β2i 
active sites – All nearby residues labelled and visible, interacting residues underlined. Coloured by general 
amino acid characteristics where red = polar, green = hydrophobic, blue = basic, orange = acidic. 
 
β2i 
β2c 
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β2c interactions are relatively consistent with at least 70% in common. Ser129 showcases 
important hydrogen bonding with the Trp moiety of argyrin B and some interactions are observed 
in neighbouring chains. Thr1 itself has minimal interaction at β2c, although the surrounding S1 
pocket shows frequent intermolecular forces with the inhibitor. Within β2i a different orientation 
is observed with a high frequency of Thr1, Gly128 and Ser 129 hydrogen bonding. However, 
overall predicted binding energies suggest no significant difference in affinity between β2c and 
β2i.  
Nevertheless, surface representations of best conformation within each active site, further reveal 
differences between site characteristics and architecture, shown in figure 27. The altered 
positioning of residues 22-24 (figure 21) affects the distance for argyrin B to interact and fit 
around the key Thr21 residue. The T48V and A97S non-conservative changes retain strong 
interactions in both fits; however the polar nature of S97 in β2i compared to the nonpolar A97 
and the polar T48 in β2c compared to the nonpolar V48 in β2i, cause interactions at different 
areas of argyrin B, changing the orientation. Y93H changes from β2c to β2i appears to shift P115 
and A96 that are each important in β2c binding. Furthermore, L132D and S131Q differences alter 
the shape and position of surrounding residues and reduces interactions at β2i 132 position. 
 
3.2.2.5  β5c & β5i sites 
 
Table 14 reveals the frequency of residue interactions from β5 site best-fit conformation repeats. 
All bonding interactions from the most favourable binding energy conformation are displayed in 
figure 28. In addition, figure 29 shows this within a surface representation of the active site.  
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Table 14 – β5c human and humanised β5i residue interactions from argyrin B AutoDock simulations – 
Best-fit of each 10 replicates analysed. Bold denotes presence in best conformational fit overall and italics 
denote residues in different subunit chain. 
β5c Human   β5i Humanised 
Amino Acid 
Interactions 
Occurrence 
/10 
H bond 
occurrence /10   
Amino Acid 
Interactions 
Occurrence 
/10 
H bond occurrence 
/10 
ASN24 10 1 x single   ALA49 10   
GLU117 10     GLY47 10 1 x single 
GLY129 10 6 x single   MET45 10   
GLY47 
10 8 x single   SER21 10 
2 x single, 7 x 
double, 1 x triple 
SER130 
10 5 x single   SER46 10 
5 x single, 5 x 
double 
TYR113 10     THR1 10 7 x single 
TYR169 10     TYR169 10   
THR1 9     VAL31 10   
ALA32 9     GLY129 8   
VAL128 8     LYS33 7 1 x single 
SER96 7           
ASP115 6           
ASP167 6           
SER116 6           
TYR134 6           
SER23 5           
ALA46 4           
GLN33 4           
PHE137 4           
GLY98 3           
ILE30 2           
ALA22 1           
GLY99 1           
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Figure 28 - 3D representation of all argyrin B interactions at β5c and humanised β5i sites from AutoDock 
predicted best conformation – Displayed residues are interacting with argyrin B whilst green dotted line 
represents H-bonding. 
β5c 
β5i 
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Figure 29 - AutoDock simulated argyrin B best-fit with surface representation at β5c and humanised β5i 
active sites – All nearby residues labelled and visible, interacting residues underlined. Coloured by general 
amino acid characteristics where red = polar, green = hydrophobic, blue = basic, orange = acidic. 
 
β5c 
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There are 8 β5i site residues that interacted in all 10 best-fit conformations and only 10 unique 
interactions from all best-fit repeats. In contrast, β5c showed 15 residue interactions in the 
overall best-fit and 23 from the top 10. Despite more interactions at β5c, the hydrogen bonds and 
positioning in β5i predicted lower binding affinities. Despite displaying more consistent amino 
acid interactions, humanised β5i also showed a greater range of binding energy values. Through 
AutoDock binding energy estimations, β5i displayed a significantly favourable binding energy 
compared to β5c and conformations were distinct, highlighted by very few interacting residues in 
common.  
The increased hydrophobic and polar nature of β5i (figure 29) is observed by key residue 
substitutions such as A46S, G48C and V128T. In B5i, all bonding is based around the Trp moieties 
whilst no residues strongly interacted at the opposing end of the inhibitor. The Trp rings of argyrin 
B wrapped around Ser46, each forming hydrogen bonds. Whereas, β5c showed hydrogen bond 
interactions from around the thiazole ring to Gly47 and Ser130.  Argyrin B interacted with 
residues only from the β5 subunit in the IP, whereas conformations within the CP also displayed 
interactions with nearby subunit chains. Notably, Ser23 and Asn24 from the neighbouring β4 and 
Ala32 on the β3 from the opposing ring shown in the best conformational fit.  
 
3.2.3  FRED Docking results 
 
Pose predictions and interacting residues of argyrin B were tested using FRED, an alternative 
molecular modelling software. Ligand shape is treated as rigid, therefore at each active site, the 
resulting conformation and coordinates from the best-fit AutoDock simulations were tested. 
Resulting interactions are summarised in tables 15-17.   
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Table 15 – Comparison of argyrin B residue interactions at β1 and humanised β1i from AutoDock and 
FRED simulations – Comparison between single best-fit from all repeats, or frequency out of top 10 
AutoDock repeats. Bold = hydrogen bonding, italics = different subunit chain and underscore = interactions 
unique to FRED docking. 
β1c residue interactions 
 
β1i residue interactions 
 FRED with AD 
best-fit 
conformation 
AutoDock 
best-fit 
 FRED with AD 
best-fit 
conformation 
AutoDock 
best-fit 
ARG35 ARG35  ALA49 ALA49 
GLY128 GLY128  ALA50   
GLY129 GLY129  ALA96 ALA96 
GLY31 2/10  ARG19 ARG19 
GLY47 GLY47  GLY128 GLY128 
GLY97 GLY97  GLY47 GLY47 
LEU33 LEU33  HIS97 HIS97 
MET116 MET116  MET5 MET5 
MET5 MET5  SER129 SER129 
MET95 MET95  SER131   
PRO4    SER168   
SER130 6/10  SER21 SER21 
SER132    SER46 SER46 
SER133 SER133  SER48 SER48 
SER46 SER46  SER95 SER95 
THR1 6/10  THR1 THR1 
TYR30 TYR30  VAL20 VAL20 
TYR134 1/10  
TYR136    
  PRO115 
 
β1c interactions closely match between FRED and AutoDock tests as well as hydrogen bonding 
with Gly129 and Ser46 remaining key sites. New interactions suggested from FRED docking of 
Pro4 and Ser132 neighbour other identified interactions at Met5 and Ser133. Likewise, Pro115 
shown in AutoDock that is missing in FRED docking is situated adjacent to Met115, shown to 
interact in both. The same is observed in β1i, with the exception of Ser168 as a novel interaction 
predicted. Hydrogen bonding at Ser129, Ser21 and Thr1 are present in both simulations.  
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Table 16 - Comparison of argyrin B residue interactions at β2 and humanised β2i from AutoDock and 
FRED simulations – Comparison between single best-fit from all repeats, or frequency out of top 10 
AutoDock repeats. Bold = hydrogen bonding, italics = different subunit chain and underscore = interactions 
unique to FRED docking. 
β2c residue interactions 
 
β2i residue interactions 
FRED with 
AD best-fit 
conformation 
AutoDock 
best-fit 
 FRED with 
AD best-fit 
conformation 
AutoDock 
best-fit 
ALA27    ALA20 ALA20 
ALA46 ALA46  ALA46 ALA46 
ALA97 ALA97  ALA49 ALA49 
GLY128 4/10  ALA50   
GLY23    ARG19 ARG19 
GLY47 GLY47  ASN22   
GLY95 GLY95  ASP124 ASP124 
MET127 MET127  ASP23   
PHE33 PHE33  GLN131 GLN131 
SER129 SER129  GLY128 GLY128 
THR21 3/10  GLY168   
THR22    GLY47 GLY47 
THR48 THR48  GLY92 GLY92 
TYR114 2/10  GLY95 GLY95 
TYR144 TYR144  LYS33 2/10 
TYR25 TYR25  PRO115 PRO115 
  ALA96  SER129 SER129 
  LEU132  SER97 SER97 
  PRO115  THR1 THR1 
  SER131  THR21 THR21 
  THR126  VAL48 VAL48 
 
β2c shows greater contrast with a number of interactions proposed by AutoDock, not established 
by FRED docking. The predicted FRED conformation appears to be a greater distance from Thr1, 
with argyrin B able to hydrogen bond the neighbouring chain Thr22. This may orientate the 
argyrin B out of reach to Ser131 and Leu132. Whilst Thr48 hydrogen bonding is predicted in both, 
Gly128 and Ser129 are suggested from FRED and AutoDock, respectively. β2i residue interactions 
show great similarities between each test. Although more interactions are suggested from FRED 
docking, these are neighbouring other residues predicted by both. Gly168 appears to be a distinct 
suggestion of an additional interaction and hydrogen bonding slightly differs.   
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Table 17 - Comparison of argyrin B residue interactions at β5 and humanised β5i from AutoDock and 
FRED simulations – Comparison between single best-fit from all repeats, or frequency out of top 10 
AutoDock repeats. Bold = hydrogen bonding, italics = different subunit chain and underscore = interactions 
unique to FRED docking. 
β5c residue interactions 
 
β5i residue interactions 
FRED with 
AD best-fit 
conformation 
AutoDock 
best-fit 
 FRED with 
AD best-fit 
conformation 
AutoDock 
best-fit 
ALA46 4/10  ALA20   
ALA32 ALA32  ALA22   
ASN24 ASN24  ALA49 ALA49 
ASP115  ASP115  ARG19   
ASP167 ASP167  ASN32   
GLY129 GLY129  ASP125   
GLY47 GLY47  CYS52   
GLY98 3/10  GLY23   
MET28    GLY47 GLY47 
PHE137 4/10  LYS33 LYS33 
SER130 SER130  MET45 MET45 
SER23 SER23  SER21 SER21 
SER96 SER96  SER46 SER46 
TYR113 TYR113  SER96   
TYR169 TYR169  SER24   
VAL128 8/10  THR1 THR1 
VAL133    TYR169 TYR169 
  GLU117  VAL31 VAL31 
  SER116    GLY129 
  THR1  
  TYR134  
 
 
AutoDock β5c interactions include Ser116 and Glu117 at the Trp moiety. However, FRED poses did 
not suggest such interactions, instead Met28 of a neighbouring chain and Val133 were predicted. 
Interestingly FRED docking did not include Thr1 as a major interaction, despite similar binding in 
nearby areas. β5i showed the greatest variation of all active sites in docking predictions. A 
number of additional interactions and an additional Ser21 hydrogen bond close to Thr1 are 
suggested from FRED docking. With the exception of the more distant Gly129, all AutoDock 
interactions and hydrogen bonds are matched in FRED predictions, yet FRED also predicts 9 
additional interactions. Together, this suggests a potentially stronger affinity at β5i than AutoDock 
predicts. 
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Overall, many interactions and hydrogen bonding predictions between the docking software are 
shared. Those that are different between FRED and AutoDock are mostly neighbouring other 
shared interactions. Only β5i shows more of a variance and casts some doubt over the validity of 
the interactions listed by AutoDock. 
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Chapter 4.  Discussion 
4.1  Inhibitor kinetic studies  
4.1.1  Determining enzyme activity 
 
The use of peptide-AMC substrates has been an established method for determining proteolytic 
enzyme activity (Wildeboer et al., 2009), including use in proteasome active site specific studies 
(Harris et al., 2001; Bülow et al., 2010). Kinetic assays to measure argyrin B inhibition were based 
upon measuring the rate of reaction. The properties of short peptides in active site specific 
substrates allow for binding and cleavage at only one active site, where β1c cleaves after the 
acidic glutamine of Suc-LLE-AMC, β1i hydrolyses Ac-PAL-AMC and β5 cleaves after hydrophobic 
tyrosine of Suc-LLVY-AMC (Miller et al., 2013). However, it is important to note the range of 
substrates available (Kisselev and Goldberg, 2005). Whilst those used in this investigation are 
common and established, additional tests with alternative substrates would be beneficial to re-
inforce active site specific activities.  
The fluorescence of AMC was quantified by the electron excitation at 355nm, followed by a fall 
and release of light, measured at the emission wavelength 460nm. Coumarin fluorescence is 
quenched when bound to the P1 position amino acid of the substrate. However, upon cleavage of 
this peptide bond, the coumarin is released as shown in figure 30; allowing sensitive fluorescence 
increases to be continually measured. 
 
 
Figure 30 – β1c specific substrate reaction - Structure of β1 specific substrate Z-Leu-Leu-Glu-AMC, 
undergoing hydrolysis of peptide bond between carboxylic acid of P1 amino acid and the amino group of 
coumarin. The release of AMC is subsequently measured by fluorescence. 
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As a result, a substrate reaction with enzyme to form a single product is observed, as represented 
in equation 4. During initial stages of reaction the relative increase in [P] is greater than the 
decrease in [S] therefore; the accumulation of [P] is a more accurate measure. The molar 
concentration of substrate used was in excess of enzyme concentration, hence allowing sufficient 
substrate availability to bind free enzyme (E). The reverse reaction from product (P) to enzyme-
substrate complex (ES) is not included as initial velocities were calculated whereby [P] is low and a 
steady state is assumed. Representative levels of E, ES and P are shown throughout a reaction in 
figure 31. This shows a pre-steady state as ES forms, followed by steady state of near constant ES 
at which point velocity is most appropriately measured (Copeland, 2005).  
It is important to note that a combination of variables can contribute to the enzyme kinetics of a 
reaction therefore, strict parameters must be set. Any pH variation of H+ or OH- ions can alter 
charged groups of amino acids within the active site and cause conformational changes, hence 
affect reaction rate. Similarly, temperature changes cause instability of the enzyme, influencing 
rate (Copeland, 2005). Optimal conditions of pH 7.5 and 37 ᵒC were used in accordance with 
physiological conditions, these also matched the vast majority of 20S CP investigations as 
summarised on the BRENDA database (www.brenda-enzymes.org, EC 3.4.25.1).  
 
Equation 4 – Enzyme substrate reaction - E = enzyme, S = substrate, ES = enzyme-substrate complex, P = 
product, k = rate constant. 
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Figure 31 – Concentration of reaction components over time - Representative concentrations of free 
enzyme, substrate, enzyme-substrate complex and product concentrations in a reaction over time. Area of 
steady state assumption highlighted in grey. 
Upon rate determination it is important to estimate Km values before subsequent kinetic analysis, 
particularly as IC50 is measured at a single [S]. To determine IC50 values a [S] close to Km is required 
to avoid unrepresentative values as observed in different inhibition modes, illustrated in figure 32; 
based upon theoretical values from Cheng-Prusoff equations (Cheng and Prusoff, 1973). 
 
 
Figure 32 - Impact of substrate concentration on IC50 – Variation in IC50 values dependent upon deviation of 
substrate concentration from Km values. Theoretical values based upon the Cheng-Prusoff equations in 
competitive, uncompetitive and non-competitive binding modes (Copeland, 2005). 
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The Michaelis-Menten equation and basis of non-linear regression analysis are derived from rate 
equations explained in supplementary figure 16. The series of equations facilitate understanding 
of how equation 4, representative of the reaction in this investigation, is quantified with kinetic 
constants using non-linear regression analysis. 
It is the model in equation 10 (of supplementary figure 16) that is used in non-linear regression 
analysis to determine Km, as well as forming the basis of models for different modes of inhibition 
and kinetic analysis. Km represents the concentration of substrate that produces half of the 
maximal enzyme activity (Strelow et al., 2012). 
In this investigation, Michaelis-Menten graphs (figure 17) show apparent first order reaction with 
respect to substrate concentration, until higher concentrations when all enzymes are saturated 
with substrate. Therefore the rate is proportional to the concentration of substrate. Alternative 
methods using double reciprocal analysis of a Lineweaver-burk plot distort experimental error 
with lower concentrations producing a greater impact on the linear regression slope, evidenced in 
supplementary figure 3 analysis. Therefore non-linear analysis is generally regarded as more 
appropriate when a sufficient range of substrate concentrations are covered and this is indeed 
the prominent analysis method in enzyme studies (Kakkar et al., 2000; Motulsky and 
Christopolous, 2003; Bisswanger, 2014). Nonetheless, some assumptions incorporated within 
regression analysis software are still questioned for accuracy and appropriateness (Cornish-
Bowden, 2014).  
Although figure 17 shows good fit and small SE bars, the 95% confidence level of Km remain 
relatively broad. 95% confidence levels are created from SE multiplied t-distribution constant that 
is determined by degrees of freedom. The large range observed is therefore explained by lack of 
repeats whereby, when n=3, SEM is multiplied by 4.303, whereas with n=9, SEM is multiplied by 
2.306. Overall, reasonable rates of reaction were produced under appropriate conditions and 
similar Km values were obtained for each active site. This is expected since given an appropriate 
substrate, the proteasome is not known to have significantly greater efficiency at any particular 
active site (Kisselev and Goldberg, 2005). 
 
4.1.2  Argyrin B IC50 values 
 
Results from table 8 reveal lower IC50 values at IP active sites over their CP counterparts, in 
particular at β1i where a significant difference is observed. The IC50 represents the concentration 
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of inhibitor that causes 50% inhibition of the maximal activity (Mohan et al., 2013) and is 
commonly used in pharmacological studies, including proteasome inhibition. Therefore, a lower 
value represents a greater functional strength of the inhibitor. 
An appropriate range of concentrations are tested where values generally reach within 15% of 
maximal and minimal values, as well as spanning above and below the IC50 (Strelow et al., 2012). 
An explanation for the curve plateau above 0% (observed in figure 18) may be due to insufficient 
mixing and time allowed for enzyme-inhibitor complexes to form, before the addition of substrate. 
Since sufficient data points were tested, a variable slope model was used as opposed to standard 
hill-slope of -1.0 of inhibitory dose-response curves. More negative hill slope values represent a 
steeper curve, observed in β5c, β5i and β1i of figure 18.  An increased hill-slope value indicates a 
more dramatic change of inhibition over a narrow inhibitor concentration range. Whereas a low 
hill-slope value may be indicative of binding multiple active sites (Copeland, 2005), suggesting 
weak and off target effects of argyrin B at β1c. This is corroborated by a proposed non-
competitive binding mechanism analysed in supplementary table 8. Existing, potent proteasome 
inhibitors typically display high hill-slope values around 1 due to covalent, competitive 
interactions (Lightcap et al., 2000). 
 
It is interesting to observe differences of argyrin B inhibition between each active sites of the CP, 
which has not been previously reported. Table 8 strongly suggest argyrin B displaying a greater 
functional binding strength at β5c over β1c with well characterised IC50 plots. This was tested 
using a wide range of argyrin B concentrations, substrate concentration equal to Km and analysis 
of initial velocity data. In comparison, research by Bülow et al., (2010) shown in table 18, displays 
percentage activity assays with 1.2 µM argyrin producing 52%, 55% and 58% remaining activity at 
β1, β2 and β5 sites respectively; suggesting similar argyrin B inhibition at each site. The approach 
from Bülow et al., (2010) (table 18) that used a single inhibitor concentration, low substrate 
concentration and percentage activity measurement differs from this investigation methods 
outlined in section 3.1.2 & 3.1.3. The latter is considered a more appropriate kinetic measurement 
method (Copeland, 2000).  
IC50 values are also reported by Bülow et al., (2010), from MTT cytotoxicity assays in SW-480 colon 
cancer cells. This assay measures overall metabolic activity to reflect cell viability and therefore 
compound toxicity towards the cells. When compared to micromolar range IC50 values reported in 
table 8 from purified assays, an argyrin B IC50 of 4.6 nM (in table 18) suggests a substantial 
synergistic effect of each active site inhibition. Furthermore the long, 5-day incubation may 
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results in additional effects of the compound on other cellular processes, leading to increased 
toxicity and potency.  
Table 18 – Argyrin analogue inhibition at constitutive proteasome active sites - Argyrin analogues A-F are 
tested in purified assays using 1.2 µM argyrin, 2 µg 20s CP and 50 µM site specific fluorogenic substrates at 
37 ᵒC and pH 7.8. IC50 values are determined from MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay measuring cytotoxicity following argyrin B incubation at 37 ᵒC and 10% 
CO2 for 5 days (Bülow et al., 2010). 
Compound 
Remaining proteasome activity (%) 
IC50 (nM) SW-480 
Caspase-like - β1 Trypsin-like - β2 Chymotrypsin-like - β5 
Argyrin A 29 +/- 5.2 45 +/- 4.5 30 +/- 6.0 3.8 +/- 0.3 
Argyrin B 52 +/- 3.0 55 +/- 8.5  58 +/- 6.5 4.6 +/- 0.6 
Argyrin C 38 +/- 8.3 40 +/- 7.0 43 +/- 5.5 1.5 +/- 1.1 
Argyrin D 50 +/- 6.0 62 +/- 8.0 64 +/- 5.2 3.6 +/- 2.0 
Argyrin E 65 +/- 4.0 70 +/- 3.0 70 +/- 5.5 520 +/- 270 
Argyrin F 35 +/- 7.0 38 +/- 6.5 28 +/- 2.5 4.2 +/- 0.4 
Argyrin G 60 +/- 6.5 75 +/- 3.0 65 +/- 4.5 63 +/- 55 
Argyrin H 52 +/- 5.5 60 +/- 7.0 51 +/- 8.0 30 +/- 2 
 
 
As shown in table 18, argyrin A is suggested to be a more potent inhibitor of the CP compared to 
argyrin B. Further studies have tested argyrin A inhibition at each active site, revealing similar 
potencies to bortezomib when measured as weight/volume (Nickeleit et al., 2008). Tests were 
performed with site specific fluorogenic substrates at 20S CP and results are not directly 
quantified, although rough graphical estimates suggest argyrin A IC50 values of 121 µM, 38.3 mM 
and 68.18 µM at β1, β2 and β5, respectively. The lower inhibition at β2c corroborates with 
percentage remaining activity findings from (Bülow et al., 2010), whilst concentration values are 
relatively high compared to findings for argyrin B in table 8, despite a suggested greater potency 
of argyrin A. Nevertheless, argyrin A displayed low nanomolar IC50 values at cell lines from MTT 
cell proliferation assays and potent antitumour activities (Nickeleit et al., 2008). The structural 
differences between argyrin analogues are summarised in figure 12 that may account for 
differences in binding. Proteasome inhibitors typically display IC50 values at each active site in the 
nanomolar range, although non-covalent inhibitors are often less potent (Blackburn et al., 2010; 
Duibella et al., 2014; Sosič et al., 2016). Indeed, control tests with epoxomycin and vinyl sulfone 
produced near complete inhibition at low, 1 µM concentrations. 
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At the IP, β1i and β5i reveal similar IC50 values. However, interestingly these are both lower than 
their CP counterparts, with statistical significance for β1i. At the time of writing, there is no 
literature available on argyrin A-F inhibition at the IP. A 16-fold increase in IC50 at β1c compared to 
β1i suggests strong selectivity and potential therapeutic application. Similar ratios and IP 
selectivity have been achieved with other inhibitor compounds, as later discussed in 4.3.2. 
However, the majority of studies are performed on β5 sites and comparatively few show 
selectivity towards β1. β5 has traditionally been considered the most influential active site, 
although recent studies suggest the importance is exaggerated (Kisselev et al., 2006). Due to 
minor differences in structure and characteristics of β2 sites (Huber et al., 2012), very few β2i 
selective compounds have been discovered or synthetically developed (de Bruin et al., 2014), 
therefore β2 sites were not tested with argyrin B as priority, as potency is predicted to be similar 
in each.  
Although IC50 is commonly reported alone in pharmacological studies, the addition of Ki data is 
considered valuable in determining mechanism and binding affinity (Copeland, 2005; Cornish-
Bowden, 2014). The relationship between IC50 and Ki values is not always straightforward. The 
Cheng-Prusuff equation (Cheng and Prusoff, 1973) links these values for different inhibition 
modes as shown in equation 5, although use of direct conversion from IC50 to Ki is not widely 
appreciated as a reliable estimation (Copeland, 2005). As such, further kinetic analysis was 
performed to determine the mechanism of action and absolute Ki values.  
 
Equation 5 - Cheng-prusoff equations – Equations displaying the link between IC50 and Ki values in 
competitive, non-competitive and uncompetitive inhibition modes, respectively (Cheng and Prusoff, 1973). 
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4.1.3 Modes of inhibition 
 
The different modes of inhibition are summarised in table 19, showing where the inhibitor binds 
and its impact on Km and Vmax values. 
 
Table 19 – Different modes of inhibition – Different types of inhibitor action, characterised by binding 
interactions and changes to Michaelis-Menten (Km) and maximal velocity (Vmax) values. 
Type of 
Inhibitor 
Description Impact on Km 
Impact on 
Vmax 
Impact on 
Km/Vmax 
ratio 
General Equation 
Competitive 
Inhibitor 
binds to free 
enzyme 
↑Km 
↑[S] required to 
compete with I. 
 
Same Vmax 
Excess 
substrate 
can 
overcome I. 
↑ 
Km/Vmax 
 
Non-
competitive 
Inhibitor 
binds 
equally to E 
and ES 
complex 
Same Km   
↓Vmax 
Always some 
E bound to I 
↑ 
Km/Vmax 
 
Kic = Kiu 
Mixed 
Inhibitor 
binds E and 
ES with 
different 
affinities 
Variable Km 
 
↓Vmax 
ESI complex 
can prevent 
P formation 
 
 
Mixed ratio of Kic and Kiu 
 
Un-
competitive 
Inhibitor 
binds ES 
complex 
only and 
cannot bind 
free E 
↓Km 
Some S bound to 
ESI therefore not 
converted to P. 
 
↓Vmax 
Always some 
E bound to I 
Same 
Km/Vmax 
 
 
 
 
In competitive inhibition, the inhibitor binds only the free enzyme and a high concentration of 
substrate can overcome the inhibitor. This constitutes a high proportion of existing inhibitor drugs 
(Copeland, 2005). More rarely observed is uncompetitive inhibition where only the ES complex is 
bound by the inhibitor, reducing Km and Vmax. Alternatively, mixed inhibition occurs when the 
inhibitor is able to bind both the free enzyme and the ES complex, reversibly; quantified by Kic and 
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Kiu values that can be linked by an alpha value. When α=1, (the inhibitor affinity for E matches 
that of ES), the inhibition is termed non-competitive. Alpha close to 0 suggests that the EI complex 
enhances substrate binding and the model is uncompetitive. Finally, a large alpha value indicates 
EI preventing substrate binding and a competitive mode of inhibition. Within literature, the use of 
non-competitive is often interchangeable with mixed inhibition, where exact alpha values of 1 are 
relatively rare (Mohan et al., 2013).  
In the presence and absence of inhibitor, comparing Km and Vmax values can help determine the 
mode of inhibition. In addition, graphical representations such as the Dixon and Cornish-bowden 
plots can be used (Cortés et al., 2001). This is demonstrated in supplementary figure 5-6, each 
predicting mixed inhibition close to non-competitive, in accordance with SNLR results from 
supplementary table 7-8. It is not sufficient to simply use r-squared values to determine a best-fit 
nonlinear model (Spiess and Nuemeyer, 2010). 
From Akaike’s information criteria test, the model with the smaller AICc value is correct, although 
the difference between AICc values is reported in supplementary table 7; from that of the simpler 
model minus the more complicated model with increased parameters. As such, a positive 
difference in AICc shows preference for the more complicated model whilst a negative value 
represents preference for the simpler model (Kakkar et al., 2000; Motulsky and Christopolous, 
2003). Subsequently, probability values are reported based on the AICc difference. Competitive 
inhibition has fewer parameters than mixed that have fewer than non-competitive inhibition 
models. In each case a mixed or non-competitive model was preferred from argyrin B inhibition 
analysis. 
In supplementary table 8 an extra sum-of-squares F test is used to distinguish between the nested 
models of mixed and non-competitive inhibition. This method tests with a p-value, therefore 
random scatter of data is taken into consideration. The F ratio defines the association between 
relative increases in sum-of-squares and degrees of freedom. An F ratio close to 1 suggests that 
the simpler model is more suitable, whereas greater than 1 favours the model with more 
parameters (Motulsky and Christopolous, 2003). For argyrin B at each active site, the non-
competitive model was preferred, as a variant of mixed inhibition. 
A non-competitive mode of inhibition was unexpected for argyrin B, with the majority of 
proteasome inhibitors characterised as competitive, including argyrin A (Nickeleit et al., 2008) and 
F (Bülow et al., 2010).  The small molecule cyclic peptide is expected to block the active site as 
predicted in section 3.2 showing docking closely around Thr1, also shown in computational 
studies on argyrin A & F by (Stauch et al., 2010; Loizidou and Zeinalipour-Yazdi, 2014). Although 
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allosteric interactions and ES binding are also likely, inhibition of the ES complex is difficult to 
determine with small peptide substrates. Cellular conditions of long peptide chain substrates may 
exhibit different affinities of argyrin B binding and steric blocking of binding sites surrounding the 
catalytic centre.  
It is suggested that concentrations of 0.5 x Km to 5 x Km are used and higher concentrations of 
substrate facilitate the ability to distinguish between competitive and non-competitive inhibition. 
Results from figure 20 use substrate concentrations up to 2.5xKm due to limitations of plate 
reader reading limits and plate design. Some guidelines also suggest at least 8 inhibitor 
concentrations at each substrate concentration, ranging up to 10xKi (Strelow et al., 2012) whilst 
others suggest 4 up to 3 x IC50 (Copeland, 2005). The latter was followed in this experiment, 
however a greater range may prove useful. Despite this, many literature reports contain minimal 
range of concentrations tested, such as the 4 substrate and single inhibitor concentrations of 
argyrin F by (Bülow et al., 2010), analysed with linear transformations. 
As well as determining mechanism of action, Ki values were generated to support IC50 values. 
 
4.1.4  Argyrin B Ki values 
 
Ki indicates the potency of an inhibitor, measuring binding affinity through determining the 
concentration required for half maximal inhibition. Lower values represent tighter binding whilst 
higher values indicate weaker interactions (Mohan et al., 2013).  
Table 9 results for argyrin B at each active site reveal similar trends between the CP and IP, 
compared to table 8 IC50 data. In both cases, the Ki is lower at the IP site compared to CP 
counterpart, also observed to a greater extent at β1. The lower Ki is a valuable pharmacodynamic 
property associated with reduced toxicity. β1i shows the lowest Ki of all sites, in contrast to β5i 
displaying the lowest IC50. However, in both cases neither were statistically significant from each 
other. Relatively high ranges of 95% confidence are observed for Ki estimations due to low 
number of degrees of freedom. Numerical values are relatively similar compared to IC50, although 
these are expected to be near equal for non-competitive inhibition, as demonstrated in equation 
5 (Cheng and Prusoff, 1973). 
No experimental data of argyrin B Ki values at the CP or IP were available at the time of writing. 
However, (Bülow et al., 2010) estimates the Ki of argyrin F at 81nM, 112nM and 76nM for β1c, 
β2c and β5c active sites, respectively. These are noticeably lower than reported argyrin B values 
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and do not show the same weak binding at β1c. Although it is important to note that argyrin F Ki 
values were determined from only a single 120 nM inhibitor concentration with 3 low substrate 
concentrations of 40 µM, 20 µM and 10 µM. Due to the similar structures and characteristics, 
kinetic properties of argyrin B were expected to be similar to its analogues, however minor 
structural changes in key areas have been shown to have a significant simulated effect on binding 
(de Bruin et al., 2014; Loizidou and Zeinalipour-Yazdi, 2014). 
It is important to note that whilst an inhibitor may express great affinity, tight binding, to the 
enzyme, this does not necessarily translate to efficacy, the biological response. Cell based assays 
and in vivo studies would provide valuable data building upon kinetic parameters.  
Overall, interesting trends have been observed with argyrin B inhibition at each active site. 
Notably a preference towards IP active sites, in particular β1i. This selectivity shows great 
therapeutic potential for treatments associated with lower toxicity and fewer side effects as 
discussed in section 1.4.3. Findings from computational molecular modelling can postulate 
reasons for the increased affinity through analysis of predicted binding conformations, 
interactions and energetics.  
 
4.2  Computational modelling and structure-based drug design 
4.2.1  Structural data 
 
Recent findings contribute towards a growing number of residues deemed important for inhibitor binding. In figure 
33 
Figure 33, sequence alignments ascertained from structural data shown in supplementary figure 
12 are presented with additional information regarding specificity pockets, displayed with colour 
coding (Stauch et al., 2010, Huber et al., 2012, de Bruin et al., 2014). This information facilitates 
the identification of key amino acid differences between the CP and IP sites that may result in the 
greater IP affinity exhibited by argyrin B. Furthermore, novel structure based drug design is no 
longer always focussed on Thr1 targeting, with success of alternative non-catalytic targets such as 
Cys48 of β5 (Duibella et al., 2015). 
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Figure 33 - Sequence alignment of human CP and humanised IP active sites with key binding residues 
highlighted - ‘|’ = full conservation of the same residue, ‘:’ = strongly similar properties and ‘.’ = weakly 
β1c Human         1  TTIMAVQFDGGVVLGADSRTTTGSYIANRVTDKLTPIHDRIFCCRSGSAA   50 
                     ||||||:||||||:|:|||.:.|..:.|||.|||:|:|:||:|..||||| 
β1i Humanised     1  TTIMAVEFDGGVVMGSDSRVSAGEAVVNRVFDKLSPLHERIYCALSGSAA   50 
 
 
β1c Human         51 DTQAVADAVTYQLGFHSIELNEPPLVHTAASLFKEMCYRYREDLMAGIII  100 
                     |.|||||...|||..|.||| |||||..||::.:.:.|:|||||.|.::: 
β1i Humanised     51 DAQAVADMAAYQLELHGIEL-EPPLVLAAANVVRNISYKYREDLSAHLMV  100 
 
 
β1c Human        101 AGWDPQEGGQVYSVPMGGMMVRQSFAIGGSGSSYIYGYVDATYREGMTKE  150 
                    ||||.:||||||.. :|||:.||.||||||||::|||||||.|:.||:.| 
β1i Humanised    101 AGWDQREGGQVYGT-LGGMLTRQPFAIGGSGSTFIYGYVDAAYKPGMSPE  149 
 
 
β1c Human        151 ECLQFTANALALAMERDGSSGGVIRLAAIAESGVERQVLLGDQIPKFAVA  200 
                     ||.:||.:|:||||.|||||||||.|..|..:||:.:|:||:::|||... 
β1i Humanised    150 ECRRFTTDAIALAMSRDGSSGGVIYLVTITAAGVDHRVILGNELPKFYDE  199 
 
 
β1c Human        201 TL    202 
                        
β1i Humanised    200 --    198 
 
 
β2c Human         1 TTIAGVVYKDGIVLGADTRATEGMVVADKNCSKIHFISPNIYCCGAGTAA   50 
                    |||||:|::||::||||||||...|||||:|.|||||:|.|||||||.|| 
β2i Humanised     1 TTIAGLVFQDGVILGADTRATNDSVVADKSCEKIHFIAPKIYCCGAGVAA   50 
 
 
β2c Human        51 DTDMTTQLISSNLELHSLSTGRLPRVVTANRMLKQMLFRYQGYIGAALVL  100 
                    |.:|||::..|.:|||:|||||.|||.|..|:|:|.||||||::||:|:: 
β2i Humanised    51 DAEMTTRMAVSKMELHALSTGREPRVATVTRILRQTLFRYQGHVGASLIV  100 
 
 
β2c Human       101 GGVDVTGPHLYSIYPHGSTDKLPYVTMGSGSLAAMAVFEDKFRPDMEEEE  150 
                    ||||:|||.||.::||||..:||:..:|||..||:||.||:|:|:|..|. 
β2i Humanised   101 GGVDLTGPQLYGVHPHGSYSRLPFTALGSGQDAALAVLEDRFQPNMTLEA  150 
 
 
β2c Human       151 AKNLVSEAIAAGIFNDLGSGSNIDLCVISKNKLDFLRPYTVPNKKGTRL   199 
                    |:.|:.||:.|||..|||||.|:|.|||:|.....||..:.|.:...|. 
β2i Humanised   151 AQGLLVEAVTAGILGDLGSGGNVDACVITKTGAKLLRTLSSPTEPVKRSG  200 
 
β5c Human         1 TTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAA   50 
                    ||||||||:||||.|.||||:||:||::..|.|||||||||||||:|.|| 
β5i Humanised     1 TTTLAFKFQHGVIAAVDSRASAGSYISALRVNKVIEINPYLLGTMSGCAA   50 
 
 
β5c Human        51 DCSFWERLLARQCRIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTM   100 
                    ||.:||||||::||:|.|||.|||||:||||||:||:.||:|||||||:| 
β5i Humanised    51 DCQYWERLLAKECRLYYLRNGERISVSAASKLLSNMMCQYRGMGLSMGSM   100 
 
 
β5c Human       101 ICGWDKRGPGLYYVDSEGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVE   150 
                    ||||||:||||||||..|.|:||..||.|||:.|||||||.||..:|..| 
β5i Humanised   101 ICGWDKKGPGLYYVDEHGTRLSGNMFSTGSGNTYAYGVMDSGYRPNLSPE   150 
 
 
β5c Human       151 QAYDLARRAIYQATYRDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYS   200 
                    :||||.||||..||:||:||||.||:||::||||::|.|.:|:||..:|. 
β5i Humanised   151 EAYDLGRRAIAYATHRDSYSGGVVNMYHMKEDGWVKVESTDVSDLLHQYR   200 
 
 
β5c Human       201 G    201 
                    . 
β5i Humanised   201 E    201 
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similar properties. Residues contributing towards substrate specificity pockets are coloured as: green = S1, 
blue = S2, brown = S3, red = importance for active site (Adapted from: Huber et al., 2012). 
Comparisons between active sites are first discussed then later covered in greater detail with 
respect to argyrin B binding in section 4.2.2. 
Comparing the β1c and humanised β1i sites, numerous differences can be observed at the S1 
pocket, namely: T20V, T31F, R45L and T52A, none of which retain strongly similar properties (de 
Bruin et al., 2014). The S3 pocket also shows variation, with contrasting T22A and A27V from CP 
to humanised IP (Huber et al., 2012). Several other residues of importance to the active site 
remain conserved, although β1i humanised lacks a residue at 115 for which β1c has a proline 
present which may cause a shift in the chain resulting in structural differences. None of the 
substitutions made in preparation of humanised β1i from murine β1i (supplementary table 9) 
involved amino acids known as important for the active site or specificity pockets. Although 
alternative substitutions may alter architectural arrangement, this suggests high sequence 
conservation amongst the main specificity pocket amino acids, as previously described in (Huber 
et al., 2012). 
Between β2c and humanised β2i, there are few residue differences within active sites and 
specificity pockets. Only T48V of S2 and T52A as well as conservative D53E of S1 are noted as 
different. T52A was a difference also observed between murine β2i and human β2i sequences, 
revealing potentially key species differences of the IP. Beyond the catalytic centre, there are many 
differences in the overall sequences that can affect the chemical property and structural 
characteristics of each site. 
β5c and humanised β5i appear remarkably conserved amongst key residues. However, A46S and 
V128T from β5c to β5i humanised, differ which are suggested to modulate the active site. The 
previous M31V substitution from murine β5i to humanised β5i further highlights the species 
differences (supplementary figure 11). 
In addition to focus on the active site subunit chain, the surrounding beta subunits have also been 
shown to influence inhibitor binding (figure 26). By producing active site cuts, there were overlaps 
into neighbouring chains, which in some cases proved influential to the overall architecture as 
well as interactions observed. 
CP and IP active site sequence alignments of multiple organisms has also been tested by (Huber et 
al., 2012), showing high levels of conservation between human, murine, zebrafish and rat species, 
amongst several more. Interestingly, many key changes between CP and IP counterpart sites are 
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also conserved, suggesting that different species models retain strong relevance in translation to 
human application.      
The highlighted residues in figure 33 are noted in literature as being relevant in ligand and 
inhibitor binding, with potential for structure-based drug design to enhance selectivity (Blackburn 
et al., 2010; Miller et al., 2013; Huber et al., 2016). Although, in the case of non-covalent, 
inhibition by the cyclic peptide argyrin B, additional interactions and conformations predicted in 
table 12-14 may also play key roles. 
 
4.2.2  Argyrin B binding at constitutive and immuno- proteasome 
4.2.2.1  β1c & β1i sites 
 
Purified assay IC50 results shown in figure 18 reveal a significantly greater strength of argyrin B 
binding at β1i compared to β1c. This is further corroborated in Ki estimations figure 19-20 and 
molecular docking binding energy predictions table 11. Analysis of the positioning and 
interactions predicted can postulate structural reasons for the greater binding affinity observed.  
 
The β1c caspase-like site typically cleaves after acidic residues, whilst β1i shows a more trypsin-
like activity, cleaving after basic residues (Pellom and Shanker, 2012; Johnston-Carey et al., 2015). 
This is due to different size and characteristic of the binding pockets, which appear to also impact 
the affinity of argyrin B. Argyrin B at β1c showed more variation with interactions, compared to 
β1i where a particular fit was evident. At β1c, the 2 different conformations shown in repeats 
suggest no clear pocket for strong interactions. 
R45L substitution in β1i creates a more hydrophobic region at the base of the S1 pocket; where 
the positively charged arginine in β1c that would not attract argyrin’s hydrophobic region, is 
replaced. This is observed with carfilzomib (structure in figure 11) where the hydrophobic P1 
leucyl group is disfavoured at the polar β1c S1 pocket (Harshbarger et al., 2015). Further 
substitutions T20V, T31F, T52A, replace the polar threonines in β1c with hydrophobic residues 
that are positioned at the S1 pocket. Of these, argyrin B only interacts directly with Val20, 
although there are increased interactions around the S1 pocket area with neighbouring residues. 
To potentially strengthen these interactions, hydrophobic and branched residues could be 
extended around the base of the cyclic peptide inhibitor. As also suggested in literature stating 
bulky, hydrophobic P1 residues as prerequisites for β1i selectivity (de Bruin et al., 2014). 
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Furthermore, the T21S conservative substitution in β1i allows consistent hydrogen bonding at this 
residue (figure 24), not observed in β1c perhaps due to the smaller size of serine and proximity to 
S1 (de Bruin et al., 2014). Loizidou and Zeinalipour-Yazdi (2014) also report lack of T21 bonding of 
argyrin A (structure figure 12) at humanised β1c, although, Stauch et al., (2010) suggest T21 
hydrogen bonds across all humanised active sites in argyrins A-D & F. 
The T22A and A27V substitutions in β1i create a smaller S3 pocket (Huber et al., 2012); however 
argyrin B shows little interaction at this site in either favourable conformation. This is contrary to 
reports by Stauch et al., (2010) identifying dispersive interactions at these residues for argyrins A-
D & F in humanised β1c. G97H in β1i creates a more basic and protruding residue which 
differentially accommodated the orientation and interaction of argyrin B’s bulky tryptophan rings. 
Key interactions with Trp1 are shown whilst also orientating the N of Trp1 to allow H-bonding 
with nearby Ser46 (figure 25). Furthermore, M95S creates a polar region for Trp2 O to form 
dipole-dipole interactions. In contrast, β1c shows few interactions at either Trp moiety which may 
partly explain an overall lower binding affinity.   
Lack of Val114 in β1i may have affected the chain positioning compared to β1c, as illustrated in 
figure 15. This subsequent shift of spatial arrangement may favour the proximity and ability of 
argyrin’s thiazole ring to hydrogen bond multiple times with Thr1, only observed in β1i. This 
spatial arrangement may also explain the consistent hydrogen bonds observed in β1i at the polar 
Ser129, whereas β1c contains a neutral glycine at this position.  
Whilst selectivity towards the β1i over β1c active site is sought after, the additional interactions at 
β2i and β5i are also important. Kisselev et al., (2003) shows how caspase-like active site selective 
inhibitors can stimulate trypsin-like activity and allosterically inhibit chymotrypsin-like activity, 
therefore understanding affinity and interactions across all active sites is paramount. 
 
4.2.2.2  β2c & β2i sites 
 
Despite neither site displaying an energetically favourable bind with argyrin B (table 11), the 
different conformations and interactions (figure 26) suggest the possibility of developing 
specificity. This is interesting since the substrate binding pockets of β2c and β2i have been 
reported as difficult to distinguish and shallow in size (Huber et al., 2012), with only 1 β2i selective 
inhibitor reported to date (Koroleva et al., 2015).  
Some substitutions within the active site result in distinct conformations of argyrin B between 
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each, leading to the possibility of synthetically developing selectivity. Key interactions are 
observed around residues 46-49, 96-97 and 128/129 in both β2 sites. Several of these residues 
have suggested importance of binding in literature (figure 33)(Huber et al., 2012). In addition, 
argyrin B interacts at residues 19-21 and Thr1 of β2i at a greater frequency than β2c, perhaps due 
to E22N and G23D differences from β2c to β2i. Although not directly involved as interactions, 
these appear to shift the positioning of Thr21. Furthermore G23D and M24S in β2i may create 
steric hindrance and inhibitor stabilisation discrepancies between β2c and β2i. These larger and 
more polar residues in β2i are in close proximity to the S1 pocket and appear influential. Indeed, 
Stauch et al., (2010) report E22 in humanised β2c to play a role in coordinating the polar indole H 
of argyrin Trp2 ring into a hydrophobic side pocket. 
T48V and A97S from B2c to B2i, within key regions of interactions, may affect argyrin B 
positioning. S97 in β2i creates a polar region amongst largely hydrophobic residues. This 
subsequently favours interactions with Trp1, in some cases forming hydrogen bonds. Residue 48 
plays a role in the S2 binding pocket (Stauch et al., 2010; Huber et al., 2012) and although Thr and 
Val have similar composition, an additional hydroxyl on Thr results in polar properties. Both are 
key for argyrin B interactions, although at different areas of the compound. 
T52A and D53E from β2c to β2i are positioned around the S1 pocket, accounting for substrate 
recognition (Huber et al., 2012; Koroleva et al., 2015). However, these do not appear to interact 
with argyrin B or play any significant role in affinity. Similarly, Y114H in β2i, of importance to the 
S3 pocket, does not directly impact argyrin B binding. However this substitution may influence 
positioning of P115 in each active site, subsequently increasing interactions with argyrin B at β2c, 
whilst being out of reach at β2i.  
Recently, Koroleva et al., (2015) have reported exquisite β2i over β2c selectivity achieved by 
bisbenzimidazole derivatives measured by computed binding energy values and kinetic data. As 
observed with argyrin B, monomeric bisbenzimidazole (structure in figure 34) did not interact 
with β2c S1 pocket 53 residue either. However, the dimeric form, through an aromatic stacking 
folding conformation was able to interact at the β2i S1 pocket. These large compounds were 
often predicted to dock across large portions of the β2 and β3 sites and on occasions adopt 
allosteric binding (Koroleva et al., 2015). 
Overall, the differences of interactions and conformations balance similar final binding energies 
for argyrin B at each β2 site (table 11). Upon identifying different predicted poses and interactions, 
as well as novel developments of β2 selective compounds, it would be interesting to perform 
kinetic assays of argyrin B at β2c and β2i.     
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4.2.2.3  β5c & β5i sites 
 
Docking simulations showed statistical significance of argyrin B binding at β5i to a greater affinity 
than β5c (table 11). Different interactions and conformations were predicted that can be 
attributed to specific changes in the active sites. It is important to note that whilst values from 
kinetic studies suggested the same trend of IP preference in IC50 (figure 18) and Ki (figure 20) 
values, these were not shown to be statistically significant.  
Argyrin B adopted a more complete fit within the β5c subunit, displaying interactions with 
residues around most regions of the cyclic peptide and hydrogen bonds often forming from the 
thiazole ring (figure 28). In contrast, within β5i fewer residue interactions were observed with 
most occurring around Trp1 and Trp2, including hydrogen bonds. This suggests that binding could 
be further enhanced by modifications to argyrin B that extend at R1 and R2 of argyrin B in figure 12, 
to allow closer proximity to the subunit. 
Argyrin B shows multiple interactions with β5i chain at positions 45-49, whereas β5c only 
interacts at Gly47. Although, Gly47 is conserved in the CP and IP, residues 46 and 48 are 
substituted. The CP contains hydrophobic Ala46 and Gly48 which are each smaller in size and less 
polar, compared to hydroxylic Ser46 and sulfhydryl containing Cys48 in the IP. An increase in 
specifically hydrophobic interactions has been previously shown to enhance inhibition at β5c for 
the natural phenol, epigallocatechin gallate analogues (Kanwar et al., 2010); identifying this 
modification as influential to enhance binding. Together with A27S, the G48C substitution in β5i 
results in a smaller and more hydrophilic S2 pocket (Huber et al., 2012). This can contribute to 
possible dipole-dipole interactions at Trp2 in the β5i conformation that are not observed in β5c. 
Aforementioned substitutions may also explain the alternative positioning of argyrin B whereby 
the thiazole hydrogen bonds to Gly47 of the CP. This is similar to Loizidou and Zeinalipour-Yazdi 
(2014) showing argyrin A hydrogen bonding between Gly47 of yeast β5c and the macrocyclic 
backbone. In contrast, within the best conformational fit of β5i, the Ser46 forms a double 
hydrogen bond bridging each Trp moiety. The tryptophans rotate to align δ+ hydrogens bonded to 
the electronegative nitrogen of the indole ring, which each bond to the Ser46 (figure 28). 
Whereas, the hydrophobic Ala46 did not display interactions at β5c. Furthermore, Ala49 of the S1 
pocket, which contributes to chymotrypsin-like activity, is conserved and shows consistent 
interactions in β5i but none in the corresponding CP subunit. Interestingly, Loizidou and 
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Zeinalipour-Yazdi (2014) identified hydrogen bonds of argyrin A at yeast Ala49 of β5c but not the 
humanised counterpart.   
At β5i the configuration of Met45 increases S1 pocket size, assisted by the S53Q substitution in 
β5i. The larger side chain of glutamine is able to interact with Met45 in β5i, however the serine in 
β5c cannot attract Met45 to the same extent (Huber et al., 2012). The larger β5i S1 pocket is then 
able to accommodate a larger P1 side chain as reported with other inhibitors (Parlati et al., 2009; 
Harshbarger et al., 2015; Sosič et al., 2016). In the β5i conformation of argyrin B the aromatic Trp1 
interacts in this position, enhancing binding energies.   
The T30R and K32N substitutions from β5c to β5i have very different properties. The large, basic 
amino acids essentially switch positions either side of the Val31, between each subunit. This 
affects the overall architecture between β5c and β5i, thereby allowing the basic Lys33 and 
hydrophobic Val31 of β5i to interact around S1. This appears to be a key interaction in β5i with 
argyrin B, whilst β5c does not exhibit any interaction with this part of the active site. 
Thr1 is an important interaction at both subunits and often displays hydrogen bonds in β5i with 
the O of the amide bond between Trp1 and Trp2. This strengthens the multiple interactions 
around the tryptophans of argyrin B within β5i. Whereas, at β5c, the positioning of argyrin B is 
such that only weak interactions are formed with Thr1 which are at the opposing end of argyrin B 
compared to β5i. This unconventional conformation instead resulted in Trp1 interactions at the 
negatively charged region 113-117 and Trp2 with alternative chains in the CP, notably Ser23 and 
Asn24 from β4c. These additional intermolecular interactions may help contribute to the overall 
binding energy in β5c, partially explaining the small overall difference compared to β5i fit where 
argyrin interacts with fewer residues overall. 
Ser21 is another important interaction in β5i, often creating 1 or more hydrogen bonds between 
the thiazole and Trp2 of argyrin B. The 21 residue position is important, potentially influencing 
positioning of the conserved Ala20 and Ala22 either side that are key residues for the S1 and S3 
pockets, respectively. The β5i T21S substitutions are of similar polar properties, but serine is 
slightly smaller without the extra methyl group, potentially allowing extra space for argyrin B at 
β5i. However, Huber et al., (2012) also suggests S3 of β5i accommodates smaller, polar residues 
compared to bulky, hydrophobic side chains at S3 of β5c. Furthermore, Stauch et al., (2010) and 
Loizidou and Zeinaipour-Yazdi (2014) identify T21 to occupy bulky Trp moieties of argyrins in 
humanised and yeast β5c. Beck et al., (2015) evidence the importance of S3, through 
crystallographic analysis of non-covalent inhibition as a result of solely S3 occupation of β5c, again 
utilising T21 in hydrogen bonding.   
 
 
100 
 
The aromatic, polar Tyr169 interacts in all conformations for both subunits, although in different 
locations on the inhibitor. Positioned before the key Ser170 this is an important interaction 
(Huber et al., 2012). Gly129 is also located adjacent to a key residue, Ser130. Gly129 interacts in 
both subunits however; in β5c this can form hydrogen bonds together with Ser130 towards 
argyrin B. This appears to be an influential interaction in β5c, appearing in only the favourable 
binding energy conformations. Ser130 is not observed to interact with β5i and is positioned 
around the Trp rings. The V128T from β5c to β5i may also influence Ser130 binding, with the 
valine a common interaction in β5c although interestingly not in the best observed conformation.  
Overall, the residues of importance and substitutions from β5c to β5i shown to impact argyrin B 
binding at each site are also highlighted as relevant to substrate specificity. Additional key 
residues for argyrin B binding also often neighbour those indicated as important to specificity 
pockets. Other structure based drug design investigations have utilised similar information to 
achieve β5i selectivity (Groll et al., 2010; Beck et al., 2015; Sosič et al., 2016).  
The significantly different, although consistent positioning of argyrin B in each subunit, raises the 
possibility of an improved and selective fit at β5i. Making changes to the thiazole ring could 
strongly lower β5c interactions, without affecting β5i since there are few noteworthy interactions 
currently observed in this location. Whilst changes around the Trp rings may improve the 
interactions with β5i.  
 
4.2.2.4  Summary of argyrin B and IP selective docking 
 
Molecular docking simulations provided scoring values that matched argyrin B purified assay 
trends and suggested conformational poses, including interactions that may contribute towards 
the free energy binding values.  
From control tests with TMC-95A (supplementary table 15), 250 runs produced a single best-fit 
conformation (-9.58 Kcal/mol) predicted at a far greater affinity than all others (starting from -
8.57 Kcal/mol).  This most favourable conformation of TMC95-A (green in figure 23) was predicted 
different to the crystal structure pose (yellow) although the single occurrence suggests a possible 
anomalous result. It is therefore important to also analyse repeats and distinct conformational 
clusters. With TMC-95A docking results this revealed the most commonly occurring distinct 
conformational cluster of high scoring poses (example shown in red, figure 23). These do indeed 
closely match crystallographic data (yellow, figure 23). This highlights a good potential accuracy of 
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the docking simulations, shown to commonly identify and rank highly the correct pose. However 
also stresses the care required in analysis to investigate beyond simply the top free energy of 
binding estimations.  
This procedure was applied with argyrin B results show in figure 22 where the frequency of best 
scoring conformations were analysed. In argyrin B tests (figure 22), no top scoring conformations 
were isolated occurrences and most also identified within the main distinct conformational 
cluster (at RMSD of 2 Å), enhancing validity of findings towards matching the true crystallographic 
pose.     
Nonetheless, inconsistencies are observed from docking simulations, as reported in literature 
(Chen, 2015; Koroleva et al., 2015). To evaluate accuracy of docking software, a root-mean-square 
deviation (RMSD) between docked and crystallographic poses should be <2 Å (Guedes et al., 
2016). Tests with argyrin B showed low standard deviation from binding energies and relatively 
high consistency of conformations (figure 22), whilst control tests of TMC-95A reveal 
predominantly close predictions to crystallographic data.  
To supplement figure 33, a summary of differences between active sites that specifically lead to 
argyrin B preference towards the IP active site, are tabulated in table 20. Many of these are in 
common, or indirectly impact those deemed important for active site specificity from literature. 
Whilst others provide novel insight towards methods of achieving IP selectivity. There are some 
noticeable comparisons that can be drawn between argyrin B docking results at CP sites and 
similar aforementioned studies by Loizidou and Zeinalipour-Yazdi (2014) and Stauch et al., (2010), 
despite their use of yeast and humanised models as well as different argyrin analogues (structures 
shown in figure 12). However there are currently no literature reports available of argyrin 
analogue docking at the IP.  
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Table 20 – Key CP and IP structural differences influencing argyrin B interactions - Summary of CP to IP substitutions influencing conformation of argyrin B and possible IP site selectivity. 
Residue 
  
Active Site Significance 
 
Position β1c β1i β1c β1i Argyrin B interactions at IP 
45 Arg Leu Bulky, basic S1 Hydrophobic S1 Altered orientation of molecule 
20 Thr Val Polar S1 Hydrophobic S1 Unique β1i interactions 
31 Thr Phe Polar S1 Hydrophobic S1 β1i favours hydrophobic regions of molecule 
52 Thr Ala Polar S1 Hydrophobic S1 β1i favours hydrophobic regions of molecule 
21 Thr Ser Structure around S1 Structure around S1 Hydrogen bonding at β1i 
97 Gly His Small residue Larger, basic residue Trp1 interactions at β1i and orientation for Ser46 hydrogen bonding 
95 Met Ser Hydrophobic Polar Trp2 interactions at β1i 
114 Val - Hydrophobic Gap - Spatial arrangement Thiazole proximity closer to Thr1  
129 Gly Ser Neutral Polar Hydrogen bonding in β1i 
 
Residue 
  
Active Site Significance 
 
Position β2c β2i β2c β2i Argyrin B interactions at IP 
22 Glu Asn Acidic Polar Enhance polar region for Thr21 binding at β2i 
23 Gly Asp Small, neutral Larger, acidic Architectural changes to enhance Thr21 binding at β2i 
24 Met Ser Hydrophobic Polar Possible inhibitor stabilisation 
48 Thr Val Polar S2 Hydrophobic S2 Different orientation 
97 Ala Ser Hydrophobic Polar Trp1 interactions and H bonds in β2i 
114 Tyr His Hydrophobic Basic Alter architecture to enhance β2c P115 and A95 interactions 
 
Residue 
  
Active Site Significance 
 
Position  β5c β5i β5c β5i Argyrin B interactions at IP 
46 Ala Ser Small, hydrophobic Polar Double hydrogen bonds at β5i 
48 Gly Cys Small, hydrophobic S2 Polar S2 Nearby Trp2 interactions at β5i 
27 Ala Ser Small, hydrophobic S2 Polar S2 Nearby Trp2 interactions at β5i 
53 Ser Glu Polar Large, polar Effects Met45 configuration to enlarge S1 and bind Trp1 in β5i 
30 Thr Arg Polar Basic Structural changes to enhance Val31 and Lys33 β5i interactions around S1 
32 Lys Asn Basic Polar Structural changes to enhance Val31 and Lys33 β5i interactions around S1 
21 Thr Ser Polar Smaller, polar H bonding at β5i 
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S1 pocket changes are of particular significance in selectivity and activity evidenced by marizomib 
that achieves potent inhibition by occupying solely S1 (Groll et al., 2006b), yet additional pocket 
interactions can further enhance potency and selectivity. In fact, non-covalent S3 interactions 
alone have also shown strong inhibitory properties (Beck et al., 2015). Due to the covalent 
mechanism of many existing proteasome inhibitors, it is easy to characterise P chains that occupy 
S1-4 pockets. However, in the case of non-covalent inhibition with greater freedom to interact at 
different orientations, the S pockets may not always align with the same side groups of the 
inhibitor, incurring additional challenges to optimisation designs. Despite this, proposed 
analogues of argyrin A and F by Loizidou and Zeinalipour-Yazdi (2014) exhibited remarkably 
enhanced affinity for active sites in docking simulations, proving the potential for applying similar 
techniques to increase selectivity. Therefore with the selectivity of argyrin B towards the IP shown 
in kinetic assays, combined with understanding of predicted interactions from docking, the IP 
selectivity could be further enhanced. 
Although molecular docking simulations are widely used and provide valuable insight into drug 
interactions, it is important to back up findings with additional evidence. Secondary docking using 
FRED tested different approaches to predict inhibitor interactions. These revealed similar findings 
that help to validate AutoDock predictions (table 15-17). Only β5i raised some concern of 
AutoDock missing additional interactions. One must appreciate the limitations of computational 
docking and conclude results appropriately. 
 
4.2.3  Molecular docking software 
 
Molecular docking is becoming an increasingly utilised research tool, with numerous software 
programmes now available. In table 21, details of AutoDock and FRED docking used in this 
investigation are summarised alongside 5 of the most commonly published alternative software 
packages, in recent years. More exhaustive programme reviews can be found elsewhere (Sousa et 
al., 2013; Chen, 2015).  
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Table 21 – Overview of most common molecular docking software programmes - Summary of docking 
software used in this investigation, alongside the next most common platforms. Basic parameters are 
outlined and all software enable ligand flexibility. 
 
AutoDock, the most commonly published docking software (from 1990-2013), uses a genetic 
algorithm with stochastic conformational search whereby a random number generator creates a 
new location, orientation and torsion values for each pose. This means that results differ between 
repeats, but a sufficient coverage of the active site can be achieved (Morris et al., 2009). 
AutoDock estimates free binding energy using equation 6, in which intermolecular energy 
encompasses Van der Waals forces, hydrogen bonding, desolvation and electrostatic energies. A 
lower Gibbs free energy represents increased stability of the complex, ranked by empirical or 
force-field based scoring functions. Docking is performed with a flexible ligand and flexible side 
chains of the macromolecule; evidently favourable parameters across major docking software 
(table 21). Although in AutoDock 4.2 most bonds can be made rotatable or non-rotatable, a 
limitation is that as standard, cyclic portions of the ligand are treated as rigid to avoid distorted 
structures (Morris et al., 2009). In this investigation, argyrin B was energetically optimised using 
Avogadro (Hanwell et al., 2012), although additional steps can be undertaken to manage the 
flexibility of rings, then applied to AutoDock (Forli et al., 2007). 
 
 
 
Docking 
Software 
% of Docking 
Publications 
1990-2013 
Conformational 
Search 
Algorithm 
Protein 
Flexibility 
Main Scoring Functions Reference 
AutoDock 25.9 Stochastic 
Protein 
side chains 
flexible 
AutoDock (empirical, 
force-field based) 
(Morris  et al., 
2009) 
GOLD 16.7 Stochastic 
Partial 
flexibility 
GoldScore (force-field 
based) ChemScore 
(empirical) 
(Verdonk  et 
al., 2003) 
Glide 14.9 Systematic Flexible GlideScore (empirical) 
(Friesner  et 
al., 2004) 
FlexX 9.6 Systematic Flexible FlexX (empirical) 
(Kramer  et 
al., 1999) 
Surflex-
Dock 
4.2 Systematic Flexible Hammerhead (empirical) 
(Spitzer and 
Jain, 2012) 
FITTED 3.3 Systematic Flexible 
Rank Score 5 (force-field 
based) 
(Corbeil  et al., 
2007) 
FRED n/a Systematic Rigid ChemGauss4 (empirical) 
(McGann, 
2012) 
Estimated free energy of binding = Intermolecular energy + Final total internal energy + 
Torsional free energy – Unbound systems energy 
 
Equation 6 – AutoDock free binding energy calculation – Equation used to derive estimated free enrgy of 
binding from AutoDock molecular modelling simulations. All components in Kcal/mol units. 
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Literature analysis of multiple docking software revealed striking inconsistencies that highlight the 
value of repeat testing on additional software (McGann, 2011, 2012). FRED was chosen as an 
alternative method to provide useful comparison and validation of results in this experiment due 
to different parameters used. FRED docking utilises a systematic, exhaustive search where gradual 
variations of conformation are applied; effective for most likely binding modes in localised spaces, 
although less effective at global minimum (Ferreira et al., 2015). FRED docks with multiple ligand 
conformers produced by OMEGA that identifies and enumerates rotatable bonds and flexible 
rings, to essentially mimic flexible ligand docking. Finally, top poses undergo systematic solid body 
optimisation through local exhaustive searches of rotational and translational degrees of freedom 
(McGann, 2011).  
Alternative software generally follows genetic algorithms and systematic conformational searches. 
Empirical scoring functions count favourable interactions between 2 molecules, including details 
such as hydrophobic effect. This method is generally preferred to force-field based scoring 
functions that add intermolecular and electrostatic interactions between all atoms of the ligand-
protein complex (Wang et al., 2002). Alternatively, knowledge-based scoring utilises existing 
molecule-protein complex crystallisation data to inform favourable binding affinities (McGann, 
2012) and would prove valuable tools for optimisation design where ligand-protein crystallisation 
data is available.  Furthermore, the benefit of fully flexible macromolecules of alternative 
software is a useful function that would allow changes in protein conformation and pocket size 
upon ligand binding. These induced-fit docking methods have shown an impressive improvement 
in RMSD values to crystal structures, compared to rigid-receptor docking (Sherman et al., 2006).   
Choice of docking software is difficult and highly dependent on experimental aims. 
Aforementioned docking software each have particular benefits suited for certain needs, for 
example the ability of GOLD and FITTED to test pharmacophore orientated covalent docking 
(Verdonk et al., 2003; Corbeil et al., 2007), that would be useful for the majority of existing 
proteasome inhibitors. To test a broad active site area for non-covalent interactions, AutoDock is 
appropriate software that has been commonly used for proteasome inhibition investigations 
(Yang et al., 2008; Kanwar et al., 2010; Loizidou and Zeinalipour-Yazdi, 2014). 
It is commonly reported that although predicted ligand binding conformations may correspond 
with crystallographic data, proving successful docking methods, the estimated energies are often 
in disagreement between different software and laboratory data (Chen, 2015). This is largely due 
to a lack of physical data in the model to determine entropic contributions accurately, as well as 
neglecting solvent considerations that detriment desolvation predictions (later discussed in 4.4.1) 
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(Ferreira et al., 2015). Indeed, force-field and empirical based scoring functions of AutoDock are 
liable to these limitations and as such, should be reported with laboratory data. 
Advancements from molecular docking are molecular dynamics (MD) simulations with systems 
such as GROMACS (Hess et al., 2008) and Desmond (Shivakumar et al., 2010) including force fields 
such as CHARMM (Brooks et al., 1983) and AMBER (Cornell et al., 1995). Ligand parameter and 
topology identification for use in MD programmes can be generated using software such as 
SwissParam (Zoete et al., 2011) and LigParGen (Dodda et al., 2017). These methods are difficult to 
research due to heavy demands on computational power, but would test and reveal any physical 
movements of molecules over time, upon ligand binding (Ferreira et al., 2015). Full flexibility of 
the target and monitoring changes upon ligand interaction may reveal cryptic pockets and 
dynamic binding conformations. 3 Dynamic states of the 26S proteasome are known to allow 
recognition and entry into the 20S core where it is possible a ligand causes further proteasome 
flexibility (Huang et al., 2016).  
 
4.3  Current IP inhibitor status 
4.3.1  Advances in structure-based drug design 
 
The importance of suitable proteasome structures is highlighted by species variations. Geurink et 
al., (2013) show the difference between use of yeast or mammalian structures that reveal how 
single residue changes can have a significant effect upon structure related activity studies. For 
example, oprozomib and PR-924 show 20 and 130-250 fold selectivity to human β5i over β5c 
(Parlati et al., 2009), with the latter on account of worse β5c affinity rather than greater β5i. 
However, this difference is not observed between mouse ratio of β5i and β5c affinity where 
oprozomib selectivity remains 20-fold yet PR-924 is reduced to 16-fold (Huber et al., 2016). It is 
therefore important to use models that map as closely as possible to the human CP and IP. There 
are examples of successful use of homology models and molecular docking approaches, similar to 
those described in this investigation, to test proteasome inhibitors (Loizidou and Zeinalipour-Yazdi, 
2014; Guedes et al., 2016). These are required because crystallographic structure determination 
involves challenges such as: overcoming high mobility, losing protein fractions and combination 
with other structures (Ferreira et al., 2015). Therefore, human CP structures were only recently 
elucidated (Harshbarger et al., 2015) whilst human IP structural data is not currently available.  
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Crystal structures of compound and proteasome help to fully elucidate binding interactions and 
are considered the gold standard of testing inhibitor interactions. Therefore, to overcome species 
differences and crystallisation limitations, sophisticated chimeric humanised yeast proteasomes 
have recently been developed (Huber et al., 2016). Human β5i fragment chain 1-138 and 
neighbouring β6 subunit residues that can be involved in ligand interactions, were incorporated 
into yeast proteasomes then crystallised to create a structural model. X-ray analysis with 
inhibitors and mutant variants revealed the cause of species difference between PR-924 
selectivity. The Met31 in murine β5i increases the P1 size and causes steric hindrance for 
inhibitors such as PR-924 endowed with bulky N-caps, although those with smaller groups 
including oprozomib can be accommodated. Whilst substituted Val31 in yeast humanised 
chimeric β5i allows a kinked binding mode with increased potency. These findings further validate 
structure-based design and introduce a yeast proteasome with incorporated human β5i subunit, 
as a powerful tool for advanced inhibitor studies (Huber et al., 2016). Similar methods have also 
been used on a smaller scale of single mutations on yeast proteasomes then crystallised to reveal 
residue orientation (Duibella et al., 2015). However, despite credibility for crystallisation studies, 
these chimeric proteasomes are not advised as an alternative for enzymatic assays as β5 activity is 
significantly reduced by growth irregularities and temperature sensitisation (Huber et al., 2016). 
Supplementary figure 17 shows an alignment of yeast proteasome with human β5i (in red) (Huber 
et al., 2016, Cui et al., 2017) to humanised β5i homology model (green) created in this 
investigation, with differences in blue and β5i subunit chains in magenta. Significant changes 
within the β5 chains are shown at Thr1 and Gly188 with the remainder closely matched. Gly188 is 
positioned towards the back of the site and not involved in ligand binding, however slightly 
differing positioning of the catalytic Thr1 is of interest. As expected, some changes are observed 
in neighbouring chains within the 28 Å cut, as the yeast proteasome differs from mouse IP. This 
shows the humanised β5i homology model as suitable due to close resemblance of human β5i 
structural data; however the minor difference in Thr1 position may influence docking. It is 
expected that β1i and β2i humanised models would achieve comparable findings to structural 
data, if available.       
Since the human 20s CP was first crystallised to a resolution of 2.6 Å (Harshbarger et al., 2015), 
advances in structural elucidation have revealed further, novel data.  A cryo-electron microscopy 
structure of the human 26S CP at 3.5 Å reveals greater conformational dynamics for 
understanding substrate processing (Huang et al., 2016). Additionally, a series of extra production, 
purification and crystallisation steps accompanied by technological advances have led to a 1.8 Å 
human 20S CP structure with clear electron densities (Schrader et al., 2016). Novel co-
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crystallisation studies of the CP in complex with inhibitors revealed differences in binding 
mechanisms to those originally proposed and further characterisation of the β5c active site 
(Schrader et al., 2016). Specifically, the previous epoxyketone mechanism thought to form a 1-4 
morpholino adduct formation has been shown to in fact produce a seven-membered ring adduct 
between the inhibitor and threonine residue (Schrader et al., 2016). With this newfound 
information, new classes of boronic acid or epoxyketone inhibitors may be developed based upon 
formation of a seven-membered adduct, allowing for example, different positioning of the leaving 
group. Additionally, electron diffraction techniques have recently been implemented to reveal 
hydrogen atom localisation in organic material, a current limitation to x-ray diffraction 
crystallisation data (Palatinus et al., 2017). Overall, these higher resolution 3-dimensional 
structures allow more accurate details on the topology of the macromolecule sub pockets, clefts 
and cavities, whilst also providing electrostatic properties. Therefore, where possible, the highest 
resolution data should therefore be used in molecular docking studies.  
A crystallographic screening procedure approach has recently been utilised with yeast CP on a set 
of compounds, providing rapid elucidation of inhibitor-proteasome complex structural data (Beck 
et al., 2015). This is a powerful approach allowing detailed investigations on a wider variety of 
compounds; effectively used to identify agents with a novel mode of action. 
These novel advances and approaches have rapidly increased the development of proteasome 
inhibitors, particularly in understanding and achieving selectivity. 
 
4.3.2  Immunoproteasome selective inhibitors 
 
Using approaches such as high throughput screening and synthetic modifications of existing 
inhibitors based upon structural data, an increasing number of IP selective inhibitors are being 
discovered. Compounds to date, with proposed IP selectivity, quantified through IC50 values, are 
summarised in table 22. 
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Table 22 - IP selective inhibitors determined by IC50 values at each active site – Inhibitors are grouped by class of binding mode and a brief outline of methods is included. * represents 
Kinact/Ki (M
-1
s
-1
), a preferred measure for irreversible inhibitors. 
Class Compound 
IC50 (µM) Ratio of IP 
Selectivity  
Method 
β5c β5i 
Peptidyl aldehyde IPSI-001 (calpeptin) 
2.9 0.022 131 Purified assays (Parlati et al., 2009) 
Ki 105 Ki 1.03 102 Z-GGF-pAB purified assays (Kuhn et al., 2009) 
Epoxyketone 
ONX 0914 (PR-957) 
0.236 0.028 8 
Suc-LLVY-AMC purified assays  
(Muchamuel et al.,, 2009) 
0.16 0.015 11 (Sosič et al., 2016) 
0.513 0.057 9 (Duibella et al., 2014) 
0.487 0.024 20 (Huber et al., 2016) 
0.054 0.0057 9.5 
Raji cell lysates, activity-based protein profiling with BODYIP-NC005 probe 
(de Bruin et al., 2014) 
From ONX 0914:           
Lu-005i (8) 0.29 0.0066 44 
Raji cell lysates. Activity based protein profiling with BODYIP-NC005 probe 
(de Bruin et al., 2014) 
Lu-025i (11)  1.9 0.036 52 
Lu-045i (15) 0.83 0.032 26 
Peptido sulfonyl fluoride 
compound 3 
3.927 0.139 28 Suc-LLVY-AMC purified assays (Duibella et al., 2014) 
PR-924 13.02 0.051 255 Suc-LLVY-AMC purified assays (Huber et al., 2016) 
From PR-924:           
Lu-015i (9) 4.6 0.0083 554 
Raji cell lysates. Activity based protein profiling with BODYIP-NC005 probe 
(de Bruin et al., 2014) 
Lu-035i (13) 5.5 0.011 500 
Lu-055i (25) 25 0.053 471 
Chloroacetamide 
Carfilzomib derived 
decarboxylated peptide with 
amide P3 sidechain 
>100 0.64 >150 Purified assays (Dubiella et al., 2015) 
Oxathiozole 
HT2004 0.23* 1093*
  
 4750 
Suc-LLVY-AMC purified assays (Fan et al., 2014) 
HT2106 0.7* 151* 215 
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HT2210 3.2* 83* 26 
Compound 42 1.07 0.013 82 Suc-LLVY purified assays. (Sosič et al., 2016) 
Non-peptide, 
reversible 
Psoralene based compound 
3 
Ki 172.2 Ki 1.6 108 Suc-LLVY purified assays. (Sosič et al., 2016) 
Non-covalent 
Capped dipeptide inhibitor 
Compound 4 
Compound 5 
 
470 
340 
41 
27 
11 
13 
Ac-WLA-AMC, Ac-ANW-AMC purified assays (Blackburn et al., 2010) 
Non-covalent, 
non-peptidic 
Ro19 28.85 0.42 69 Proteasome-Glo
TM
 Suc-LLVY-aminoluciferin substrate (Cui et al., 2017) 
 
Class Compound 
IC50 (µM) Ratio of 
IP 
Selectivity  
Method 
β1c β1i 
Peptidyl aldehydes 
IPSI-001 (calpeptin) 
Ki 239 Ki 1.45 165 BrAAP assay (Kuhn et al., 2009) 
Peptidyl aldehydes 
Epoxyketone 
UK-101 15 0.104 144 
Raji cell lysates - Activity based protein profiling with 
BODYIP-NC001 probe (Ho et al., 2007; de Bruin et al., 2014) 
Lu-001i 
24 0.095 252 
Raji cell lysates - Activity based protein profiling with 
BODYIP-NC001 probe (de Bruin et al., 2014) 
47 0.13 360 RPMI-8226 cells (de Bruin et al., 2014) 
 
Class Compound 
IC50 (µM) Ratio of 
IP 
Selectivity  
Method 
β2c β2i 
Non covalent 
bisbenzimidazoles 
Monomeric 2 0.024 83 
Boc-LRR-AMC purified assays (Koroleva et al., 2015) 
Dimeric 4.1 0.024 171 
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There are currently a higher number of β5i selective compounds discovered on account of 
aforementioned structural differences and research greater focus on the β5 site, often considered 
the most influential. In addition, despite an increasing number of non-covalent inhibitors, 
summarised in table 3, few of these display IP selectivity. Therefore, the β1i selectivity and non-
covalent interactions of argyrin B are interesting findings that collectively are unique to existing 
compounds. Figure 34 displays chemical structures of non-covalent IP selective inhibitors and β1i 
selective inhibitors, of which all are covalent. 
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Non-covalent β5i selective inhibitors 
 
 
 
 
 
 
 
Non-covalent β2i selective inhibitors 
 
 
 
 
 
Covalent β1i selective inhibitors 
 
 
 
 
Figure 34 – Structures of IP selective inhibitors – β5i selective and non-covalent: A) (Sosič et al., 2016), B) 
(Blackburn et al., 2010), C) (Blackburn et al., 2010), D) Ro19 (Cui et al., 2017). β2i selective and non-covalent: 
H) and I) (Koroleva et al., 2015). β1i selective, covalent: E) (Kuhn et al., 2009), F) and G) (de Bruin et al., 
2014). 
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Purified assays, as used in this investigation, are popular methods for kinetic studies with 
proteasome inhibitors. However, variations can be observed between repeat tests of different 
research groups, as shown with PR-957 in table 22. Approximately 3-4 fold differences can be 
observed between individual IC50 values; however the measure of IP selectivity ratio is slightly 
more consistent. Indeed the inconsistencies of enzyme assays have been previously reported; 
largely due to incubation times, particularly with covalent inhibitors and the varied, single 
substrate concentration of IC50 tests.  Suggested actions emphasise the value of Ki measurements 
over IC50 (Cisneros et al., 2016a).  
Alternative methods are also reported, notably use of raji cell lysates for activity based protein 
profiling probes (de Bruin et al., 2014). B-cell lymphoma cell lines are incubated with inhibitor 
concentrations and following cell lysis, specific probes added to bind active sites. SDS-PAGE 
(polyacrylamide gel electrophoresis) separation then allows fluorescent densitometry of bands for 
quantification (de Bruin et al., 2014). This method has advantages of using a cellular environment, 
however arguably not as sensitive as purified fluorescence assays for ascertaining kinetic profiles. 
Advances in detection probes and measurements have also revealed potential use for 
fluorescence polarisation-based assays, as an efficient and accurate inhibitor binding 
measurement for dissociation constant (Kd) determination (Cisneros et al., 2016b). Further 
laboratory based methods are previously outlined in section 1.6.1.  
Additional argyrin B tests with alternative assay methods would prove useful to investigate the 
effects in cells and across all active sites together. Further analysis of mechanism using knockout 
models as described with argyrin A by Nickeleit et al., (2008) would also prove valuable 
information towards drug development. However, initially strategies to enhance argyrin B 
potency would be a priority.  
Although the potency observed by argyrin B is relatively low in comparison to ranges observed in 
table 22, understanding the interactions and mode of binding can facilitate further development. 
Synthetic additions of groups can further enhance potency. Other IP selective inhibition screens 
and studies have revealed proof-of-principle and leads for further investigation, despite selectivity 
in only low micromolar ranges (Kuhn et al., 2009). To investigate, free energy perturbation (FEP) 
calculation simulations are a valuable approach, using aforementioned molecular dynamics 
packages (section 4.2.3). Able to compute differences in free energy from chemical perturbations 
of a compound, this can reduce the demand on physical synthesis and facilitate greater variety of 
testing (Wang et al., 2015). 
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An argyrin B IP selectivity ratio of 16 (table 8) measures against the capped dipeptide non-
covalent β5i inhibitor (structure in figure 34) (Blackburn et al., 2010) in terms of ratio and potency. 
However compared to β1i inhibitors (Kuhn et al., 2009; de Bruin et al., 2014) and the non-
covalent bisbenzimidazole β2i inhibitors (Koroleva et al., 2015), potency and selectivity are 
relatively low. Nonetheless, predicted interactions that result in the binding preferences observed 
table 20, may prove valuable information in future development of selective inhibitor drug design. 
 
4.4  Evaluation 
4.4.1  Experimental limitations 
 
There remain limitations associated with the results gathered in this investigation, some of which 
have been previously mentioned.   
Whilst Ki values have been estimated these are currently single tests that require further repeats, 
the value of which is evidenced by variation to IC50 values. Where possible the inhibitor 
concentrations should range from 0, 0.33, 1 & 3 x IC50 value, whilst substrate concentrations cover 
0.2-5 x Km (Copeland, 2015). However, due to plate reader detection limits and the presence of 
additional controls limiting space on a 96-well plate, these were not always experimentally 
practical. Importance of Ki values is clear (Cisneros et al., 2016a) therefore further tests to confirm 
and perform statistical analysis on argyrin B Ki values would enhance conclusions.  
DMSO solvent was essential to solubilise argyrin B and substrate assay components (table 5); 
water solubility of argyrin A and F have been characterised at low micromolar levels (Bülow et al., 
2010). As compound stocks were stored in DMSO it is possible that the stability is affected by 
freeze-thaw cycles increasing moisture absorption from the air (Cheng et al., 2003). Where 
possible aliquots or fresh stocks were prepared, however there may remain a source of error with 
unrepresentative compound concentrations after prolonged freezing and use. Furthermore, at 
high concentrations of compound, the respective final DMSO levels remained high and exhibited 
significant effect upon the rate of reaction (figure 19). Whilst concurrent DMSO control correction 
at corresponding DMSO concentrations accounted for the impact of solvent, the consequence 
towards reaction conditions must also be considered. Despite correction, the impact upon 
reagent concentrations can be significant enough to create a different reaction environment that 
is no longer appropriate for kinetic studies.  
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The type of microplate used can be influential, with (Cui et al., 2014) revealing the significant 
impact of colour and binding surface. In this experiment, standard assay kit component NBS white 
plates although this is likely to vary amongst other studies.  
Whilst at the time of experiments, PDB:4R30 (Harshbarger et al., 2015) was the highest resolution 
human CP structural data available, there is now greater detail available in the PDB:5LE5, 1.8 Å 
data (Schrader et al., 2016). This would be a more appropriate source to create active site cuts 
used in molecular docking. In homology preparation of humanised IP structures, newly 
substituted residues are predicted orientations at the given site. However, the recent 
crystallisation of humanised yeast β5i by Huber et al., (2016) provide more solid evidence of 
residue positioning and side chain orientation. Due to the minor change in Thr1 position observed 
(supplementary figure 17), this would be considered more appropriate data for β5i docking 
experiments. 
The type of docking software used can include some limitations as previously discussed in 4.2.3, 
particularly compared to the rapidly emerging molecular dynamic programmes. Inability to test 
argyrin B with a fully flexible active site target may limit the simulations performed in this 
investigation. 
Furthermore, the absence of water molecules in AutoDock is considered a limitation when 
compared to the true in vivo state. Water molecules can possess a variety of thermodynamic 
energetic states, including ‘unhappy’ waters often in lipophilic regions due to preference over the 
absence of water, yet disfavoured to positioning within the bulk solvent (Mason et al., 2013). 
Therefore energetically ‘unhappy’ water may be displaced by ligand binding to augment strength, 
‘happy’ water may be removed in a less favourable binding, or water molecules may be trapped 
by a ligand. Additionally, new water molecules forming around the ligand-protein complex can 
enhance entropy and mediate interactions to residues (Beuming et al., 2012). Understanding and 
including the positioning and energetics of water molecules is therefore valuable with ligand-
binding simulations. WaterMAP (Abel et al., 2008) and WaterFLAP (Mason et al., 2013) may be 
used in conjunction with molecular dynamics software to assess the impact of water and 
potentially be exploited to enhance selectivity (Beuming et al., 2012; Mason et al., 2013).  
Results concluded from purified assay and docking experiments can be limited. Whilst inhibition 
of an active site can be observed, this may not translate in cellular or in vivo conditions. In more 
complex environments, issues such as mixed active sites and compensatory proteolytic activity 
may reduce or silence inhibition previously observed (Kisselev et al., 2006). It is also argued that 
proteasome variation (figure 7), post-translational modifications and other interacting proteins 
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may cause differences observed in active site specificities (Geurink et al., 2013). Therefore, results 
are limited to impacts on a simplified model and only proposed or indicative cellular effects and 
therapeutic potential. 
 
4.4.2  Future Developments 
 
Whilst this investigation indicates argyrin B selectivity towards the IP, further repeats are required 
to validate Ki values. In addition, determination of Kd values would be valuable to define 
reversibility strength and lasting action of the inhibitor (Cisneros et al., 2016b). When sufficient 
kinetic data is collected, it is important to consider the way in which inhibitor data is reported. It is 
commonly suggested to follow guidelines outlined as standards for reporting enzyme data 
(STRENDA) to sufficiently report experimental detail and functional data from enzyme kinetic 
experiments (Tiptona et al., 2014)(full guidelines provided at http://www.beilstein-
institut.de/en/projects/strenda/guidelines should be used when possible). Within a field 
containing frequent high throughput screening and early stage compound characterisation, these 
details of kinetic data using rigorous methods are often overlooked, despite the value of such 
information. 
Argyrin B has shown promising early signs of IP selectivity and information has been gathered on 
possible interactions that contribute towards a greater affinity at IP sites. Furthermore, with 
increased understanding of each active site and proposed binding characteristics, modifications to 
the inhibitor may enhance potency and or selectivity. It would be logical to first test this 
computationally through molecular docking which can be quantified through comparison of 
binding energies. Further to this, upon synthetic development of a new analogue, the difference 
in Ki values can be indicative of binding affinity that could be further quantified by change in 
binding energy using equation 7 (Copeland, 2005). 
Equation 7 - Gibbs free binding energy - R = ideal gas constant, T = temperature (kelvin), Ki – inhibition 
constant (moles). 
 
∆𝑮𝒃𝒊𝒏𝒅𝒊𝒏𝒈 = 𝑹𝑻𝒍𝒏(𝑲𝒊) 
 
Equation 7 can also be modified to calculate the difference in binding energies between 2 
inhibitors, by using a ratio of Ki
A/Ki
B. Differences in calculated binding energy can also help to 
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confirm the type of interactions that are introduced. For example, a binding energy difference of 
approximately -2.5 kcal/mol would be indicative of an extra hydrogen bond which may be 
attributed to the structural change of the compound (Copeland, 2005).  Combined with 
computational modelling, this can be a powerful approach to validate predictions and optimise 
compounds. This approach would be particularly useful with IP studies where co-crystallisation is 
difficult to achieve. At the CP it would be valuable to co-crystalise argyrin B to confirm binding 
orientation and interactions. With novel chimeric yeast proteasome with human β5i subunit 
(Huber et al., 2016), argyrin B may also be crystallised into the human β5i site, as achieved with 
Ro19 inhibitor by Cui et al., (2017).  
Beyond simplified, pharmacokinetic assays, proteasome inhibitors can be measured in whole 
blood samples and more complex models (Lightcap et al., 2000; Parlati et al., 2009). These 
experiments can be useful to identify pharmacodynamic properties and molecular mechanisms of 
the inhibitor. Such experiments have been performed with argyrin A revealing anti-tumoural 
activity achieved through preventing the breakdown of p27kip1 (Nickeleit et al., 2008). As this is a 
unique mechanism (figure 9) to existing proteasome inhibitor therapeutics (figure 11), there are 
associated benefits of potentially overcoming resistance in relapsed cases. It would therefore be 
interesting to investigate whether the argyrin B analogue displays the same mechanism of action. 
Exposure of the compound in cell lines followed by western blot analysis may be used to test the 
impact upon key regulatory protein levels. However, there are also difficulties that arise from 
testing in cell lines. Such as variance in permeability across cell lines and in some inhibitor classes 
off target effects for example cathepsin protease inhibition, can occur making it difficult to 
establish the true causality (Geurink et al., 2013).   
With the suggestion of non-competitive inhibition of argyrin B, it would be interesting to test 
argyrin binding at α-subunits. Competition assays with chloroquine can be performed as 
described by Stauch et al., (2010). Here resonance transferred-NOE signals measured chloroquine 
that is able to bind in the presence of argyrin A, where chloroquinone would typically bind α-
subunits.  
Additionally, some protein targets have recently discovered cryptic pockets that reveal upon drug 
binding. In some cases these allosterically alter enzymatic activity and could provide alternative 
targeting sites (Bowman and Geissler, 2012). Although not currently identified within literature 
for proteasomes, advances in molecular dynamic modelling software combined with enhanced 
computational power, may allow longer simulations and further details of protein flexibility. 
Future investigations with software such as TRAnsient pockets in proteins (TRAPP) could provide 
information on changes in a binding pocket’s spatial and physiochemical properties, potentially 
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revealing cryptic sub-pockets (Stank et al., 2017). 
Finally, if drug development were to continue as a lead compound, complex tests and 
considerations are required regarding appropriate solubility, permeability, metabolism and 
toxicity (Strelow et al., 2012). Basic analysis of argyrin B absorption, distribution, metabolism and 
excretion, contributing towards drug-likeness of the molecule are summarised in figure 35, 
calculated using SwissADME (Daina et al., 2017). 
            
Figure 35 – Drug-likeness properties of argyrin B and carfilzomib – Shaded red zone represents guideline 
suitable physiochemical properties for oral bioavailability. Measures of lipophilicity (LIPO), size, polarity, 
insolubility (INSOLU), insaturation (INSATU) and flexibility (FLEX) (Daina et al., 2017). 
Figure 35 reveals potential challenges in size, solubility and polarity of argyrin B, in medicinal 
chemistry. These would particularly cause challenges in drug delivery and absorption. 
Furthermore, 7 hydrogen bond donors are above the recommended 5 maximum, combined with 
a molecular weight above 500, cause argyrin B to violate the Lipinski drug-likeness 
recommendations (Lipinski et al., 2001). For comparison, figure 35 also shows drug development 
difficulties in polarity, size and flexibility for carfilzomib, yet these have been overcome and FDA 
approval has been successful.  
 
 
 
 
 
 
Argyrin B Carfilzomib 
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4.5  Conclusion 
 
In conclusion, the naturally occurring, cyclic peptide argyrin B was tested for inhibition at the CP 
and IP. Purified enzymatic assays reveal argyrin B IC50 values of 8.76 µM at β1i that is 16-fold 
lower and statistically significant to 146.5 µM at β1c. Meanwhile, low micromolar IC50 values are 
observed at β5 sites, with slight preference of β5i over β5c. The same trend is corroborated by Ki 
dissociation constants and molecular docking estimated free binding energies. AutoDock and 
OEDocking FRED simulations predicted best-fit binding poses and key interactions of argyrin B at 
each CP and IP active site, revealing differences that are associated with contributing towards 
selectivity. T20V, T31F and T52A substitutions from β1c to β1i appear significant in creating a 
more hydrophobic β1i S1 pocket that enhances multiple argyrin B interactions. T21S from β1c to 
β1i allow β1i hydrogen bonding with argyrin B and facilitate orientation for multiple Trp moiety 
interactions. At β5c a small, hydrophobic S2 pocket is replaced with more polar characteristics at 
β5i that promote argyrin B interactions. In addition, V31 and K33 are identified as important 
residues surrounding the β5i S1 pocket.  
These findings reveal argyrin B as a novel β1i over β1c selective proteasome inhibitor with 
reversible, non-covalent binding mode. Select structural differences are suggested to contribute 
towards selectivity and may be beneficial information towards future design of IP selective 
compounds. The non-covalent mechanism and ability to target the IP over CP is associated with 
lower toxicity of proteasome inhibitors that exhibit great therapeutic potential against a variety of 
diseases. 
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Supplementary table 1- Stock, working and final concentrations of reagents used. 
Reagent Stock 
concentration 
Working concentration Final concentration 
Argyrin B 10 mg/ml in DMSO As required, in proteasome 
buffer 
As required, in 
proteasome buffer 
β1c substrate 37.5 mM in DMSO 375-500 µM, in proteasome 
buffer 
As required, in 
proteasome buffer 
β1i substrate 37.5 mM in DMSO 375-500 µM, in proteasome 
buffer 
As required, in 
proteasome buffer 
β5c / β5i substrate 37.5 mM in DMSO 375-500 µM, in proteasome 
buffer 
As required, in 
proteasome buffer 
Constitutive proteasome 1 mg/ml 10 µg/ml 0.1 µg/well 
Epoxomycin 500 µM in DMSO As required, in proteasome 
buffer 
As required, in 
proteasome buffer 
Immunoproteasome 1 mg/ml 10 µg/ml 0.1 µg/well 
Vinyl Sulfone 500 µM in DMSO As required, in proteasome 
buffer 
As required, in 
proteasome buffer 
 
 
Supplementary Table 2 – Lamarckian 4.2 genetic algorithm parameters used in AutoDock simulations. 
Genetic Algorithm Parameters  
Number of runs per test 50 
Population size 150 
Maximum number of evals 2500000 
Maximum number of generations 27000 
Maximum number of top individuals that 
automatically survive 
1 
 
Rate of gene mutation 0.02 
Rate of crossover 0.8 
Genetic algorithm crossover mode Two pt 
 
 
Supplementary table 3 - Chain and coordinates of grid box centre for each active site cut – Structural data 
from PDB:4R30 for human CP, PDB:3UNH for human IP and PDB:1JD2 for yeast CP. ‘h’ represents 
humanised, ‘y’ represent yeast. 
Active Site Chain 
Threonine 1 coordinate positioning of grid box 
x y z 
β1c H -44.697 77.350 -80.590 
β2c I -59.837 60.333 -97.139 
β5c Z -42.749 25.372 -104.397 
hβ1i N 23.238 -78.082 -11.152 
hβ2i H 3.687 -59.799 -18.031 
hβ5i K 52.961 -24.734 -1.942 
yβ2c o 4.857 -159.860 43.634 
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Supplementary figure 1 – Effect of solvent on rate of IP reaction –  Increasing DMSO solvent concentration 
on a logarithmic scale, against the percentage of control IP reaction rate. β1i purified assay with Ac-PAL-
AMC substrate. Nonlinear regression analysis fit with normalised response and variable slope. Data 
presented as average with standard error bars. 
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Supplementary figure 2 – β1c and β1i IC50 estimation – Tested at [CP] and [IP] = 0.1 µg/well and [S] = 50 
µM. Analysed using SNLR variable slope. β1i IC50 9.6 µM +/- 1.5 and β1c IC50 = 173.9 µM +/-1.1. 
 
Supplementary table 4- β1c Kic values determined from Dixon plot – Calculated from intersecting lines of 
different substrate concentrations. 
β1i [S] (µM) 10.9 21.9 43.8 87.5 175 
10.9   2.5 3.67 3.68 3.68 
21.9 2.50   5.85 5.18 5.00 
43.8 3.67 5.85   3.78 3.76 
87.5 3.68 5.18 3.78   3.72 
175 3.68 5.00 3.76 3.72   
 
 
Supplementary table 5 – β1i Kiu values determined from Cornish-Bowden plot – Calculated from 
intersecting lines of different substrate concentrations. 
β1i [S] (µM) 10.9 21.9 43.8 87.5 175 
10.9   30.58 13.24 13.07 10.97 
21.9 30.58   7.96 7.43 9.06 
43.8 13.24 7.96   12.93 10.54 
87.5 13.07 7.43 12.93   9.77 
175 10.97 9.06 10.54 9.77   
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Supplementary figure 3 - β5c and β5i Lineweaver-Burk plots to estimate Km and Vmax – Linear 
transformations with line equations solved to determine axis intercepts. β5c: Vmax = 0.2320 µM/min, Km = 
119.3 µM. Excluding 3.9 µM data point Km = 89.9 µM. β5i: Vmax = 0.05035 µM/min, Km = 115.714 µM. 
Excluding 3.9 µM data point Km = 100.1 µM. 
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Supplementary table 6 - Unpaired t-test p values  calculated from IC50 mean from independent 3 
replicates - Bold denotes statistical significance between active sites, at p<0.05. 
 
β1c β1i β5c β5i 
β1c 
 
0.0002 0.0002 0.0001 
β1i 0.0002 
 
0.8586 0.0744 
β5c 0.0002 0.8586 
 
0.1015 
β5i 0.0001 0.0744 0.1015 
 
 
 
Supplementary table 7 – Best-fit model analysis results from Akaike’s information criteria. 
Active Site 
Probability (%) AICc 
Difference Competitive Mixed Non-competitive 
β1i 0.01 99.99 
 
18.10 
 
<0.01 
 
>99.99 20.38 
  
24.2 75.8 -2.28 
β5c <0.01 >99.99 
 
45.31 
 
<0.01 
 
>99.99 44.57 
  
59.19 40.81 0.74 
β5i <0.01 >99.99 
 
31.44 
 
<0.01 
 
>99.99 33.76 
  23.86 76.14 -2.32 
 
 
Supplementary table 8 – Best-fit model analysis from extra sum of squares F test at p<0.05. 
Active 
Site 
Mixed 
Non-
competitive 
p-value F ratio 
β1i reject accept 0.7609 0.09352 
     β5c reject accept 0.089 2.996 
     β5i reject accept 0.8099 0.05841 
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Supplementary figure 4 – Argyrin B inhibition at β1c - Tested at 183.7 µM argyrin B with DMSO correction 
equal to 1.54% DMSO. [CP] = 0.1 µg/well and SNLR analysis fit with non-competitive model. Estimated Ki of 
265 µM from single inhibitor concentration. 
 
 
 
Supplementary figure 5 – Dixon plot with range of argyrin B and substrate concentrations at β1i – 
Intersecting lines estimate Kic =  4.08 µM. 
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Supplementary figure 6 - Cornish Bowden plot with range of argyrin B and substrate concentrations at β1i 
– Intersecting lines estimate Kiu = 10.55 µM. 
 
 
Supplementary figure 7 - Hanes-Woolf plot of [S]/v against [S] for argyrin B at β1i - Y intercept values 
represent Km/Vapp for each inhibitor concentration, used to estimate Ki. 
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Supplementary figure 8 – Ki estimate from Km/Vapp against [I] for argyrin B at β1i – Ki value from x-
intercept = 4.14 µM. 
 
 
 
Supplementary Figure 9 - BLASTp alignment from murine β1i active site cut (query), to human sequence 
β1i (subject) – Murine IP sequence from PDB:3UNH, human β1i sequence from UniProt:P28065. 
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Supplementary Figure 10 - BLASTp alignment from murine β2i active site cut (query), to human sequence 
β2i (subject) – Murine IP sequence from PDB:3UNH, human β1i sequence from UniProt:P40306. 
 
 
 
Supplementary Figure 11 - BLASTp alignment from murine β5i active site cut (query), to human sequence 
β5i (subject) – Murine IP sequence from PDB:3UNH, human β1i sequence from UniProt:P28062. 
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Supplementary table 9  - Substitutions performed in humanisation of IP active site structural data - 
Mutations performed using swissPDB viewer, from 20S Mouse IP PDB:3UNF active site cuts aligned to 
human LMP2 (P28065) for β1i, PSMB10 (P40306) for β2i, PSMB8 (P28062) for β5i sequences. ‘+’ denotes 
conservative subsititutions. 
β1i Mouse   β1i Human β2i Mouse   β2i Human β5i Mouse   β5i Human 
Val14 + Met14 ARG 9 + GLN9 VAL14   ALA14 
Thr24   Glu24 THR52   ALA52 THR21 + SER21 
Gly39 + Glu39 ALA60   VAL60 SER28 + ALA28 
Phe42 + Tyr42 VAL99 + ILE99 MET31 + VAL31 
Ile55 + Val55 ASN106   THR106 LEU88   CYS88 
Leu68 + Ile68 GLU112   GLY112 ASP116 + GLU116 
Lys84 + Arg84 GLY132   ASP132 ASN117 + HIS117 
Leu95   Ser95 VAL135 + LEU135 GLN124   ASN124 
Ile99 + Met99 LEU137 + VAL137 GLN145   PRO145 
Met115 + Leu115 GLU153   GLY153 ASP146 + ASN146 
Ile120   Thr120 ILE159 + VAL159 ASN168 + SER168 
Thr125   Ala125 SER165   GLY165 SER190 + THR190 
Ser132 + Thr132 ALA180   LYS180 TYR197 + HIS197 
Tyr133 + Phe133 GLY181   THR181 LYS198 + GLN198 
Thr147 + Ser147 GLN186   LEU186 GLY201   ARG201 
Asn157 + Asp157 ALA188   THR188       
Thr160   Ala160 THR191 + SER191       
Asn164 + Ser164 GLN197 + LYS197       
Asp191 + Asn191 ALA199 + SER199       
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β1c Human         1  TTIMAVQFDGGVVLGADSRTTTGSYIANRVTDKLTPIHDRIFCCRSGSAA   50 
                     ||||||:||||||:|:|||.:.|..:.|||.|||:|:|:||:|..||||| 
β1i Humanised     1  TTIMAVEFDGGVVMGSDSRVSAGEAVVNRVFDKLSPLHERIYCALSGSAA   50 
 
 
β1c Human         51 DTQAVADAVTYQLGFHSIELNEPPLVHTAASLFKEMCYRYREDLMAGIII  100 
                     |.|||||...|||..|.||| |||||..||::.:.:.|:|||||.|.::: 
β1i Humanised     51 DAQAVADMAAYQLELHGIEL-EPPLVLAAANVVRNISYKYREDLSAHLMV  100 
 
 
β1c Human        101 AGWDPQEGGQVYSVPMGGMMVRQSFAIGGSGSSYIYGYVDATYREGMTKE  150 
                     ||||.:||||||.. :|||:.||.||||||||::|||||||.|:.||:.| 
β1i Humanised    101 AGWDQREGGQVYGT-LGGMLTRQPFAIGGSGSTFIYGYVDAAYKPGMSPE  149 
 
 
β1c Human        151 ECLQFTANALALAMERDGSSGGVIRLAAIAESGVERQVLLGDQIPKFAVA  200 
                     ||.:||.:|:||||.|||||||||.|..|..:||:.:|:||:::|||... 
β1i Humanised    150 ECRRFTTDAIALAMSRDGSSGGVIYLVTITAAGVDHRVILGNELPKFYDE  199 
 
 
β1c Human        201 TL    202 
                        
β1i Humanised    200 --    198 
 
 
β2c Human         1 TTIAGVVYKDGIVLGADTRATEGMVVADKNCSKIHFISPNIYCCGAGTAA   50 
                    |||||:|::||::||||||||...|||||:|.|||||:|.|||||||.|| 
β2i Humanised     1 TTIAGLVFQDGVILGADTRATNDSVVADKSCEKIHFIAPKIYCCGAGVAA   50 
 
 
β2c Human        51 DTDMTTQLISSNLELHSLSTGRLPRVVTANRMLKQMLFRYQGYIGAALVL   100 
                    |.:|||::..|.:|||:|||||.|||.|..|:|:|.||||||::||:|:: 
β2i Humanised    51 DAEMTTRMAVSKMELHALSTGREPRVATVTRILRQTLFRYQGHVGASLIV   100 
 
 
β2c Human       101 GGVDVTGPHLYSIYPHGSTDKLPYVTMGSGSLAAMAVFEDKFRPDMEEEE   150 
                   ||||:|||.||.::||||..:||:..:|||..||:||.||:|:|:|..|. 
β2i Humanised   101 GGVDLTGPQLYGVHPHGSYSRLPFTALGSGQDAALAVLEDRFQPNMTLEA   150 
 
 
β2c Human       151 AKNLVSEAIAAGIFNDLGSGSNIDLCVISKNKLDFLRPYTVPNKKGTRL    199 
                    |:.|:.||:.|||..|||||.|:|.|||:|.....||..:.|.:...|. 
β2i Humanised   151 AQGLLVEAVTAGILGDLGSGGNVDACVITKTGAKLLRTLSSPTEPVKRSG   200 
 
β5c Human         1 TTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAA    50 
                    ||||||||:||||.|.||||:||:||::..|.|||||||||||||:|.|| 
β5i Humanised     1 TTTLAFKFQHGVIAAVDSRASAGSYISALRVNKVIEINPYLLGTMSGCAA    50 
 
 
β5c Human        51 DCSFWERLLARQCRIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTM   100 
                    ||.:||||||::||:|.|||.|||||:||||||:||:.||:|||||||:| 
β5i Humanised    51 DCQYWERLLAKECRLYYLRNGERISVSAASKLLSNMMCQYRGMGLSMGSM   100 
 
 
β5c Human       101 ICGWDKRGPGLYYVDSEGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVE   150 
                    ||||||:||||||||..|.|:||..||.|||:.|||||||.||..:|..| 
β5i Humanised   101 ICGWDKKGPGLYYVDEHGTRLSGNMFSTGSGNTYAYGVMDSGYRPNLSPE   150 
 
 
β5c Human       151 QAYDLARRAIYQATYRDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYS   200 
                    :||||.||||..||:||:||||.||:||::||||::|.|.:|:||..:|. 
β5i Humanised   151 EAYDLGRRAIAYATHRDSYSGGVVNMYHMKEDGWVKVESTDVSDLLHQYR   200 
 
 
β5c Human       201 G    201 
                    . 
β5i Humanised   201 E    201 
 
 
 
 
Supplementary figure 12- Sequence alignment of human CP and humanised IP active site chain cuts – 
Performed using pBLAST, ‘|’ = full conservation of the same residue, ‘:’ = amino acids with strongly similar 
properties and ‘.’ = weakly similar properties. 
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Supplementary table 10 - Raw data lowest binding energy from AutoDock simulations of argyrin B at CP 
and humanised IP sites – Lowest binding energy selected from 50 conformations over 10 replicates.  
Lowest binding energy (Kcal/mol) 
 
β1ihumanised β1c 
β2i 
humanised β2c 
β5i 
humanised β5c 
-11.78 -9.99 -10.45 -10.84 -10.97 -10.52 
-11.32 -9.55 -10.40 -10.56 -10.79 -10.51 
-11.71 -9.70 -11.02 -10.17 -10.88 -10.61 
-11.74 -9.68 -10.87 -10.58 -10.48 -10.72 
-11.61 -9.74 -10.90 -11.07 -10.51 -10.59 
-11.70 -9.69 -11.05 -10.90 -10.97 -10.60 
-11.83 -9.97 -10.66 -10.77 -10.78 -10.55 
-11.65 -9.66 -10.45 -10.89 -10.60 -10.50 
-11.58 -10.12 -10.63 -10.36 -10.64 -10.46 
-11.66 -10.04 -10.45 -11.13 -10.67 -10.70 
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Supplementary Figure 13 - Normality test probability plots from AutoDock simulation lowest binding 
energies of argyrin B at each CP and humanised IP active site – Using lowest binding energy from each of 
10 repeats, analysis performed on Minitab 17. 
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Supplementary table 11 - Normality p-values on AutoDock lowest binding energy repeats at each CP and 
humanised IP active site - Calculated using Minitab 17 where if p>0.05, normal distribution is assumed. 
Binding energy 
(Kcal/mol) 
β1c β1i β2c β2i β5c β5i 
Normality p-value 0.093 0.151 0.701 0.131 0.528 0.703 
Mean 9.81 -11.66 -10.73 -10.69 -10.58 -10.73 
SD 0.1959 0.1408 0.3065 0.2531 0.0853 0.1774 
 
 
 
Supplementary Figure 14 - Test for equal variance on AutoDock lowest binding energy repeats of argyrin 
B at each CP and humanised IP active site. 
 
Supplementary table 12 – Qualitative results for equal variance between AutoDock lowest binding 
energies of argyrin B at CP and humanised IP active sites - Y = equal variance, N = not of equal variance. 
Determines subsequent significance tests: Y = 2 sample t-test, N = non parametric Mann-Whitney test. 
 β1c β1i β2c β2i β5c β5i 
β1c  N N N N N 
β1i N  N N N N 
β2c N N  Y Y Y 
β2i N N Y  Y Y 
β5c N N Y Y  Y 
β5i N N Y Y Y  
 
B5c
B5i humanised
B2c
B2i humanised
B1c
B1ihumanised
-9.5-10.0-10.5-11.0-11.5-12.0
Data
Boxplot of B1ihumanised, B1c, B2i humanise, B2c,...
Binding energy (Kcal/mol) 
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Supplementary Figure 15 - Boxplots displaying 2 sample t-test results between AutoDock lowest binding 
energies of argyin B at CP and humanised IP active sites - Data of normal distribution and equal variance. 
 
Supplementary table 13 - 2 sample t-test p-values between AutoDock lowest binding energies of argyrin 
B at CP and humanised IP active sites – Data of normal distribution and equal variance. Analysis performed 
using Minitab 17 where, >0.05 = no statistical significance and <0.05 = significant difference. 
 β1c β1i β2c β2i β5c β5i 
β1c  - - - - - 
β1i -  - - - - 
β2c - -  0.760 0.164 0.986 
β2i - - 0.760  0.212 0.680 
β5c - - 0.164 0.212  0.030 
β5i - - 0.986 0.680 0.030  
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Supplementary table 14 - Non-parametric Mann-Whitney tests p-values between AutoDock lowest 
binding energy of argyrin B at CP and humanised IP sites – Using data of normal distribution and non-equal 
variance. Analysis using Minitab where p>0.05 = no statistical significance and p<0.05 is of statistical 
significance. 
 β1c β1i β2c β2i β5c β5i 
β1c  0.0002 0.0002 0.0002 0.0002 0.0002 
β1i 0.0002  0.0002 0.0002 0.0002 0.0002 
β2c 0.0002 0.0002  - - - 
β2i 0.0002 0.0002 -  - - 
β5c 0.0002 0.0002 - -  - 
β5i 0.0002 0.0002 - - -  
 
 
Supplementary table 15 - AutoDock lowest binding energies for TMC-95A at yeast β2c – Upper quartile of 
best conformations selected from 5 repeats each of 50 conformations  Bold = similar pose position to 
crystal structure data. 
TMC-95A yeast β2c 
Lowest binding energy (Kcal/mol) 
1 2 3 4 5 
-8.94 -8.70 -8.77 -8.81 -9.86 
-8.55 -8.53 -8.74 -8.80 -8.52 
-8.45 -8.51 -8.74 -8.73 -8.67 
-8.38 -8.29 -8.38 -8.57 -8.66 
-8.27 -8.24 -8.19 -8.45 -8.45 
-8.14 -8.15 -8.19 -8.34 -8.17 
-8.08 -8.12 -8.18 -8.30 -8.03 
-8.03 -8.07 -7.99 -8.26 -7.99 
-7.99 -8.02 -7.93 -8.15 -7.93 
-7.97 -8.00 -7.92 -8.14 -7.92 
-7.93 -7.99 
 
-8.09 -7.92 
 
-7.99 
 
-8.08 
 
 
-7.96 
 
-8.05 
 
 
-7.96 
 
-7.97 
 
 
-7.95 
 
-7.95 
 
   
-7.95 
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   Equation 1. 
     
 
    
    Equation 2.  
         
    
 
    Equation 3. 
                 
    
 
    Equation 4.  
          
 
    Equation 5.  
     
 
    Equation 6. 
            
 
 
Velocity is dependent on k2 and 
concentration of ES complex. 
 
The rate of change in the concentration of 
the enzyme-substrate complex is 
determined by the formation of ES subtract 
the breakdown of ES, either by the forward 
reaction to P + E, or reverse to E + S. 
Initial velocities are measured and a steady 
state assumption is used. By using a low [E], 
this ensures that a significant proportion of 
the reaction was under the assumption that 
[ES] is constant, since [ES] will not 
significantly change unless a high [S] has 
been consumed. Therefore d[ES]/dt = 0, 
along with rearrangement forms equation 3. 
 
At the start of the reaction the total [E] is 
the free E plus ES complex; see equation 4, 
including rearrangement. 
 
 
 
 
Substituting equation 4 into 3 gives equation 
5. Following this, the brackets are multiplied 
out, ES was arranged onto a single side and 
subsequently made the factor of the 
equation that is finally arranged alone. 
 
 
 
 
For simplification, dividing the right hand 
side numerator and denominator by k1 
produces equation 6. 
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    Equation 7. 
        
 
    Equation 8. 
       
 
    Equation 9. 
      
 
    Equation 10. 
       
 
 
 
 
 
 
 
 
From rearrangement of equation 3, [E][S]/[ES] has 
been termed as the Michaelis-Menten constant 
(Km), that produces equation 7. 
 
 
With this in common, substituting equation 7 into 6 
creates equation 8. 
 
Combining equation 1 and 8, then multiplying both 
sides by k2 for simplification, produces equation 9. 
 
The highest initial rate, termed Vmax, occurs when 
all enzyme is saturated in ES complexes. At this 
stage, [ES] = total [E]. Therefore, k2[E0] = Vmax. 
Introducing this factor creates the final Michaelis-
Menten equation 10. 
 
 
Supplementary figure 16 - Derivation of Michelis-Menten equation – Series of equations showing the basis 
of Km and Vmax constants as well as parameters that non-linear regression analysis is based upon. E = 
enzyme, S = substrate, ES = enzyme-substrate complex, P = product, k = rate constant, d = ‘difference in’, v 
= velocity, Km = Michaelis constant, Vmax = maximal velocity. 
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Supplementary figure 17 - Humanised β5i aligned to chimeric yeast proteasome with human β5i subunit – 
Humanised β5i (red) created from mouse IP (PDB:3UNH) with substituted human β5i sequence 
(UniProt:P28062). Yeast proteasome contains human β5i (green) residues 1-138 and human B6 residues 97-
11, 118-133, (PDB:5M2B). β5 chains shown in magenta and differences presented in blue. Interacting 
residues are cut within 28 Å of Thr1.  
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